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In 2006, Yamanaka and his coworkers elegantly demonstrated the 
derivation of induced pluripotent stem cells (iPSCs) from mouse fibroblasts 
using four defined transcription factors, namely c-MYC, KLF4, OCT4 and 
SOX2. Following reprogramming, forced exogenous expression of 
transcription factors confers somatic cells to iPSCs with pluripotent embryonic 
stem cells (ESCs)-like characteristics. Subsequently, numerous studies have 
reported the successful derivation of cancer-specific iPSCs from tumors and 
malignant cancer cell lines. Presumably, optimal reprogramming of cancer 
cells to a pluripotent state requires complete reversion of cancer epigenome 
into an ESCs-like state. However, a comprehensive survey of the epigenome 
changes in cancer-specific iPSCs has not been reported to date. It is, therefore, 
vital to address whether these epigenetic changes are necessary for nuclear 
reprogramming or a consequence of the process to determine to what extent 
epigenetic alterations influence the reprogramming process in tumors. In this 
study, we described a successful generation of induced pluripotent cancer cells 
(iPCCs) from non-small cell lung cancer (NSCLC) cell lines (termed as 
iPCCs-NSCLC). Following reprogramming, iPCCs-NSCLC possessed 
morphological, molecular and functional characteristics that similar to those of 
human ESCs. For the first time, our whole genome methylation analysis 
showed that aberrant cancer-associated methylomes were reversed upon direct 
reprogramming of NSCLC. The hypomethylation events observed in iPCCs-
NSCLC translated into restored gene expression and even stably maintained in 
the differentiated iPCCs-NSCLC. Moreover, the regulations of oncogenes and 
 xi 
 
tumor suppressors were reverted to normal upon induction of pluripotency and 
the reversal was partially explainable by DNA methylation. Moreover, direct 
reprogramming of NSCLC resulted in alterations of cisplatin sensitivity. 
Cisplatin-inflicted DNA damage elicited G1/S growth arrest via activation of 
p21 coupled with a reduction in the residual DNA double strand breaks foci in 
the differentiated iPCCs-NSCLC. Further dissecting the cisplatin resistant 
mechanism revealed hypermethylation in cisplatin resistant genes in the 
differentiated iPCCs-NSCLC, suggesting that direct reprogramming altered 
the drug sensitivity by reversing the cisplatin resistant genes. Together, this 
provide evidence that direct reprogramming of NSCLC reverses the aberrantly 
dysregulated genes in NSCLC both epigenetically and transcriptionally. 
 
iPSCs generation is an inefficient and slow process. Two contending 
models, namely the stochastic model and elite model was proposed for the 
mechanism of iPSCs generation. Despite the stochastic model prevails in 
explaining the inherent low efficiency of iPSCs generation, the same model 
cannot be said in the context of reprogramming cancer cells. Tumor is 
inherently heterogeneous and reprogramming cancer cells offers a suitable 
platform to test whether the reprogramming process is biased. We observed 
that all randomly picked iPCCs-NSCLC established previously do not possess 
mutations known in the parental cancer cell population. To explain such 
intriguing observations, we hypothesized that our starting cancer cell 
populations are heterogeneous with respect to varying degrees of genetic 
insults. Despite lack of experimental data supporting the heterogeneity in 
cancer cells, our study has shown that reprogramming of cancer cells enriches 
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a minor subpopulation which is mutation-free, against the majority. This 
unanticipated observation is most parsimoniously explained by the elite model, 
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Chapter 1 Introduction 
 
1.1 Pluripotency and cellular reprogramming 
 
Embryonic stem cells (ESCs) are pluripotent stem cells isolated from 
inner cell mass (ICM) of a pre-implantation embryo. ESCs represent an 
inexhaustible source of pluripotent cells that are self renewing which fulfill the 
following characteristics: (i) limitless proliferation capacity; (ii) express core 
pluripotency transcriptional regulatory genes, for instance, NANOG, OCT4 
and SOX2; (iii) possess high telomerase activity; and (iv) ability to 
differentiate into any of the three embryonic tissues, but not the 
extraembryonic tissues. The isolation of murine ESCs from mouse blastocycts 
was first reported in 1981 by two independent groups (Evans and Kaufman 
1981, Martin 1981). It was not until 1998, almost two decades after the 
derivation of murine ESCs, that the first human ESCs were successfully 
isolated from human embryos (Thomson, Itskovitz-Eldor et al. 1998).  
 
Since its initial isolation, ESCs have been widely used in investigating 
human development biology through in vitro differentiation. Moreover, 
genetically defective embryos were used to derive disease-specific human 
ESCs, thus providing a valuable tool to study a multitude of human genetic 
diseases, including thalassaemia, Fanconi anemia, neurofibromatosis type I, 
fragile-X syndrome, myotonic dystrophy, Marfan’s syndrome, Huntington’s 
disease, adrenoleukodystrophy, Duchenne and Becker muscular dystrophy 
(Verlinsky, Strelchenko et al. 2005). Nonetheless, the use of human embryos 
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in regenerative medicine has been fraught with ethical, legal and social 
controversies. To this end, researchers have developed alternative means to 
obtain pluripotent embryonic-like stem cells from terminally differentiated 
cells. These include somatic cell nuclear transfer (SCNT), cell fusion with 
pluripotent stem cells, exposure to pluripotent stem cell extracts and 
generation of induced pluripotent stem cells (iPSCs) using defined factors. 
 
1.1.1 Reprogramming by somatic cell nuclear transfer 
 
Cellular differentiation is a unidirectional process where there is a 
progressive restriction in cell plasticity and potency. It begins with the 
establishment of totipotent zygote to more restricted multipotent progenitors, 
and ends with the formation of 220 highly specialized cell types. In 1957, the 
biologist Conrad H. Waddington proposed an epigenetic landscape idea to 
illustrate the developmental pathways of a cell in an embryo. Each cell 
population is characterized by its unique epigenetic marks that correlated with 
its differentiation potential. Waddington, in his proposed epigenetic landscape, 
envisioned that cellular differentiation is like a ball rolls down a landscape of 
hills with valleys where the endpoint of each valley represent a discrete cell 
type. The potential of the ball (cell) to choose different valleys (cell fates) 
gradually decreased at each bifurcation point. For a long time, it is generally 
perceive that cell specialization is an irreversible process – when a cell had 
become specialized, it could not change its fate. Enormous progress has been 
made in the field of stem cells since the turn of the century. Discoveries have 
challenged the conventional paradigm that cellular differentiation is not as 
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irreversible as previously thought. In fact, differentiated cells can be 
reprogrammed to a less differentiated state under certain conditions.  
 
In 1952, in collaboration with Thomas K. King, Robert W. Briggs 
developed a novel approach, known as somatic cell nuclear transfer (SCNT) to 
assess nuclear potency of the differentiated cells (Briggs and King 1952). 
They transplanted the nucleus from an early stage embryo into an enucleated 
Rana pipiens egg, which then developed into normal embryos and thereafter 
normal tadpoles (Briggs and King 1952), and normal metamorphosed frogs in 
their subsequent study (Briggs and King 1960). It was not until 1962 that John 
B. Gurdon reported the first transplantation of nucleus from a fully 
differentiated cell. Gurdon, in his landmark paper, elegantly demonstrated that 
the transplantation of tadpole intestinal epithelium cell nuclei into enucleated 
Xenopus laevis eggs was able to support early development to the tadpole 
stage (Gurdon 1962). This experiment, together with his subsequent studies, 
provided the first clear evidence that cellular differentiation is not an 
irreversible process and the nucleus of a differentiated cell retains the genes 
required for normal development despite its specialization. The mammalian 
nuclear transfer experiments in subsequent years marked the major milestones 
in nuclear reprogramming (Bromhall 1975, McGrath and Solter 1983). 
Notably, it took more than a decade after the mammalian nuclear 
transplantation to the successful cloning of the first mammal Dolly the sheep 
from adult cells (Wilmut, Schnieke et al. 1997). Together, these experiments 
supported Gurdon’s initial finding that the genome of a fully specialized cell is 
able to support normal development.  
 4 
 
These remarkable discoveries have sparked the ideas of using SCNT to 
obtain pluripotent cells for cell replacement therapy. For instance, Rideout and 
his colleagues, in 2002, demonstrated the first proof-of-principle finding that a 
combination of SCNT and gene therapy was able to treat genetic disease 
(Rideout, Hochedlinger et al. 2002), indicating the potential application of 
SCNT in therapeutics. However, one of the major drawbacks of using SCNT 
for therapeutic application is its low induction efficiency (Byrne, Pedersen et 
al. 2007). Furthermore, nuclear transfer with human cells or cloning remains 
largely debatable and controversial. 
 
1.1.2 Reprogramming by cell fusion and cell-free extracts 
 
Another method for obtaining pluripotent ESCs-like cells is cell fusion 
where it involves the hybridization of a pluripotent cell with a normal somatic 
cell. A pioneered study carried out by Sir Henry Harris and John F. Watkins 
demonstrated that erythrocytes was activated upon fusion of Sendai virus with 
HeLa cell, a malignant cancer cell (Harris and Watkins 1965). This elegant 
experiment laid the groundwork for other researchers to explore the possibility 
of generating pluripotent ESCs-like cells using cell fusion. Miller and Ruddle 
in 1976 showed that the fusion between thymocytes and mouse embryonic 
carcinoma cells (ECCs) resulted in cell hybrids that adopted pluripotency 
phenotypes, similar to that of ECCs (Miller and Ruddle 1976). This suggested 
that the pluripotency phenotypes were not affected by the introduction of 
somatic cells. Moreover, the pluripotency phenotypes dominated over the 
somatic cells state in the cell hybrids fate. Thereafter, similar studies were 
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reported where the pluripotency phenotypes prevailed in the resulting cell 
hybrids when other pluripotent stem cells such as ESCs or embryonic germ 
cells (EGCs) were used (Sidhu and Han 2008). Fusion of human somatic cells 
with human ESCs was pioneered by Cowan and his coworkers in 2005, where 
the resulting cell hybrids acquired gene expressions, epigenetic status and 
differentiation ability similar to those of human ESCs (Cowan, Atienza et al. 
2005). Moreover, the resulting cell hybrids possessed a stable tetraploid DNA 
content. Matsumura and coworkers, in the subsequent year, reported a 
selective elimination of specific ESCs-derived chromosomes from tetraploid 
ESCs-somatic cell hybrids (Matsumura, Tada et al. 2006). The removal of a 
complete set of chromosomes from the tetraploid ESCs-somatic cell hybrids, 
nonetheless, has yet to be determined and the tetraploid DNA content remains 
a major hurdle for its use in clinical application.  
  
 An alternative approach to reprogram somatic cells involves the use of 
nuclear and cytoplasmic extracts, with the rationale that the essential 
regulatory components can be found in these extracts. The potential of egg 
extracts in the nuclear process, especially in chromatin remodeling, has been 
extensively studied in the last decade (Wangh, DeGrace et al. 1995, Kikyo, 
Wade et al. 2000). In 2002, Håkelien and coworkers reported that terminally 
differentiated cells were able to express T cell-specific functions when 
incubated in a T-cell extract (Håkelien, Landsverk et al. 2002). Later, 
Taranger and his colleagues showed a successful induction of pluripotency in 
differentiated cells following the reprogramming using extract from a 
pluripotent human carcinoma cell line (Taranger, Noer et al. 2005). However, 
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reprogramming somatic cells using cell extracts has severe technical and 
practical limitations that hamper the development and widespread application 
of this method. 
 
1.1.3 Reprogramming by defined factors 
 
 An alternate method to embryo- and oocyte-based reprogramming 
involves the use of defined factors. The pioneering study by Taylor and Jones 
in 1979 demonstrated the induction of new mesenchymal phenotypes, 
including myogenic cells, adipocytes and chondrocytes in fibroblast cell lines 
following treatment with 5-azacytidine, a DNA demethylating agent (Taylor 
and Jones 1979). Their findings provided solid evidence that genes in 
fibroblasts were able to be demethylated and such demethylation allowed the 
phenotypic switch to other cell types. Later in 1987, Robert Davis and his 
colleagues, in an elegantly designed set of experiments, demonstrated that a 
single transcription factor myoblast differentiation protein 1 (MYOD1) could 
induce myoblast-like phenotype in fibroblast cell lines (Davis, Weintraub et al. 
1987). Similarly, another group also reported a stepwise reprogramming of B 
cells into macrophages by inhibiting PAX5, a B cell commitment transcription 
factor (Xie, Ye et al. 2004). These remarkable contributions laid the 
foundation for subsequent breakthrough in induced pluripotency.  
 
In 2006, Takahashi and Yamanaka screened a panel of 24 
pluripotency-associated candidate genes in an attempt to identify 
transcriptional regulators necessary for reprogramming differentiated cells 
 7 
 
(Takahashi and Yamanaka 2006). For this purpose, a fusion of the neomycin-
resistant gene and β-galactosidase (a β-geo cassette) were knocked into the 
mouse F-box protein 15 (FBX15) gene locus by homologous recombination. 
FBX15 expression is indispensable for mouse ESCs development as well as 
self-renewal (Tokuzawa, Kaiho et al. 2003). The combination of 24 factors 
was transduced into FBX15-reporter-fibroblasts retrovirally. Upon obtaining 
pluripotency, cells expressing the neomycin resistance gene became resistant 
to G418 selection, which in turn gave rise to drug-resistant ESCs-like colonies 
formation. A minimally required core set of four genes, namely c-MYC, 
Kruppel-like factor 4 (KLF4), octamer-binding transcription factor 4 (OCT4) 
and sex-determining region Y (SRY)-box 2 (SOX2) was identified after 
stepwise elimination of the transcription factors. These FBX15-selected 
induced pluripotent stem cells (iPSCs) resembled ESCs in their ESCs-specific 
markers expression and in vivo teratoma formation. Furthermore, they were 
able to give rise to various tissues of an embryo upon blastocyst injection. 
These iPSCs, nonetheless, failed to produce germline chimeras, suggesting an 
incomplete reprogramming in these first-generation of iPSCs.  
 
In the same vein, Yu and coworkers screened a panel of 14 ESCs-
enriched genes that are implicated in pluripotency and self-renewal of human 
ESCs (Yu, Vodyanik et al. 2007). The combination of 14 genes was 
lentivirally transduced into a differentiated derivative of an OCT4 knock-in 
human ESCs lines. They identified a core set of 4 genes, namely LIN28, 
NANOG, OCT4 and SOX2 which were sufficient to activate OCT4 promoter in 
the differentiated cells and reprogram them back to an ESCs-like state. 
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Subsequently, a team led by Yamanaka reported an improvement in iPSCs 
pluripotency by replacing the selection marker for reprogrammed cells from 
FBX15- to NANOG-expression (Okita, Ichisaka et al. 2007). Within the same 
year, other groups also reported similar findings using either NANOG- or 
OCT4-expression as indicators of reprogramming (Maherali, Sridharan et al. 
2007, Wernig, Meissner et al. 2007). Functionally, these iPSCs not only 
contributed to teratoma, they also gave rise to chimeric mice and adult 
germline, thus suggesting that these iPSCs have similar developmental 
potency with those of ESCs (Boland, Hazen et al. 2009, Kang, Wang et al. 
2009, Zhao, Li et al. 2009). 
 
1.2 Advances in iPSCs derivation 
 
The major caveats in the use of ESCs and their derived cells include 
the destruction of embryos and lack of identical genetics between donor and 
recipient cells. The arrival of iPSCs technology has opened a new page for 
translational medicine. These iPSCs not only have genetic fundamental 
advantages than ESCs, they are also amenable to in vitro genetic manipulation 
and ex vivo expansion, therefore constituting an alternate source of autologous 
cells. To date, human iPSCs have been derived from a broad range of somatic 
cells, such as skin fibroblasts, cord blood cells and peripheral blood 
mononuclear cells (Giorgetti, Montserrat et al. 2009, Loh, Agarwal et al. 
2009), keratinocytes (Aasen, Raya et al. 2008), pancreatic β cells (Stadtfeld, 
Brennand et al. 2008), amniotic fluid-derived cells (Li, Zhou et al. 2009) and 
adult stem cells (Kim, Greber et al. 2009, Sun, Panetta et al. 2009), indicating 
 9 
 
the universality of induced pluripotency. However, different tissues show 
variable susceptibility to reprogramming (Aoi, Yae et al. 2008, Maherali, 
Ahfeldt et al. 2008, Kim, Doi et al. 2010). Besides mouse (Takahashi and 
Yamanaka 2006) and human (Takahashi, Tanabe et al. 2007, Yu, Vodyanik et 
al. 2007), iPSCs have also been generated from other mammals, such as rat (Li, 
Wei et al. 2009, Liao, Cui et al. 2009), pig (Esteban, Xu et al. 2009), rhesus 
monkey (Liu, Zhu et al. 2008) and marmoset (Wu, Zhang et al. 2010), 
suggesting an evolutionary conservation of the transcriptional circuitry for 
pluripotency across different species. 
 
In addition, iPSCs hold immense potential for disease modeling and 
drug development. Till date, iPSCs have been derived from patients suffering 
from neurological disorders including familial dysautonomia (Lee, Papapetrou 
et al. 2009), Rett’s syndrome (Marchetto, Carromeu et al. 2010), spinal 
muscular atrophy (Ebert, Yu et al. 2009), Duchenne and Becker muscular 
dystrophy, Down syndrome, Parkinson’s disease and Huntington’s disease 
(Park, Arora et al. 2008); hematological diseases, for instance sickle-cell 
anemia (Ye, Chang et al. 2009), Shwachman-Bodian-Diamond syndrome and 
adenosine deaminase deficiency-related severe combined immunodeficiency 
(Park, Arora et al. 2008); and metabolic diseases such as Gaucher disease type 
III, juvenile onset type I diabetes mellitus and Lesch-Nyhan syndrome (Park, 
Arora et al. 2008). There is a growing body of evidence demonstrating that 
these disease-specific iPSCs were able to recapitulate cellular disease 
phenotypes (Lee, Papapetrou et al. 2009, Itzhaki, Maizels et al. 2011). 
Moreover, recent experiments by Jaenisch’s group have demonstrated 
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dramatic rescue effects in the disease phenotypes after engrafting gene-repair 
sickle-cell anemia iPSCs- and Parkinson’s iPSCs-derived differentiated cells 
into the diseased mice model (Hanna, Wernig et al. 2007, Wernig, Zhao et al. 
2008). These findings provide proof-of-concept for the application of disease-
specific iPSCs, coupled with gene correction technology, in disease treatment. 
 
1.2.1 Factor delivery into target cells 
 
Induction of pluripotency in differentiated cell types can be achieved 
by the addition of defined transcription factors. These factors can be delivered 
by integrative viral system, for instance, retroviral, lentiviral and inducible 
lentiviral vectors where the reprogramming vectors are integrated randomly 
into the host genome. Retroviral vectors provide prolonged defined factors 
expression, a fundamental advantage than other viral vectors, which is 
essential for efficient reprogramming.  
 
Unlike integrating viral vectors, excisable vectors such as the 
piggyback transposon system (Woltjen, Michael et al. 2009) and loxP-flanked 
lentiviral vectors; non-integrating vectors such as adenoviral (Stadtfeld, 
Nagaya et al. 2008, Zhou and Freed 2009) and plasmid vectors (Okita, 
Nakagawa et al. 2008) are developed to minimize genomic integration. In 
addition, integration-free iPSCs have been successfully generated by DNA-
free methods, for instance, synthesized mRNA (Warren, Manos et al. 2010), 
direct protein delivery (Kim, Kim et al. 2009), Sendai virus (Fusaki, Ban et al. 
2009), episomal vectors (Yu, Hu et al. 2009), microRNA (miRNA) and 
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minicircle vector (Jia, Wilson et al. 2010). However, one major caveat of 
integration-free reprogramming methods is the impractically low 
reprogramming efficiency in most cases. Furthermore, preparing synthesized 
RNA or modifying Sendai virus vectors is technically challenging. Moreover, 
direct delivery of proteins or RNA is labor-intensive and requiring repeated 
delivery of the reprogramming factors. 
 
Alternatively, small molecules or chemical compounds which target at 
ESCs signaling pathways or epigenetic modifications are used to enhance 
reprogramming efficiency or even replace individual factors. These chemical 
genetics include histone deacetylase inhibitors such as valproic acid (Huangfu, 
Osafune et al. 2008) or butyrate (Ware, Wang et al. 2009); histone 
methyltransferase inhibitors BIX 01294 (Shi, Do et al. 2008); vitamin C 
(Esteban, Wang et al. 2010); transforming growth factor-beta (TGFβ) receptor 
inhibitor SB 431542 (Ichida, Blanchard et al. 2009) and a combination of a 
chromatin-associated protein, undifferentiated embryonic cell transcription 
factor 1 (UTF1) and anti-p53 specific small interfering RNA (Zhao, Yin et al. 
2008). 
 
1.3 Mechanisms of iPSCs generation 
 
iPSCs generation involves a complex multi-step cascade of events, 
which is a slow kinetic (approximately four weeks) and highly inefficient (≤ 
0.01%) process (Plath and Lowry 2011). In the early phase of reprogramming, 
cells exhibit noticeable changes in the cellular morphology and proliferation 
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rate (Hanna, Saha et al. 2009, Ruiz, Panopoulos et al. 2011). Using high-
resolution, time-lapse imaging technology, Smith and coworkers demonstrated 
that successfully reprogrammed cells underwent dramatic change in their 
cellular proliferation rate coupled with a decrease in cell size as early as 24 
hours after forced expression of defined transcription factors (Smith, Nachman 
et al. 2010). At the molecular level, somatic programmes associated with the 
maintenance of cellular identity are silenced (Mikkelsen, Hanna et al. 2008).  
 
During the middle phase of reprogramming, somatic cells undergo 
mesenchymal-to-epithelial transition (MET) where cells acquire epithelial 
cells characteristics (Takahashi and Yamanaka 2006, Qin, Li et al. 2007, 
Samavarchi-Tehrani, Golipour et al. 2010). Pro-epithelial-to-mesenchymal 
transition (EMT) signals are suppressed by c-MYC, OCT4 and SOX2; whereas 
KLF4 activates E-cadherin and other epithelial genes during reprogramming 
(Li, Liang et al. 2010). Moreover, blockade of MET impairs the 
reprogramming process whereas suppression of EMT in epithelial cells allows 
the derivation of iPSCs without c-MYC and KLF4 (Li, Liang et al. 2010).  
 
Late phase of reprogramming involves the establishment of core 
pluripotency network. Increasing studies have reported that the induction of 
pluripotency in somatic cells is often accompanied by extensive remodeling of 
epigenetic marks (Mikkelsen, Hanna et al. 2008, Hawkins, Hon et al. 2010, 
Koche, Smith et al. 2011). These include the loss of repressive histone 
methylation marks and DNA demethylation at the pluripotency genes 
(Mikkelsen, Hanna et al. 2008, Bhutani, Brady et al. 2010, Hawkins, Hon et al. 
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2010), implying the fundamental significance of epigenetic regulation in cell 
state transition. The reprogrammed state, once attained, is stably maintained 
(Brambrink, Foreman et al. 2008, Stadtfeld, Maherali et al. 2008).  
 
1.3.1 Role of reprogramming factors in iPSCs generation 
 
Octamer-binding transcription factor 4 (OCT4), also known as octamer 
4 or POU domain class 5 homeobox 1 (POU5F1) or OCT3, was the first factor 
that reported to be ubiquitously expressed in early embryos and ESCs (Scholer, 
Hatzopoulos et al. 1989). Subsequent studies have proven that OCT4 
expression is pivotal for in vivo ICM development, as well as ESCs 
maintenance (Nichols, Zevnik et al. 1998). It tightly regulates target genes that 
are involved in maintaining pluripotency. Upregulation in OCT4 expression 
causes ESCs to differentiate into mesoderm and primitive endoderm, while 
suppression of OCT4 results in loss of pluripotency and dedifferentiation to 
trophectoderm, suggesting that the precise OCT4 levels are necessary for 
pluripotency maintenance (Niwa, Miyazaki et al. 2000). In addition, OCT4 
heterodimerizes in a complex with sex-determining region Y (SRY)-box 2 
(SOX2), in maintaining ESCs pluripotency (Boiani and Scholer 2005). 
However, unlike OCT4, SOX2 expression is not specific to pluripotent stem 
cells (Brafman, Moya et al. 2013).  
 
Kruppel-like factor 4 (KLF4), the third member of Yamanaka’s quartet, 
can both activate and repress transcription. It functions both as an oncogene 
and tumor suppressor (Zhao, Hisamuddin et al. 2004). Despite its exact role in 
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reprogramming is largely unknown, studies has suggested that the induction of 
apoptosis is probably inhibited by KLF4 expression (Rowland, Bernards et al. 
2005). Moreover, a genome-wide mapping of the four transcription factor 
binding sites has revealed that OCT4 and SOX2 co-occupy promoters of 
highly expressed genes, and KLF4 shares approximately half of the targets 
with these two transcription factors (Sridharan, Tchieu et al. 2009).  
 
The c-MYC oncoprotein belongs to a family of basic-helix-loop-helix-
Zip. Its pleiotropic roles has been implicated in various cellular responses, 
include cellular proliferation, growth, cell cycle regulation, differentiation and 
metabolism (Schmidt 1999). Studies have shown that c-MYC is the key 
effector of the LIF/STAT3 self-renewal pathways and increased level of c-
MYC is dispensable for ESCs proliferation (Cartwright, McLean et al. 2005, 
Xu, Wei et al. 2013). Although the precise role of c-MYC in direct 
reprogramming is not well understood, studies have suggested that c-MYC 
may be pivotal to immortalize the cells and to open the chromatin (Knoepfler, 
Zhang et al. 2006).  
 
Alternatively, reprogramming can be induced by NANOG, LIN28 (Yu, 
Vodyanik et al. 2007) and other factors which promote the establishment of 
the core transcriptional circuitry of ESCs. Homeoprotein Nanog is 
indispensable in maintaining ESCs cell identity (Chambers, Colby et al. 2003). 
Lack of NANOG causes differentiation of ESCs into extraembryonic 
endoderm cells (Mitsui, Tokuzawa et al. 2003). Together with NANOG, OCT4 
and SOX2 form the core transcriptional regulatory circuitry that is important 
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for ESCs identity (Chambers and Smith 2004, Boyer, Lee et al. 2005). These 
factors co-activate other target of the many factors in ESCs that further 
provide stability to the ESCs state (Chen, Xu et al. 2008). On the other hand, 
LIN28, a highly conserved RNA-binding protein, is ubiquitously expressed in 
early embryos, ESCs and ECCs (Yang and Moss 2003, Darr and Benvenisty 
2009). LIN28 has been found to be involved in pluripotency, development, 
and metabolism. Its expression is repressed during the differentiation of ESCs 
(Yang and Moss 2003, Darr and Benvenisty 2009). 
 
1.3.2 Epigenetic modifications underlying iPSCs generation 
 
Recent high-throughput global profiling revealed that iPSCs shared 
high similarities in gene expression and epigenomes with those of ESCs 
(Okita, Ichisaka et al. 2007, Takahashi, Tanabe et al. 2007, Yu, Vodyanik et al. 
2007). The promoters of pluripotency genes in normal somatic cells are 
methylated, reflecting their transcriptionally repressed state. On the contrary, 
iPSCs derivation involves demethylation at these promoters, thus leading to 
reactivation of endogenous pluripotency-associated genes as well as repression 
of lineage-specifying genes (Mikkelsen, Hanna et al. 2008, Deng, Shoemaker 
et al. 2009). Moreover, the promoters occupied by the reprogramming 
transcription factors in iPSCs resemble to those of ESCs, and this correlates 
well with their closely-related global transcriptome profiles. In addition, large 
scale chromatin analysis revealed that there is a high similarity in the 
chromatin structure map between iPSCs and ESCs (Mikkelsen, Hanna et al. 
2008, Guenther, Frampton et al. 2010), implying that ESCs and iPSCs were 
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nearly identical cell types. Similarly, analysis of whole-genome, single-base 
profiling of DNA methylomes revealed that iPSCs and ESCs have very similar 
DNA methylation patterns (Maherali, Sridharan et al. 2007, Mikkelsen, Hanna 
et al. 2008, Doi, Park et al. 2009, Lister, Pelizzola et al. 2011), particularly at 
pluripotency-related genes, transcription factor-binding sites and enhancers 
region (Lister et al., 2011). 
 
Despite sharing high similarities, iPSCs and ESCs are not identical 
(Mikkelsen, Hanna et al. 2008, Deng, Shoemaker et al. 2009, Doi, Park et al. 
2009, Polo, Liu et al. 2010, Bock, Kiskinis et al. 2011). These cancer-derived 
iPSCs harbor surface markers or oncogenes as their parental counterparts, and 
these oncogenes are not detected in ESCs (Miyoshi, Ishii et al. 2010). 
Moreover, the variations could be attributed to iPSCs-specific differential 
DNA methylation. Differentially methylated regions (DMRs) that were 
aberrantly methylated seem to be common in several independent iPSCs lines, 
suggesting that some genomic areas may be susceptible to aberrant 
methylation in iPSCs (Lister, Pelizzola et al. 2011). Further, DNA 
demethylation is a bottleneck in inducing somatic cells to iPSCs (Mikkelsen, 
Hanna et al. 2008) and active demethylation is necessary for induction of 
pluripotency in human somatic cells (Bhutani, Brady et al. 2010). On top of 
that, these variations could be attributed to the somatic epigenetic memory in 
early passages of iPSCs (Kim, Doi et al. 2010, Ohi, Qin et al. 2011, Zhu, 
Lensch et al. 2011). Such epigenetic memory may influence the iPSCs 
differentiation susceptibility (Polo, Liu et al. 2010, Bar-Nur, Russ et al. 2011, 
Kim, Zhao et al. 2011). Serial passage of these iPSCs, however, decreased the 
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deviations between ESCs and iPSCs, suggesting the progressive loss of 
epigenetic memory in iPSCs and accustom to closely resemble ESCs over 
time (Chin, Mason et al. 2009, Polo, Liu et al. 2010, Nishino, Toyoda et al. 
2011, Ohi, Qin et al. 2011).  
 
1.3.3 Stochastic or elite event for iPSCs generation 
 
Generation of iPSCs from most somatic cells is often characterized by 
asynchronous, slow speed and low efficiency (0.01 to 0.1%). Moreover, the 
overall reprogramming efficiency remains low (< 5%) even when somatic 
cells homogeneously express the defined transcription factors. In view of this, 
Yamanaka proposed two models, namely the stochastic model and elite model, 
to account for the low reprogramming efficiency (Yamanaka 2009). The 
stochastic model proposes that every cell is equally amenable to 
reprogramming by transcription factors. Only a few cells, however, may pass 
the stochastic epigenetic roadblocks before attaining pluripotency, resulting in 
the overall low efficiency (Hanna, Saha et al. 2009). By elite model definition, 
only a subset of cells in a cell population is susceptible to reprogramming, thus 
resulting in low reprogramming efficiency. Current evidences seem to favor 
the stochastic model, which suggesting that each cell can be induced to 
pluripotency given that appropriate combination of reprogramming factors 
(Yamanaka 2009). Using a homogenous population as starting cell, Hanna et 
al. (2009) reported that direct reprogramming of B-cell lineage-committed 
monoclonal populations followed a continuous stochastic process where 
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majority, if not all, have the potential to give rise to iPSCs, albeit with 
different latencies (Hanna, Saha et al. 2009).  
 
Although the stochastic model prevails in explaining the low efficiency 
of iPSCs generation, it is possible that certain types of the cells follow elite, a 
non-stochastic model. Byrne and his colleagues reported that stage-specific 
embryonic antigen 3 (SSEA3+) fibroblasts demonstrated enhanced iPSCs 
generation efficiency, meanwhile no iPSCs colonies were seen in 
reprogrammed SSEA3- fibroblasts (Byrne, Nguyen et al. 2009). However, the 
characteristics of these SSEA3+ fibroblasts were not studied and the process of 
iPSCs generation from these SSEA3+ fibroblasts remains elusive. Similarly, 
Utikal et al. showed that fibroblasts with low ARF expression are more prone 
to reprogramming than those with higher ARF transcript level, corroborated 
with the notion that the existence of elite cells in cell populations (Utikal, Polo 
et al. 2009). In addition, there is increasing studies suggesting that certain cell 
types and their differentiation status affect the reprogramming efficiency 
(Eminli, Foudi et al. 2009). Wakao and coworkers reported that only 
multilineage-differentiating stress-enduring (Muse) cells, a subset of 
preexisting adult stem cells in human dermal fibroblasts can give rise to iPSCs 
colonies upon c-MYC, KLF4, OCT4 and SOX2 transduction (Wakao, Kitada et 
al. 2011). However, no iPSCs colony was derived in non-Muse cells following 
the same transduction protocol, suggesting that elite model was more 
favorable in the context of Muse cells. A recent finding reported similar 
phenomenon in somatic cell reprogramming. Guo and colleagues reported that 
the existence of privileged somatic cells, characterized by unusually fast cell 
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cycle, acquire pluripotency in a non-stochastic manner (Guo, Zi et al. 2014). 
Further analysis on the underlying mechanism to account for such differential 
reprogramming competency will pave way towards the wide applications of 
iPSCs technology in basic science and regenerative medicine.    
 
1.4 Induction of pluripotency in cancer cells 
 
Recent advances in stem cell research open a new perspective to study 
the biology of different diseases, including cancer. In 1969, McKinnell and 
coworkers, in their pioneer frog experiments, demonstrated that 
transplantation of nuclei from renal carcinoma to enucleated oocytes was able 
to give rise to an early development of a normal tadpole (McKinnell, Deggins 
et al. 1969). Similarly, transplanted medulloblastoma nuclei led to a 
preimplantation development (Li, Connelly et al. 2003). It is not until 2004 
where Konrad Hochedlinger demonstrated the first proof-of-principle study 
that cancer nuclei can support preimplantation development to the blastocyst 
stage and gave rise to ESCs when they transplanted nuclei from melanoma 
into enucleated oocytes (Hochedlinger, Blelloch et al. 2004), suggesting that 
cancer cells are amenable to nuclear reprogramming. Nonetheless, in the same 
study, transplantation of nuclei from leukemia, lymphoma and breast cancer 
cells failed to produce ESCs (Hochedlinger, Blelloch et al. 2004), implying 
that not all cancer genomes can be epigenetically reprogrammed to achieve 
pluripotency. The discovery of human iPSCs further revolutionized the field 




A growing body of studies have reported the successful 
reprogramming of a number of solid tumors and derived tumor cell lines, both 
from humans and animals. For instance, melanoma (Lin, Chang et al. 2008, 
Utikal, Maherali et al. 2009, Yin, Fan et al. 2013), gastric cancers (Miyoshi, 
Ishii et al. 2010), pancreatic adenocarcinoma (Kim, Hoffman et al. 2013), 
chronic myeloid leukemia (CML) (Carette, Pruszak et al. 2010), sarcoma 
(Zhang, Cruz et al. 2013), prostate cancer (Vencio, Nelson et al. 2012), breast 
cancer (Allegrucci, Rushton et al. 2011) and ECCs (Chang, Miao et al. 2010) 
have been reprogrammed using different reprogramming methods. Upon 
reprogramming, cancer-specific iPSCs express pluripotency markers and 
acquire the differentiation ability to give rise to tissues of all three germ layers, 
be it in vitro and in vivo (Carette, Pruszak et al. 2010, Miyoshi, Ishii et al. 
2010, Zhang, Cruz et al. 2013). Interestingly, in vivo experiments revealed a 
reduction of tumorigenicity in colorectal cancer cells DLD-1 (Miyoshi, Ishii et 
al. 2010). In addition, differentiated iPCCs showed higher sensitivity to 
chemotherapy with respect to their parental counterparts (Miyoshi, Ishii et al. 
2010). Similarly, exposure of breast cancer nuclei with amphibian oocyte 
extract was able to attenuate the malignant phenotypes of breast cancer cells 
MCF7 and HCC1945 (Allegrucci, Rushton et al. 2011). Zhang and coworkers 
recently showed that all reprogrammed sarcoma cells became less aggressive 
or proliferative following ectopic expression of four canonical Yamanaka 





1.4.1 Reprogramming and oncogenic transformation 
 
Compelling evidence has shown that reprogramming to pluripotency 
and oncogenic transformation share some common ground (Banito and Gil 
2010). For instance, constitutive expression of oncogenes activates oncogene-
induced senescence in somatic cells, which in turns limits the oncogenic 
transformation. When senescence mechanism is disabled, cells become more 
susceptible to oncogenic transformation, yielding cells with limitless 
proliferation capacity, a characteristic shared with iPSCs. Similarly, 
reprogramming-induced senescence is a barrier in the reprogramming process 
(Banito, Rashid et al. 2009) and ablation of senescence effectors dramatically 
increase the reprogramming efficiency. However, it is unlikely to delineate the 
mechanisms of oncogenic transformation using patient samples or established 
cancer cells where oncogenic transformation events have already occurred. As 
such, cancer-derived iPSCs could be useful to clarify the links between 
pluripotency and tumorigenesis and shed lights to the key players that 
influence tumor progression. A recent proof-of-concept study by Kim and his 
coworkers demonstrated that human iPSCs derived from human pancreatic 
ductal adenocarcinoma was able to model different stages of carcinogenesis, 
from cancer initiation to the hierarchical organization of established 
malignancies (Kim, Hoffman et al. 2013). Moreover, using pancreatic cancer 
derived-iPSCs, a previously unappreciated network, i.e., HNF4α network in 
pancreatic cancer was found to be associated with early- to intermediate- stage, 
and this sheds light on discovery of potential biomarkers in early to 
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intermediate stages of the disease. Notably, these cancer-derived iPSCs have 
essential advantages over animal models of human cancers in consideration of 
their diverse genetic backgrounds and unable to fully recapitulate many 
aspects of original human cancers.  
 
In addition, reprogramming cancer cells to a pluripotent state provides 
a novel tool in modeling cancer pathogenesis as well as drug resistance. 
Reprogramming cancer cells results in an immature state of cells which allow 
them to redifferentiate, a characteristic lack in aggressive malignant tumors. 
Moreover, these cancer-specific iPSCs which can further differentiated into 
the various tissues affected in each condition may serve as alternative to study 
the underlying mechanism on a cellular level. It allows the study of the 
interaction of specific oncogenic mutations with different tissues types. This 
was elegantly demonstrated in chronic myeloid leukemia (CML), a clonal 
disorder that originates from hematopoietic stem cells caused by BCR-ABL 
oncoprotein. Previously, Carette and coworkers reported that, unlike 
hematopoietic cells, the neuronal cells and fibroblast-like cells differentiated 
from the reprogrammed CML acquired resistance to imatinib (Gleevec), a 
BCR-ABL tyrosine kinase inhibitor (Carette, Pruszak et al. 2010). This 
indicates that a specific differentiated epigenetic cell state (hematopoietic cells 
in this case) is needed to maintain BCR-ABL oncogene dependency. Moreover, 
reprogramming imatinib-sensitive CML resulted in lost of BCR-ABL oncogene 
dependency in the reprogrammed CML although they consistently expressing 
BCR-ABL oncoprotein (Kumano, Arai et al. 2012). Further delineation of the 
imatinib resistance showed a significant reduction in the phosphorylation of 
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signal transducer and activator of transcription 5 (STAT5) and CRKL in 
reprogrammed CML (Kumano, Arai et al. 2012), implying that the signaling 
for pluripotency might compensate for the inhibition of oncogenic signals 
during the reprogramming process. This may explain why imatinib has been 
unable to completely eradicate the recurrence of the BCR-ABL clone.  
 
1.4.2 Reprogramming and cancer epigenetics 
 
The advent of induced pluripotency in cancer research has opened up 
unchartered territories for oncologists to further understand cancer. Cancer is a 
complex disease and it evolves by a dynamic process of clonal expansion, 
genetic diversification and clonal selection (Greaves and Maley 2012). 
Classical tumor formation theory, i.e., clonal evolution theory, suggests that 
each cell in a tumor is biological homogenous (Nowell 1976), whereas the 
alternative theory considers that the cells within cancer are not identical, 
which is also known as tumor heterogeneity (Park, Bergsagel et al. 1971). 
Isaiah J. Fidler and Margaret L. Kripke, in their landmark paper, demonstrated 
that tumor is inherently heterogeneous and tumor cell variants arose within 
developing tumors with respect to metastatic ability (Fidler and Kripke 1977). 
The diversity of biological capabilities in cancer cells is attributed to the 
genomic instability due to genetic alterations and epigenetic modifications.  
 
Aneuploidy hypothesis of cancer formation was first proposed by a 
German biologist, Theodor Boveri. In 1914, Boveri, in his seminal experiment, 
proposed that malignant cells could arise from a failure of chromosome 
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segregation during cell division (Boveri 1914). Gain or loss in chromosomes 
number or aneuploidy destabilizes the karyotype and increases the 
spontaneous rate of gene mutations, resulting in cell functions dysregulation 
which eventually lead to cancer (Li, Sonik et al. 2000, Duesberg, Fabarius et 
al. 2004). Another popular hypothesis of cancer formation is gene mutation. 
Somatic gene mutation hypothesis predicts that cancer arises with a genetic 
change in a single cell that is passed down to its progeny, thereby forming a 
clone of malignant cells (Tyzzer 1916, Muller 1928). This hypothesis predicts 
that cancer is irreversible and till date, spurious mutations are sufficient to 
cause malignant transformation (Hanahan and Weinberg 2000). Despite the 
debatable of aneuploidy and gene mutation theories of cancer, it is nowadays 
widely accepted that epigenetic dysregulation play a pivotal role in 
tumorigenesis (Sharma, Kelly et al. 2010). Epigenetic marks, which are 
reversible, entail stable changes in the downstream gene expression. 
Dysregulation in DNA methylation or histone modification results in either 
upregulation of oncogenes or aberrant silencing of tumor suppressors and 
plays an important role in tumor initiation and progression.  
 
Recent advances in high resolution, high throughput profiling assays 
has been shown that direct reprogramming of cancer cells reset and reestablish 
repertoire epigenetic signatures of cancer cells, while leaving untouched their 
genetic mutations (Dewi, Ishii et al. 2012). Considering epigenetic plays a 
pivotal role in altering cancer cell status, the iPSCs technology or epigenome 
modification using defined factors would be useful in understanding the nature 
of cancer cells and facilitating the study of the relative importance between 
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cancer genetics and cancer epigenetics. A study led by Ron-Bigger and 
coworkers have reported the reversal of epigenetically silenced tumor 
suppressors in immortalized cells upon induction of pluripotency (Ron-Bigger, 
Bar-Nur et al. 2010). Restored tumor suppressor expression was stably 
maintained and passed on when the cells were induced to differentiate. 
Similarly, exposure of breast cancer nuclei with Xenopus laevis oocyte extract 
was able to demethylate as well as remove the repressive histone marks at the 
promoters of tumor suppressors in breast cancer cells MCF7 and HCC1945 
(Allegrucci, Rushton et al. 2011). In agreement with previous studies, Zhang 
and his colleagues reported that reprogramming sarcoma cells results in an 
epigenetic alteration in c-MYC promoter as well as other oncogenes where 
they became permissive to being silenced when differentiated (Zhang, Cruz et 
al. 2013). This suggests that epigenetically modifying a reprogrammed cancer 
cell could correct some malignant effects of aberrant oncogene activation and 




As described in the preceding sections of chapter 1, optimal cancer 
cells reprogramming, presumably, resets cancer epigenome into an ESCs-like 
state. Despite its significance, a compendious study of the epigenome 
alterations in iPCCs has not been reported. It remains to be determined 
whether these cancer derived-iPCCs still retain epigenetic memory of the 
original cancer cells. Considering that reprogrammed cancer cells recapitulate 
the exact genetic complement and potentially the epigenetic variation of the 
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cell population, it allows us to understand whether these epigenetic changes 
are necessary for nuclear reprogramming or a consequence of the process to 
determine the extent to which epigenetic alterations influence the 
reprogramming process in tumors. This project has been dedicated to examine 
the effects of direct reprogramming on cancer cells and adds knowledge of 
cancer cell reprogramming by answering the following questions in the 
proceeding chapters.  
 
 Can human cancer cells, particularly NSCLC cells, be reprogrammed 
using defined transcription factors? (Discuss in Chapter 3) 
 To what extent does NSCLC cancer cell reprogramming alter cancer-
associated epigenetic alterations? (Discuss in Chapter 3) 
 To what extent does NSCLC cancer cell reprogramming alter drug 
sensitivity in cancer cells and their differentiated cells? (Discuss in 
Chapter 4) 
 What is the underlying mechanism for cancer cell reprogramming? 
(Discuss in Chapter 5) 
 
1.5.1 Study model 
 
Lung cancer is leading cause of cancer death in both men and women. 
Early detection of lung cancer can improve survival rate. However, current 
diagnostic tools are not sensitive enough to allow for early detection. More 
than two-thirds of the lung cancers are diagnosed at advanced stage with 
limited curative treatment options. The overall prognosis of lung cancer 
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remains lugubrious, with only 15% of lung cancer patients survive more than 
5 years (Siegel, Naishadham et al. 2012). Lung cancer can be further classified 
into two subgroups: small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC). NSCLC constitute 85% of all lung cancers. An estimated 
20% of all lung cancers are attributable to genetic and/or environmental 
determinants while the remaining are caused by cigarette smoking (Khuder 
2001). Moreover, only minority of heavy smokers will develop lung cancer 
(Mattson, Pollack et al. 1987, Peto, Darby et al. 2000), suggesting the potential 
roles of genetic and/or environmental factors in lung cancer formation. In view 
of its high incidence and mortality rates, we chose to reprogram lung cancer 
cells, particularly NSCLC, in this project. Two NSCLC cell lines, namely lung 
adenocarcinoma NCI-H358 and large cell carcinoma NCI-H460 were used. 
H358 carries homozygously deleted TP53 (Takahashi, Nau et al. 1989), while 
H460 was reported to be CDKN2A homozygous deleted (Ikediobi, Davies et al. 
2006) and CDKN2B mutant (our unpublished data). 
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Chapter 2 Materials and Methods 
 
2.1 Cell culture 
2.1.1 Cell lines 
 
CF-1 mouse embryonic fibroblasts (MEFs) were purchased from 
Biopolis Shared Facilities A*STAR. HEK-293 lentiviral packaging cell, HeLa 
and IMR90 were purchased from American Type Culture Collection (ATCC), 
Manassas, VA. Platinum-E (Plat-E) retroviral packaging cells were obtained 
from Cell Biolabs, Inc., San Diego, CA. Human ESCs i.e., HES-3, H1 and H9 
were courtesy of Professor Alan Colman. NCI-H358 (H358) and NCI-H460 
(H460) were kind gifts from Dr Matiullah Khan and Professor Phillip Koeffler, 
which were directly purchased from ATCC. Cell line authentication was 
validated at Centre for Translational Research and Diagnostics (CTRAD), 
Cancer Science of Institute of Singapore by short tandem repeat (STR) DNA 
fingerprinting using the Promega GenePrint® 10 System according to 
manufacturer’s instructions. The STR profiles were compared to standard 
ANSI/ATCC ASN-0002-2011 and to the Deutsche Sammlung von 
Mikroorganism and Zelkulturen (DSMZ, www.dsmz.de; includes ATCC, 
DSMZ, Riken, JCRB) and Korean Cell Line Bank (KCLB, 
www.cellbank.snu.ac.kr; for SNU) databases. The STR profiles of NCI-H358 
(H358) and NCI-H460 (H460) matched known DNA fingerprints. Table 1 lists 




Table 1  Cell lines used in the study. 
 
Cell lines Catalog ID Organism Source Tissue 
CF-1 - Mouse Embryo 
Embryonic 
fibroblasts 






Human Cervical Adenocarcinoma 
HES-3 WiCell ES03 Human Embryo - 
H1 WiCell WA01 Human Embryo - 























- Human Kidney Packaging cells 
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2.1.2 Cell culture conditions 
 
CF-1 MEFs were cultured in MEFs medium consisting of Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco®) medium, 10% heat-inactivated 
fetal bovine serum (FBS) (Gibco®), 1% of L-glutamine (Gibco®) and 1% of 
nonessential amino acids (NEAA) (Gibco®). HEK 293, HeLa and IMR90 were 
maintained in DMEM medium supplemented with 10% FBS and 1% 
penicillin-streptomycin (Gibco®). H358 and H460 were cultured in Roswell 
Park Memorial Institute (RPMI)-1640 medium (Gibco®) consisting of 10% 
heat-inactivated FBS and 1% penicillin-streptomycin. Plat-E retroviral 
packaging cells were cultured in DMEM medium supplemented with 10% 
heat-inactivated FBS, 10 µg/ml blasticidin S (Gibco®) and 1 µg/ml puromycin 
(Gibco®). Human pluripotent cells were maintained on irradiated MEFs 
(iMEFs) in human ESCs medium consisting of DMEM/F12 1:1 medium 
(Gibco®), 20% Knockout Serum Replacement (Gibco®), 100 M NEAA, 100 
M β-mercaptoethanol (Sigma-Aldrich®), 1 mM L-glutamine and 4 ng/µl 
fibroblast growth factor basic (bFGF, also known as FGF-2) (Gibco®). 
Meanwhile, human pluripotent cells cultured on MatrigelTM (BD Biosciences) 
were fed using mTeS®1 medium (STEMCELLTM Technologies). All cell lines 
were maintained at 37°C and 5% carbon dioxide in humidified incubator. 
 
Human normal lung fibroblasts and cancer cells were subcultured 
using 0.25% w/v Trypsin-ethylenediaminetetraacetic acid (EDTA) solution 
(Gibco®), following ATCC recommendation. Human pluripotent cells cultured 
on iMEFs and MatrigelTM were passaged using 1 mg/ml Collagenase Type IV 
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(Gibco®) diluted in DMEM/F12 1:1 medium. One day before splitting human 
pluripotent cells, plates were pre-coated with 0.1% gelatin (STEMCELLTM 
Technologies) for 30 minutes at 37˚C. iMEFs feeder cells were thawed and 
seeded on the gelatin-coated plates. Alternatively, plates were pre-coated with 
MatrigelTM diluted in DMEM/F12 1:1 medium for one hour at room 
temperature prior to subculture. Human pluripotent cells in 6-well plates were 
incubated with 1 ml of 1 mg/ml Collagenase Type IV at 37˚C for 20 to 30 
minutes before rinsing the wells with DMEM/F12 1:1 medium to allow the 
cell aggregates dissociation and detachment. Larger colonies were scraped off 
using 1000 µl sterile pipette tips and cell scrapers. The detached cell 
aggregates were pooled and centrifuged at 300 xg for five minutes before 
seeding onto plates with iMEFs feeder cells or pre-coated MatrigelTM at an 
appropriate volume of cell clumps.  
 
2.1.3 Irradiation of mouse embryonic fibroblasts  
  
CF-1 MEFs passage one was thawed into a 150 mm petri dish and 
allowed to grow until 95% confluent monolayer (three to four days). Once 
confluent, the cells were trypsinized using 0.25% w/v Trypsin-EDTA and 
incubated at 37˚C for five to seven minutes before resuspending in the MEFs 
medium. Cells were then subcultured at a 1:3 to 1:5 ratio every three to four 
days. CF-1 MEFs at passage four were harvested by trypsinization for 
irradiation. Prior to trypsinization, 1 ml of culture medium was collected from 
each petri dish and the presence of common mollicute contaminations 
(Spiroplasma, Entomoplasma, Acholeplasma and Mycoplasma) in the 
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collected culture media was determined using MycoAlertTM Mycoplasma 
Detection Kit (Lonza). Mycoplasma-free cell cultures were then trypsinized, 
centrifuged and resuspended in MEFs medium before transferring into a T-175 
cell culture flask at a cell density of two millions cells/ml. Cells in the T-175 
flask was exposed to γ-radiation for 10.5 minutes at 385 rads/min. Irradiated 
cells were eventually cryopreserved at the desired cell numbers in cryovials.  
 
2.2 Generation of human iPSCs/iPCCs 
2.2.1 Plasmids  
 
All plasmids used for transfection and virus production in this thesis 
were purchased from Addgene, Cambridge, MA. For lentiviral particles 
production, lentiviral vector pLenti6/UbC/mSlc7a1 (Addgene plasmid 17224) 
carrying the mouse solute carrier family 7 (cationic amino acid transporter, y+ 
system) member 1 (mSlc7a1) gene receptor was used together with the 
packaging vector pCMV-VSV-G (Addgene plasmid 8454) and the envelope 
vector pMD2.G (Addgene plasmid 12259). Retroviral vectors used in this 
study include pMXs-hC-MYC (Addgene plasmid 17220), pMXs-hKLF4 
(Addgene plasmid 17219), pMXs-hOCT3/4 (Addgene plasmid 17217) and 
pMXs-hSOX2 (Addgene plasmid 17218). 
 
2.2.2 Lentivirus production and infection 
 
HEK-293 packaging cells were seeded in 100 mm dishes and 
incubated overnight before transfection. On the transfection day, infectious 
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lentiviral particles were produced by co-transfecting enveloping vector 
pMD2.G, packaging vector pCMV and lentiviral vector pLenti6/UbC/mSlc7a1 
in a 1:2:3 ratio into monolayer culture of HEK-293 with 90% confluency 
using Lipofectamine® 2000 transfection reagent (InvitrogenTM), according to 
the manufacturer’s recommendations. OPTI-MEM® I reduced serum medium 
(Gibco®) was used as the transfection medium and OPTI-MEM® I reduced 
serum medium was changed to DMEM medium supplemented with 10% heat-
inactivated FBS after six to eight hours of transfection. Twenty-four hours 
following transfection, lentiviral transfectant was collected and filtered 
through a 0.45 µm pore-size surfactant-free cellulose acetate filter (Sartorius). 
Human normal lung fibroblasts and NSCLC cells were seeded in 100 mm 
dishes one day before transduction. On the lentivirus transduction day, the 
medium on monolayer cells with 70 to 80% confluency was replaced with 
filtered lentiviral transfectant supplemented with 8 µg/ml hexadimethrine 
bromide (also known as polybrene) (Sigma-Aldrich®) and incubated for 24 
hours. 
 
2.2.3 Retrovirus production and human iPSCs/iPCCs generation 
 
Generation of human iPSCs/iPCCs was performed in accordance to 
Yamanaka’s published protocol (Takahashi, Tanabe et al. 2007), with slight 
modifications. Approximately twenty-four hours before transfection, Plat-E 
retroviral packaging cells were plated in 100 mm dishes and allowed to grow 
overnight. On the transfection day, Plat-E monolayer cells with 70 to 80% 
confluency were transfected with pMXs-based retroviral vectors using 
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Lipofectamine® 2000 transfection reagent, following the manufacturer’s 
recommendations. OPTI-MEM® I reduced serum medium was used as the 
transfection medium. Six to eight hours post transfection, OPTI-MEM® I 
reduced serum medium was changed to DMEM supplemented with 10% heat-
inactivated FBS. 24 and 48 hours after transfection, retroviruses for c-MYC, 
KLF4, OCT4 and SOX2 were harvested and filtered through a 0.45 µm pore-
size surfactant-free cellulose acetate filter. Human normal lung fibroblasts and 
NSCLC cells expressing mouse mSlc7a1 receptors were plated in 100 mm 
dishes one day before transduction. On the day of infection, cells with 60 to 
70% confluency were transduced with equal amounts of filtered retroviral 
transfectants containing each of c-MYC, KLF4, OCT4 and SOX2 and 
supplemented with 8 µg/ml hexadimethrine bromide. The medium was 
changed to DMEM or RPMI-1640 medium supplemented with 10% heat-
inactivated FBS after 72 hours. Five days following infection, iMEFs feeder 
cells were thawed and plated on gelatin-coated 6-well plates. On day six post-
infection, all infected cells were split into 6-well plates with iMEFs feeder 
cells at a cell density of 0.2 million cells/well. The medium was changed to 
human ESCs medium on the following day and the cultures were fed with 
fresh human ESCs medium every alternate day. Two to three weeks after 
infection, individual human ESCs-like colonies were picked using 1000 µl 
sterile pipette tips, transferred to 6-well plates with iMEFs feeder cells and 
maintained in human ESCs medium. The picked colonies were defined as 




2.3 In vitro and in vivo differentiation assays 
2.3.1 Spontaneous embryoid body-mediated differentiation 
 
Spontaneous embryoid body (EB)-mediated differentiation was 
performed according to Miyoshi and coworkers’ published protocol (Miyoshi, 
Ishii et al. 2010). Collagenased human pluripotent cells were maintained in 
ultra-low attachment plates (Corning®) using DMEM/F12 1:1 medium 
containing 20% Knockout Serum Replacement, 1 mM L-glutamine, 100 µM 
NEAA and 100 µM β-mercaptoethanol for eight days. The medium was 
changed every other day. The cells formed ball-like cell aggregates, known as 
EBs. Following eight days of suspension culture, EBs were subsequently 
seeded on gelatin-coated 6-well plates and fed using the same medium for 
another eight days. Attached EBs, named as postiPS/postiPC cells, started to 
proliferate after 48 hours. EBs at day eight and postiPS/postiPC cells at day 16 
were harvested and assayed for markers of three embryonic germ layers. 
 
2.3.2 Neural ectoderm induction and differentiation 
 
Directed differentiation to ectoderm was performed in accordance to 
Zhou and coworkers’ published protocol (Zhou, Chu et al. 2008), with slight 
modifications. Briefly, human pluripotent cells grown on MatrigelTM were 
collagenased, resuspended and cultured on ultra-low attachment plates in 
neural-inducing medium comprised of DMEM/F12 1:1 medium, 20% 
Knockout Serum Replacement, 1 mM L-glutamine, 100 µM NEAA and 100 
µM β-mercaptoethanol. From the second day, cells were supplemented with 1 
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µM retinoid acid (RA) (Sigma-Aldrich®) for four days. After five days of 
floating culture, EBs were deposited on gelatin-coated 6-well plates and 
maintained in neural-inducing medium. The cells were supplied with fresh 
medium every day for another three days. Cells were then collected and 
assayed for primitive neural progenitor markers. 
 
2.3.3 Lung endoderm induction and differentiation 
 
Direct differentiation to definitive endoderm (DE) was performed in 
accordance to published protocols (Green, Chen et al. 2011, Mou, Zhao et al. 
2012), with slight modifications. Briefly, human pluripotent cells grown on 
MatrigelTM were collagenased and maintained on ultra-low attachment plates 
in RPMI-1640 medium consisted of 2% B27® supplement (Gibco®), 100 
ng/ml Activin A (R & D SystemsTM) and 5 µM phosphoinositide 3-kinase 
(PI3K) inhibitor LY 294002 (Merck Millipore) for five days to obtain DE cells. 
To generate NK2 homeobox 1 (NKX2.1+) lung endoderm cells from DE cells, 
EBs were then seeded on gelatin-coated plates and maintained in RPMI-1640 
medium with 2% B27® supplement and 10 µM transforming growth factor-
beta (TGFβ) inhibitor SB 431542 (Sigma-Aldrich®) for four consecutive days, 
followed by an enriched RPMI-1640 medium comprised of 2% B27® 
supplement, 20 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich®), 100 
ng/ml bFGF (also known as FGF-2) and 100 ng/ml WNT-3a (Merck Millipore) 




2.3.4 Teratoma formation 
  
Briefly, human pluripotent cells grown on MatrigelTM were harvested 
following collagenase type IV treatment and resuspended in 30% MatrigelTM 
diluted in DMEM/F12 1:1 medium at a concentration of 10 millions cells/ml. 
Severe combined immunodeficiency (SCID) mice were anaesthetized, and 50 
µl of the cell suspension was injected subcutaneously at the lateral side of the 
abdomen. After six to eight weeks, teratomas were dissected and fixed in 4% 
paraformaldehyde. Samples were embedded in paraffin and processed for 
hematoxylin and eosin (H&E) staining. All animal experiments were 
performed with the approval of National University of Singapore Institutional 
Animal Care and Use Committee under protocol number 117/09. 
 
2.4 Immunostaining 
2.4.1 Immunoblotting  
 
Whole cell pellets were lysed in 50 mmol/l Tris-HCl (pH 7.4) (1st 
BASE), 250 mmol/l NaCl (1st BASE), 5 mmol/l EDTA (1st BASE), and 0.1% 
NonidetTM P-40 (Sigma-Aldrich®) with freshly added protease and 
phosphatase inhibitors [1 mM NaF (Sigma-Aldrich®), 1 mM Na3VO4 (Sigma-
Aldrich®), 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich®), 1 µg/ml 
each of Aprotinin (Sigma-Aldrich®), Leupeptin (Sigma-Aldrich®) and 
Pepstatin (Sigma-Aldrich®)]. The lysates were rotated at 4˚C for at least one 
hour and centrifuged at 14,000 rpm for ten minutes at 4˚C. Total protein 
concentrations were quantified using protein assay dye reagent concentrate 
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(Bio-Rad) with reference to bovine serum albumin (BSA) (Sigma-Aldrich®) 
standard curve. Protein lysates were mixed with loading dye consisting of 10% 
w/v sodium dodecyl sulphate (SDS) solution (1st BASE), 10 mM β-
mercaptoethanol, 20% v/v glycerol (Sigma-Aldrich®), 0.2 M Tris-HCl (pH 6.8) 
(1st BASE) and 0.05% bromophenol blue (Sigma-Aldrich®), and denatured by 
boiling for 5 minutes. Denatured protein was resolved by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
polyvinylidene difluoride membranes (Merck Millipore). Membranes were 
then blocked with 5% of non-fat dry milk or BSA followed by an overnight 
incubation with primary antibody at 4˚C. Subsequently, membranes were 
incubated with horseradish peroxidase (HRP)-conjugated secondary anti-
mouse or anti-rabbit IgG antibody (Cell Signaling Technology®) for one hour 
at room temperature. Following incubations, membranes were washed thrice 
for five minutes each using rinsing buffer containing 10 mM Tris-HCl (pH 7.4) 
(1st BASE), 150 mM NaCl and 0.1% v/v Tween-20 (Sigma-Aldrich®). 
Immunoreactive bands were visualized using Amersham ECL Plus Western 
Blotting Detection Reagents (GE Healthcare) and ChemiDocTM MP System 
(Bio-Rad) with Image LabTM Software. 
 
2.4.2 Immunocytochemistry staining  
 
Cells were seeded and allowed to grow on glass coverslips in 6-well 
plates overnight. Monolayer cells with 70 to 80% confluency were first fixed 
with 4% paraformaldehyde (Sigma-Aldrich®) for 15 minutes. Subsequently, 
cells were permeabilized with 0.5% NonidetTM P-40 in phosphate buffered 
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saline (PBS) (1st BASE) for ten minutes. Cells were sequentially incubated 
with 5% BSA for one hour, followed by overnight primary antibody 
incubation at 4˚C and Alexa Fluor 488- or 568-conjugated secondary antibody 
(Molecular Probes®) for one hour. Coverslips were mounted on glass slides 
using Vectashield® Mounting Medium with 4’,6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories). Alternatively, 0.5 µg/ml Hoechst 33342 
trihydrochloride trihydrate (Molecular Probes®) diluted in PBS was used 
followed by Vectashield® Mounting Medium (Vector Laboratories). 
Immunocytochemistry images were acquired using an FluoviewTM FV1000 
confocal microscope (Olympus) and Fluoview FV10-ASW Software. 
 
2.4.3 Alkaline phosphatase staining 
 
Alkaline phosphatase (AP) staining was performed using the Alkaline 
Phosphatase Detection Kit (Merck Millipore), in accordance to the 
manufacturer’s recommendations. Five days prior to AP analysis, human 
pluripotent cells were seeded at low cell density in 12-well plates pre-coated 
with MatrigelTM. On day five, cells were fixed with 4% paraformaldehyde in 
PBS for one to two minutes and washed using rinsing buffer containing 10 
mM Tris-HCl (pH 7.4), 150 mM NaCl and 0.1% v/v Tween-20. A fresh 
mixture of Fast Red Violet solution, Naphthol AS-BI phosphate solution and 
water in a 2:1:1 ratio was prepared and added into each well and the cells were 
incubated in dark at room temperature for 15 to 30 minutes. Before imaging 
the cells using IX71® inverted microscope (Olympus), the wells were washed 
with rinsing buffer and replaced with PBS. 
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2.4.4 Metaphase spreads 
 
Metaphase spreads were performed in accordance to Jeppesen’s 
published protocol (Jeppesen 2000). Briefly, monolayer cells reached 80% 
confluency were treated with 0.1 μg/ml Demecolcine solution (Sigma-
Aldrich®) for six to eight hours, depending on the cells growth rate. Cells were 
harvested by trypsinization and centrifuged. Cell pellets were then 
resuspended in 1 ml of 75 mM hypotonic KCl (Sigma-Aldrich®) solution and 
incubated at 37°C for 15 minutes. Following incubation, cells were further 
diluted in 75 mM hypotonic KCl solution containing 0.1% v/v Tween-20 to a 
final cell density of 30,000 cells/ml. Cell suspension was subsequently loaded 
onto ShandonTM Single Cytofunnel with white filter cards (Thermo 
ScientificTM) and spun with the slides at 1000 rpm and high acceleration for 
five minutes. After centrifugation, slides were air dried at room temperature 
for 15 minutes before rinsing with KCM buffer comprised of 10 mM Tris-HCl 
(pH 7.5) (1st BASE), 20 mM NaCl, 120 mM KCl, 0.1% Triton X-100 (Sigma-
Aldrich®), 0.5 mM EDTA (Sigma-Aldrich®) for five minutes. This is followed 
by a 45-minute of incubation with 10% BSA diluted in KCM buffer. Slides 
were then stained and incubated with primary antibody for two hours followed 
by Alexa Fluor fluorescence-conjugated secondary antibody for one hour. All 
incubations were done at room temperature. Following primary and secondary 
antibodies incubations, slides were rinsed with KCM buffer, followed by a 15-
minute fixation step using 4% paraformaldehyde. Prior to mounting using 
Vectashield® Mounting Medium with DAPI, slides were rinsed with deionized 
water and air dried. Metaphase spreads images were acquired using an 
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FluoviewTM FV1000 confocal microscope (Olympus) and Fluoview FV10-
ASW Software. 
 
2.4.5 Flow cytometry  
 
Trypsinized cells were pelleted and washed twice with incubation 
buffer consists of 0.5% BSA diluted in PBS. Cells were blocked in incubation 
buffer for 10 minutes, followed by primary antibody incubation for one hour 
and Alexa fluor fluorescence-conjugated IgG antibody for half an hour. All 
incubations were done on ice. Following incubation step, cells were washed 
and resuspended in PBS prior to flow cytometry analysis using LSRFortessaTM 
cell analyser (BD Biosciences) or FACSVantageTM SE (BD Biosciences). For 
cell sorting, sorted cells were collected in polypropylene tubes supplemented 






Table 2  List of antibodies used in the study. 
 
Antibody Catalogue No. Isotype(s) Application(s) 





ATM-pS1981 Rockland #200-301-400 M WB 
CENPA Abcam Ab20665 R MS 
CHK2 Cell Signaling #2662 R WB 
CHK2-pT68 Cell Signaling #2661 R WB 
Cleaved caspase 3 Cell Signaling #9664 R WB 





HNF3-B/FOXA2 R&D Systems AF2400 G IF 







Cell Signaling #4284 R WB 
p21/Waf1/Cip1 Cell Signaling #2946 M WB 
p53 Cell Signaling #9282 M WB 
p53-pS15 Cell Signaling #9284 R WB 
Rb Cell Signaling #9309 M WB 
Rb-pS807/811 Cell Signaling #9308 R WB 
SOX17 R&D Systems AF1924 G IF 
TRA-1-60 Cell Signaling #4746 M IF 
TRF2 BD Biosciences #611200 M MS 
α-tubulin Santa Cruz 5286 M WB 
HRP-GAPDH Cell Signaling #3683 R WB 
HRP-β-actin Abcam Ab20272 M WB 
Alexa Fluor 488 Molecular Probes M, R, G IF, F, MS 
Alexa Fluor 568 Molecular Probes M, R IF, F, MS 
Legends: F: flow cytometry; IF: immunofluorescence; G: goat; M: mouse; MS: metaphase 
spreads; R: rabbit; WB: Western blot. 
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2.5 Telomerase activity assay 
 
Telomerase activity (TA) was determined using TeloExpress 
Quantitative Telomerase Detection Kit (ExpressBio), in accordance to 
manufacturer’s instructions. Briefly, cell pellets were lysed in TeloExpress 
lysis buffer, incubated on ice for 30 minutes and centrifuged at 12,000 xg for 
20 minutes at 4˚C. Total protein concentrations in the telomerase lysates were 
quantified using protein assay dye reagent concentrate with reference to BSA 
standard curve. Equal amount of protein from each sample was mixed with 
TeloExpress Master Mix and ROX reference dye. TA quantification was 
carried out in a 7300 Real-Time PCR System (Applied Biosystems®) in a two-
step reaction, namely telomerase reaction and polymerase chain reaction (PCR) 
reaction. In the telomerase reaction, samples were incubated at 25˚C for 20 
minutes, allowing active telomerase in the lysed samples to add TTAGGG 
telomeric repeats to the 3’ end of a substrate oligonucleotide. In the 
subsequent PCR reaction, the extension products were detected by SYBR 
green and the cycling conditions were as follow: Hot-start DNA polymerase 
activation at 95˚C for ten minutes, followed by 35 cycles of denaturation at 
95˚C for 30 seconds and annealing/extension at 60˚C for 90 seconds. Relative 
TA was calculated by comparing the Ct values of the samples with reference 




2.6 Genomic RNA and DNA detection and quantification 
2.6.1 Genomic RNA/DNA isolation and bisulfite conversion  
 
Total RNA was extracted using RNeasy Mini Kit (Qiagen), in 
accordance with the manufacturer’s instructions. On the other hand, total DNA 
was extracted using DNeasy Blood & Tissue Kit (Qiagen), following the 
manufacturer’s recommendations. Genomic DNA sample was bisulfite-
converted using EZ DNA Methylation Kit (Zymo Research), following the 
manufacturer’s recommendations. 
 
2.6.2 Quantitative reverse transcription PCR  
 
First strand synthesis of cDNA was carried out in a two-step protocol, 
following manufacturer’s instructions. In the first step, mixture of total RNA 
and Oligo (dT) 15 Primer (Promega) was heated to 70˚C for 10 minutes and 
cooled at 4˚C for ten minutes. In the second step, a master mix consists of M-
MLV reverse transcriptase enzymes (Promega), 5x M-MLV reverse 
transcriptase buffers (Promega), RNasin® Plus RNase inhibitor (Promega) and 
deoxynucleotide triphosphate (dNTP) mix (Promega) was added to each of the 
sample and the samples were incubated at 37˚C for one hour followed by a 
five-minute denaturation at 90˚C.  
 
To set up a quantitative PCR reaction, a master mixture containing 
Power SYBR® Green qPCR Master Mix (Applied Biosystems®) and 0.2 µM 
each of forward and reverse primers was prepared and added to diluted 
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synthesized cDNA samples. The final volume was then adjusted to 25 µl with 
nuclease-free water. qPCR was carried out on a 7300 Real-Time PCR System 
and the cycling conditions were as follows: 50°C for 15 minutes, initial 
denaturation at 95°C for ten minutes, followed by 40 cycles of denaturation at 
95°C for ten seconds, annealing at 55°C for 30 seconds and extension at 72°C 
for 30 seconds. Relative mRNA expression was calculated using the Ct 
method. Expression of a housekeeping gene, glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) was used as the reference. All qPCR experiments 
were performed in triplicates with error bars representing standard deviation.  
 
2.6.3 PCR, methylation-specific PCR and gel electrophoresis 
 
For conventional PCR and gel electrophoresis, a master mix containing 
HotStar Taq Plus Master Mix (Qiagen) and 0.2 µM each of forward and 
reverse primers was prepared and added to each of diluted synthesized cDNA 
or genomic DNA sample. The final volume was then adjusted to 25 µl with 
nuclease-free water. PCR reaction was carried out on a Veriti® 96-well 
thermal cycler (Applied Biosystems®) and the cycling conditions were as 
follows: initial denaturation at 95°C for five minutes, followed by 35 cycles of 
denaturation at 94°C for 30 seconds, annealing at 55°C for 60 seconds and 
extension at 72°C for 60 seconds. The amplified products were then resolved 
by agarose gel electrophoresis and stained with ethidium bromide (Bio-Rad). 




For methylation-specific PCR (MS-PCR), two pairs of gene-specific 
primers, namely Unmethylated (Un) and Methylated (M) primer pairs were 
designed using MethPrimer program. Un primer pair is specific for the 
unmethylated DNA, whereas M primer pair is specific for the modified and 
methylated DNA. Amplification from both Un and M pair indicates 
unmethylation and methylation, respectively. MS-PCR was performed in a 
similar setting to that of conventional PCR. The amplified products were then 
resolved by agarose gel electrophoresis and stained with ethidium bromide 
(Bio-Rad). The gel was visualized using Gel Doc System (Bio-Rad) and the 
methylation status (methylated or unmethylated) was determined according to 
the absence or presence of the amplified products. The sample was considered 
as partially methylated if both Un and M primer pairs showed amplification 
products. 
 
2.6.4 Sequencing and bisulfite sequencing 
 
DNA fragments that resolved by gel electrophoresis were excised and 
purified using QIAquick Gel Extraction Kit (Qiagen), in accordance with the 
manufacturer’s instructions. The purified PCR product was cloned into 
pGEM®-T vector (Promega). 2 µl of ligation products were added directly to 
JM109 High-Efficiency competent cells (Promega) and heat-shocked at 42˚C 
for 60 seconds. The cells were recovered by adding Luria-Bertani broth 
medium and incubated at 37˚C for 90 minutes. Transformant was later 
cultured onto Luria-Bertani agar plates with antibiotic selection and incubated 
at 37˚C overnight. Selected white colonies were amplified and purified using 
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QIAprep Miniprep Kit (Qiagen) as per manufacturer’s instructions prior to 





2.6.5 Primer lists 
 
Table 3  List of primer sequences used in the study.  
 































































Legends: Fwd, forward primer; Rev, reverse primer 
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Table 3 List of primer sequences used in the study (cont’d).  
 

































































NANOG Fwd: 5’CAGCCCCGATTCTTCCACCAGTCCC3’ 
Rev: 5’CGGAAGATTCCCAGTCGGGTTCACC3’ 




Table 3 List of primer sequences used in the study (cont’d). 
 
Primers Sequences (5’ to 3’) Application 





































pMXs-L3205 Rev: 5’CCCTTTTTCTGGAGACTAAATAAA3’ 































Table 3 List of primer sequences used in the study (cont’d). 
 
Primers Sequences (5’ to 3’) Application 
APC_M  Fwd: 5’ATTTTCGTCGGGAGTTCGTC3’ 
MS-PCR 
Rev: 5’CAACCACATATCGATCACGTACG3’ 
APC_Un  Fwd: 5’TTTTGTTGGGAGTTTGTTGA3’ 
Rev: 5’CAACCACATATCAATCACATACA3’ 
HOXA5_M  Fwd: 5’TTTTTTGTTTTTCGGGTCGT3’ 
Rev: 5’CAAACTTATCCCCCTAACGAA3’ 
HOXA5_Un  Fwd: 5’GGTTTTTTTGTTTTTTGGGTTGT3’ 
Rev: 5’CCAAACTTATCCCCCTAACAAA3’ 
HOXA7_M  Fwd: 5’GCGAGGTTATTGTAGAGTTCGG3’ 
Rev: 5’AAAACCCCTTTACGTCCGAC3’ 
HOXA7_Un  Fwd: 5’TGGTGAGGTTATTGTAGAGTTTGG3’ 
Rev: 5’TCAAAACCCCTTTACATCCAAC3’ 
HOXC9_M  Fwd: 5’GCGTTATATGCGGATTTGGTTC3’ 
Rev: 5’ACGTAATAACGACCCCCGAC3’ 
HOXC9_Un  Fwd: 5’TGTTATATGTGGATTTGGTTTGA3’ 
Rev: 5’AAAAACATAATAACAACCCCCAAC3’ 
HOXD13_M  Fwd: 5’GTTTCGGGGAGTTTCGGTAC3’ 
Rev: 5’ATACACCTAACTATTCCACCCGTT3’ 
HOXD13_Un Fwd: 5’TTTTGGGGAGTTTTGGTATGA3’ 
Rev: 5’ATACACCTAACTATTCCACCCATT3’ 
IGFBP3_M  Fwd: 5’TTTTACGAGGTATATACGAATGC3’ 
Rev: 5’TCTCGAAATAAAATCTCCCTACG3’ 
IGFBP3_Un  Fwd: 5’AGAAAGTTTTATGAGGTATATATGA3’ 
Rev: 5’CACTCTCAAAATAAAATCTCCCT3’ 
KRT19_M  Fwd: 5’TAGGTTTTCGAGGAGGACGA3’ 
Rev: 5’AAACGACGACTCCGTACGTT3’ 
KRT19_Un  Fwd: 5’GTAGGTTTTTGAGGAGGATGA3’ 
Rev: 5’CCTAAACAACAACTCCATACATT3’ 
MLH1_M  Fwd: 5’ACGTAGACGTTTTATTAGGGTCGC3’ 
Rev: 5’GACGAAACTCTAATTTTCCGACCCG3’ 
MLH1_Un  Fwd: 
5’TTTTGATGTAGATGTTTTATTAGGGTTGT3’ 
Rev: 5’ACCACCTCATCATAACTACCCACA3’ 
RPRM_M  Fwd: 5’TGGGAGCGTATTCGGATACG3’ 
Rev: 5’AACCCAACGACACTAATCGCC3’ 
RPRM_Un  Fwd: 5’TGGGAGTGTATTTGGATATGG3’ 
Rev: 5’AAAAACCCAACAACACTAATCACC3’ 
S100P_M  Fwd: 5’TTGTTAGGGAGGAGTTATCGG3’ 
Rev: 5’TTCTATTCAACCCAACCGAA3’ 
S100P_Un  Fwd: 5’TTGTTAGGGAGGAGTTATTGG3’ 
Rev: 5’TTCTATTCAACCCAACCAAA3’ 






2.7 Genome-wide microarray analysis 
2.7.1 Gene expression profiling 
 
RNA sample was assessed for its purity using NanoDrop DN-1000 
spectrophotometer (Thermo ScientificTM). In addition, the qualities of total 
RNA samples were evaluated using Agilent RNA 6000 Nano Kit (Agilent 
Technologies) and Agilent 2100 Bioanalyzer (Agilent Technologies). RNA 
samples that met the following criteria were used in this thesis: RIN number ≥ 
8; 1.8 ≤ A260/280 ≤ 2.0; A260/230 ≥ 1.8 and A310 ~ 0. Before carrying out 
comprehensive analysis of gene expression, each RNA sample was amplified 
for hybridization using Illumina® TotalPrepTM RNA Amplification Kit 
(Ambion®) as per manufacturer’s instructions. Briefly, the cRNA conversion 
involved a three-step enzymatic reactions: first-strand cDNA synthesis from 
total RNA using ArrayScript reverse transcriptase enzyme; synthesis of 
double-strand cDNA with T7 promoter using DNA polymerase; and synthesis 
of biotin-labeled cRNA by in vitro transcription using T7 RNA polymerase 
and biotin-NTP mix.  
 
HumanHT-12 v4 Expression BeadChip (Illumina®) was used to inspect 
more than 31,000 annotated genes with more than 47,000 probes from 
National Center for Biotechnology Information Reference Sequence (NCBI) 
RefSeq Release 38 and other sources. Biotin-labeled cRNA samples were 
hybridized onto BeadChip overnight at 58˚C. Following hybridization, the 
BeadChip was washed thrice, stained with streptavidin-Cy3 conjugate and 
scanned with a BeadArray Reader (Illumina®). 
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Raw data with background subtraction was exported using BeadStudio 
(Illumina®). The microarray data was normalized using the quantile method. 
The limma and lumi packages, executed in R statistical software, were used to 
analyze the microarray data (Du, Kibbe et al. 2008). Genes that were 
differentially expressed met two criteria: ≥ 2-fold change and FDR-adjusted P-
value (FDR) ≤ 0.05. Hierarchical clustering and pair-wise comparison were 
generated using two-sample T-test and inference was made through empirical 
Bayesian. Heat map was generated using gplots package software.  
 
2.7.2 DNA methylation profiling 
 
The Infinium HumanMethylation27 BeadChip (Illumina®) was used to 
detect 27,578 CpG sites genome-wide, spanning 14,495 genes from NCBI 
database, 982 cancer-related targets and 110 miRNA promoters. Two bead 
types corresponding to each CpG site per locus were found in the BeadChip: 
one bead type corresponds to methylated (C) cytosine locus and the other 
corresponds to unmethylated (T) cytosine locus, which had been converted to 
uracil during bisulfite treatment and later amplified as thymine during whole 
genome amplification. Briefly, bisulfite-treated DNA was denatured into 
single strand and neutralized for isothermal amplification overnight. The 
amplified products were fragmented by enzymatic process and precipitated 
using isopropanol. The amplified and precipitated DNA samples were 
hybridized to the BeadChip via allele specific annealing to either methylation 
specific probe or non-methylation probe. It was then followed by single base 
extension with hapten-labeled dideoxynucleotides. The ddCTP was labeled 
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with biotin whereas ddATP, ddUTP and ddGTP were labeled with 2,4-
dinitrophenol. 
 
The raw intensities for both methylated and unmethylated DNA were 
exported using Genome Studio (Illumina®). The two-color channel data was 
preprocessed separately and normalized using the quantile method. The limma 
and methylumi packages, executed on R statistical software, were used to 
analyze the microarray data (Du, Kibbe et al. 2008, Mancuso, Montfort et al. 
2011). Each interrogated locus was probed by a methylated-specific probe 
(Met) and an unmethylated-specific probe (Unmet). Signals from Met and 
Unmet probes were used to compute M-values and β-values. M-values were 
calculated as the log2 ratio of the intensities of Met probe versus Unmet probe 
(M-values = log2(Met/Unmet)) (Du, Kibbe et al. 2008). M-values, ranging 
from 0 (completely unmethylated) to 1 (completely methylated), were used for 
statistical testing. On the other hand, β-values were calculated as the ratio of 
Met probe versus overall intensity (β-values = Met/(Unmet+Met)) (Du, Kibbe 
et al. 2008). β-values were used for a more intuitive interpretation of the 
degree of methylation (Du, Kibbe et al. 2008). β-values were categorized into 
three groups: methylated if β-value  (0.8, 1.0], partially methylated if β-value 
 [0.2, 0.8] and unmethylated if β-value  [0, 0.2). In this study, a promoter 
was defined as hypomethylated if at least half of the probes of the sample 
group were in lower methylation category compared to the reference group 
(i.e., from methylated or partially methylated to unmethylated) and if FDR ≤ 
0.05 (calculated using M-values). Likewise, a promoter was defined as 
hypermethylated if at least half of the probes of the sample group were in 
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higher methylation category compared to the reference group (i.e., from 
unmethylated to partially methylated or methylated) and if FDR ≤ 0.05 
(calculated using M-values). Normalized β-values were used to compute 
hierarchical clustering and pair-wise comparison. Heat map was generated 
based on normalized β-values using gplots package software. 
 
2.7.3 Gene sets and gene ontology annotation analysis 
 
Five gene sets were generated in this study i.e., aberrantly methylated 
promoters (AMPs), commonly upregulated genes in NSCLC (CURs), 
oncogenes, tumor suppressors and cisplatin resistant genes. AMPs were 
generated by literature search (Tsou, Hagen et al. 2002, Zochbauer-Muller, 
Minna et al. 2002, Shames, Girard et al. 2006, Rauch, Wang et al. 2007, 
Helman, Naxerova et al. 2012) (Appendix 1). CURs were generated by 
literature search (Beer, Kardia et al. 2002, Kettunen, Anttila et al. 2004, Risch 
and Plass 2008, Valk, Vooder et al. 2010) as well as using a data set from 
Gene Expression Omnibus (GEO) database GSE19188 (Hou, Aerts et al. 2010) 
(Appendix 2). Oncogenes and tumor suppressors were obtained from the 
Memorial Sloan-Kettering Cancer Center (Higgins, Claremont et al. 2007). 
Cisplatin resistant genes were generated by literature search (Strathdee, 
MacKean et al. 1999, Lord, Brabender et al. 2002, Ramirez, Rosell et al. 2005, 
O'Byrne, Barr et al. 2011, Guo, Wu et al. 2013, Zhang, Zheng et al. 2014) 




On the other hand, the gene ontology enrichment analysis of 
hypomethylated promoters were assessed using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) Bioinfomatics Resources 
(Huang da, Sherman et al. 2009).  
 
2.8 Cell-based assays 
2.8.1 Drug treatment 
 
Cells were seeded to a final cell density 0.5 million cells/ml and 
allowed to settle overnight prior to drug treatment. Cisplatin, also known as 
cis-diamminedichloroplatinum(II) (Sigma-Aldrich®) was reconstituted in 0.9% 
NaCl. 0.9% NaCl was included as a negative control in each experiment. 
 
2.8.2 Cell proliferation and cytotoxicity assay 
 
Cell viability was determined using 3-(4,5-dimethythiazol-2-yl-)-2,5-
diphenyl tetrazolium bromide (MTT) colorimetric assay, according to 
manufacturer’s instructions (Sigma-Aldrich®). Cells were seeded in 96-well 
plates and treated with different cisplatin concentrations, ranged from 10 µM 
to 1 mM, for 24 hours. Dimethyl sulfoxide (Sigma-Aldrich®) was then added 
to each well followed by four-hour incubation. After incubation, 96-well 
plates were read at 470 nm using VarioskanTM Flash Multimode Reader 
(Thermo ScientificTM). Average absorbance reading of drug-treated sample 
was calculated by subtracting the average absorbance reading of negative 
control from the raw average absorbance reading of drug-treated sample. Cell 
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viability (%) was calculated as follow: cell viability = (average absorbance 
readings of drug-treated sample/average absorbance readings of negative 
control) x 100. Data representing mean value of three independent 
experiments, each performed in triplicate. Error bars indicate standard 
deviation.  
 
2.8.3 Cell cycle analysis 
 
Cell pellets were resuspended and fixed in ice-cold 70% ethanol 
(Merck Millipore) for at least two hours on ice. Following fixation, cells were 
centrifuged at 200 xg for five minutes, washed once with PBS and 
resuspended and incubated in freshly prepared propidium iodide staining 
solution contains PBS, 0.1% Triton X-100, 0.2 mg/ml RNase A (InvitrogenTM) 
and 20 µg/ml propidium iodide (Sigma-Aldrich®) at 37˚C for 15 minutes. 
Cells were immediately analyzed using LSRFortessaTM cell analyser. 
Experiments were performed in triplicates and error bars representing the 
standard deviation from the mean.  
 
2.9 Immunodeficient mice injection 
 
Two millions cells were resuspended in 30% MatrigelTM and injected 
subcutaneously into immunodeficient mice. The mice were sacrificed after 




2.10 Serial dilution assay 
 
IMR90 genome DNA was serially diluted ten-fold with H358 and 
H460 genomic DNA, respectively.  
 
2.11 Accession number 
 
All microarray data have been deposited at National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) 
database under accession number GSE35913. All sequencing data have been 
submitted to GenBank under accession numbers JQ694043-51 and JX391994. 
 
2.12 Statistical analysis 
 
Statistical analysis was carried out using Chi-square test or one-way 
analysis of variance with Tukey's post hoc test or unpaired T-test, and P value 
< 0.05 was considered statistically significant. 
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Chapter 3 Direct Reprogramming of NSCLC Cells Reverses Aberrant 




Ectopic expression of defined transcription factors i.e., c-MYC, KLF4, 
OCT4 and SOX2 has been shown to override developmentally established 
epigenetic landscapes in somatic cells, reverting cells back to an 
undifferentiated pluripotent state (Takahashi, Tanabe et al. 2007). Similarly, 
reprogramming cancer cells confer parental cancer cells into an ESCs-like cell 
state through the modulation of epigenetic status, while leaving untouched 
their genetic mutations (Dewi, Ishii et al. 2012). However, it appears to be 
technically challenging due to inherently genetically unstable in cancer cells. 
On top of that, tumor cells, unlike normal cells, are prone to accumulation of 
epigenetic dysregulation, which consequentially lead to epigenetically 
silencing of tumor suppressors or aberrant activation of oncogenes. Moreover, 
cancer cells proliferate faster than normal somatic cells, which may impede 
the formation rate of those ESCs-like colonies. Collectively, these could 
possibly act as roadblocks in cancer cell reprogramming.  
 
To address whether human cancer cells, particularly non-small cell 
lung cancer (NSCLC) cell lines, can be reprogrammed using defined 
transcription factor, which was our first study aim, lentiviral and retroviral 
transduction protocols were used in this study (Park and Daley 2009). IMR90 
lung fibroblasts, which served as reprogramming control, were transduced 
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using the same factors and conditions. Cells were first transduced with a 
cationic amino acid transporter y+ system, which is mouse solute carrier 
family 7 member 1 (mSlc7a1) gene. Studies have shown that iPSCs generation 
efficiency was greatly reduced if single retroviral transduction was performed 
(Yan, Qin et al. 2010). Mouse ecotropic retrovirus receptor mSlc7a1 
transduction mediates fusogenic interaction with the retrovirus envelope 
protein Env and enables ecotropic retroviruses to transduce human cells, thus 
improves the efficiency of retroviral transduction (Kim, Closs et al. 1991, 
Wang, Kavanaugh et al. 1991). Successfully reprogrammed cancer cells were 
distinguished based on their morphological resemblance to ESCs after two to 
three weeks of retrovirus transduction, and these ESCs-like colonies were then 
manually picked and expanded to establish iPSCs/iPCCs cell lines. Three out 
of 10 established iPSCs/iPCCs cell lines were harvested for characterization 
assays.  
 
3.2 Generation and characterization of iPCCs-NSCLC  
3.2.1 NSCLC are successfully reprogrammed to a pluripotent state 
 
Before retroviral transduction, as depicted in Figure 1, both H358 lung 
adenocarcinoma and H460 large cell carcinoma exhibited epithelial 
morphology, and IMR90 lung fibroblasts showed typical normal spindle-like 
shape of the majority of fibroblasts. NSCLC cell lines were reprogrammed by 
ectopic expression of Yamanaka’s factors c-MYC, KLF4, OCT4 and SOX2. On 
day 6 post-transduction, infected cells were split and seeded on iMEFs. iMEFs 
was used as feeder cells to support and maintain the growth of human ESCs 
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and iPSCs/iPCCs. Previous studies has shown that an optimal number of 
infected cells seeded onto iMEFs is pivotal as non-reprogrammed cells may 
have obscured the reprogrammed cells and thus the formation of ESCs-like 
colonies (Park and Daley 2009). Success rate of ESCs-like colonies formation 
improved with decreasing number of transduced cells seeded onto iMEFs (Xu, 
Wei et al. 2013). As such, 0.2 million retrovirally-transduced cells were split 
and seeded onto each 6-well of iMEFs. No colony was evident from 
untransduced NSCLC controls as these cells detached after being plated on 
iMEFs feeder cells (data not shown).  
 
Our initial selection of colony was predominantly based on 
morphological resemblance to human ESCs i.e., compact flat colonies with 
cobblestone appearance and high nucleus-to-cytoplasm ratios. Human ESCs-
like colonies with aggregated and tightly packed morphology appeared two 
weeks after vector transductions. Approximately 20 days after transductions, 
emerging colonies were individually picked and these human iPSCs/iPCCs 
colonies displayed the hallmark chacateristics of human ESCs, a round-edged, 
compact and dense, with each cell characterized by prominent nuclei and scant 
cytoplasm. On day 30, ten human ESCs-like colonies from each cell type were 
passaged and expanded for further analysis. These colonies maintained their 
ESCs-like morphology following subculture. Herein, human iPSCs derived 
from lung fibroblast IMR90 were designated as iPSCs-IMR90; and likewise, 
human iPCCs derived from lung carcinomas H358 and H460 were designated 







Figure 1  Induction of iPCCs from human NSCLC cells.  
 
Representative images of human lung fibroblasts IMR90, human NSCLC cells 
i.e., H358 and H460 on day 0 after retroviral transduction. Six days after 
transduction, infected cells were seeded on iMEFs feeder cells and changed to 
human ESCs medium on the following day. On day 14 post transductions with 
Yamanaka’s cocktail, human ESCs-like colonies in IMR90 normal lung 
fibroblasts and human NSCLC cells, i.e., H358 and H460 were seen. Manually 
picked human ESCs-like colonies formed round-edged, flat and compact 
colonies that resembled human ESCs i.e., HES-3, H1 and H9. Bars represent 




3.2.2 iPCCs-NSCLC express human ESCs markers 
 
Upon obtaining human ESCs-like colonies, their pluripotency status 
was evaluated using alkaline phosphatase (AP) staining as all pluripotent stem 
cells express high levels of AP activity. Similar to human ESCs, iPCCs-
NSCLC were positive for AP staining and stained pinkish, as shown in Figure 
2. Together, immunocytochemistry data confirmed that iPCCs-NSCLC 
expressed pluripotency cell-specific surface antigen stage-specific embryonic 
antigen 4 (SSEA-4) and tumor-related-antigen (TRA)-1-60 as well as 
undifferentiated ESCs marker NANOG (Figure 2). TRA-1-60 and SSEA-4 are 
expressed in human ECCs and human preimplantation embryos. Their 
expressions are stage-specific where the expressions are lost following the 
differentiation of human ESCs or ECCs. Immunocytochemistry staining was 
performed in three iPCCs-NSCLC colonies, with all yielded similar results. 
Same staining was done in untransduced NSCLC and none of the markers 
were expressed in untransduced NSCLC (data not shown). 
 
At the transcription levels, quantitative PCR analysis demonstrated that 
iPCCs-NSCLC expressed human ESCs-associated genes, include OCT4, 
SOX2, NANOG and fibroblast growth factor 4 (FGF4) (Figure 3A). 
Furthermore, semi-quantitative RT-PCR analysis demonstrated that iPCCs-
NSCLC expressed pluripotency-related genes such as DNA methyltransferase 
3b (DNMT3B), developmental pluripotency-associated 2 (DPPA2), DPPA4, 
reduced expression 1 (REX1) and growth and differentiation factor 3 (GDF3), 
at levels comparable to those in the human ESCs i.e., H1 and H9 (Figure 3B). 
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In contrast, NSCLC cells expressed undetectable levels of mRNA for these 
ESCs markers (Figure 3B). In addition, endogenous and exogenous mRNA 
expression for c-MYC, KLF4, OCT4 and SOX2 was analyzed to examine the 
level of retroviral silencing. For this, primer pairs which can specifically 
amplify virally-delivered transgenes were used. As shown in Figure 4, iPCCs-
NSCLC expressed detectable levels of four endogenous genes, but not in 
exogenous. In addition, NSCLC cells prior to transduction showed 
undetectable expression of both endogenous and exogenous levels of these 
four genes.  
 
Bisulfite sequencing analyses of pluripotency promoters i.e., NANOG 
and FOXD3 revealed that CpG dinucleotides were highly unmethylated in 
iPCCs-NSCLC, in contrast to those of untransduced NSCLC controls (Figure 
5A), implying that these ESCs-specific promoters were active in iPCCs-
NSCLC. Pluripotent stem cells are telomerase-positive such that high 
telomerase activity (TA) maintains the telomeric chromatin integrity. Upon 
induction of pluripotency, TA in iPCCs-NSCLC increased dramatically as 
compared to their non-transduced NSCLC, and was comparable to those of 







Figure 2  iPCCs-NSCLC express human ESCs markers. 
 
Representative phase contrast images of established iPCCs-NSCLC and 
iPSCs-IMR90 showed human ESCs-like morphology. iPCCs-NSCLC and 
iPSCs-IMR90 stained positive for AP activity (pink), and resembled to those 
of human ESCs control. Human ESCs, i.e., HES-3, was included as positive 
control. Immunocytochemistry for human ESCs-associated markers on 
representative iPSCs-IMR90 and iPCCs-NSCLC showed expressions of TRA-
1-60 (green fluorescence), NANOG (red fluorescence) and SSEA-4 (green 
fluorescence). Nuclei were counterstained with Hoechst 33342 and served as 








Figure 3  Expression of pluripotency-associated genes in 
undifferentiated iPCCs-NSCLC. 
 
(A) iPCCs-NSCLC and iPSCs-IMR90 expressed human ESCs markers, 
namely NANOG, OCT4, SOX2 and FGF4. The mRNA expressions were 
normalized to the expression of a housekeeping gene, GAPDH. The data were 
presented as mean ± standard deviation of three independent experiments. 
Error bars denote the standard deviation (**P < 0.05). (B) Semi-quantitative 
RT-PCR analysis of pluripotency-associated genes in iPSCs-IMR90 (colonies 
#1 and #9), iPCCs-H358 (colonies #1, #3 and #9) and iPCCs-H460 (colonies 
#5, #9, #12) showed expressions similar to the levels of human ESCs controls. 
H1 and H9 are human ESCs lines used as positive controls. iMEFs feeder cells 
and non-template control (NTC) were included as negative controls. GAPDH 







Figure 4  Retroviral silencing of transgenes in iPCCs-NSCLC. 
 
Semi-quantitative PCR analysis showed that all four transgenes were 
undetectable in all reprogrammed cells. On the other hand, endogenous levels 
of these factors (endo) were reactivated in iPCCs-NSCLC and iPSCs-IMR90. 
Human ESCs and parental NSCLC cells were used as positive and negative 
controls, respectively. iMEFs feeder cells and non-template control (NTC) 
were included as other negative controls. GAPDH was used as a loading 







Figure 5  Bisulfite genomic sequencing and telomerase activity 
assessment in iPCCs-NSCLC. 
 
(A) Bisulfite sequencing analysis of methylation status of pluripotency genes 
NANOG and FOXD3 promoters revealed demethylation in iPCCs-NSCLC and 
iPSCs-IMR90. Closed and open circles represent methylated and 
unmethylated CpG dinucleotides, respectively. Numbers indicate the 
percentage of methylated CpGs. At least four clones were analyzed for each 
cell line. (B) All iPCCs-NSCLC and iPSCs-IMR90 acquired significant 
upregulation in telomerase activity (TA), when compared to their respective 
non-transduced parental cells. HES-3 is a human ESCs line used as positive 
control. Data are presented as mean ± standard deviation of triplicate 




3.2.2 iPCCs-NSCLC are transcriptionally similar to human ESCs 
 
To investigate the dynamics of gene expression in iPCCs-NSCLC, we 
performed genome-wide gene expression analysis on three independent 
colonies/biology replicates of each cell line, including human ESCs, iPSCs-
IMR90, iPCCs-H358, iPCCs-H460, untransduced parental cells IMR90, H358 
and H460 using Illumina HumanHT-12 v4 Expression BeadChip. As shown in 
Figure 6, hierarchical clustering analysis of gene expression clearly 
discriminated iPCCs-NSCLC from their parent NSCLC cells. Furthermore, 
iPCCs-NSCLC were clustered together with human ESCs and iPSCs-IMR90, 
indicating similarity in their gene expression profiles.  
 
Since cellular reprogramming is often associated with resetting 
epigenetic repertoires, including DNA methylation, we proceeded to perform a 
global DNA methylation profiling using Infinium HumanMethylation27 
BeadChip. The methylation status was represented as the β-values and M-
values. Specifically, β-values, ranged from 0 to 1, represented the degree of 
methylation at each interrogated methylation promoter, meanwhile M-values 
were used for statistical testing. We further categorized β-value into three 
groups, unmethylated if β-value  [0, 0.2); partially methylated if β-value  
[0.2, 0.8]; and highly methylated if β-value  (0.8, 1.0]. As assessed by 
hierarchical clustering analysis and scatter plot, iPCCs-NSCLC and iPSCs-
IMR90 had closely-related methylation profiles, meanwhile they were 
discriminated from human ESCs and their untransduced parental counterparts 
(Figure 7A, 7B). We attributed the deviation to the early passage of 
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iPSCs/iPCCs (passages 4 to 8) used in the arrays, which was in agreement 
with studies that reported that existence of epigenetic memory of somatic 
origin in early passages of iPSCs (Chin, Mason et al. 2009, Polo, Liu et al. 
2010). Chin and coworkers reported that early passage of iPSCs have not 
efficiently silenced the gene expressions of their somatic cells of origin and 
late passage iPSCs clustered more closely with human ESCs than with early 
passage iPSCs (Chin, Mason et al. 2009). Similarly, Polo and coworkers 
reported that early passage iPSCs retain a transient epigenetic memory of their 
somatic cells of which they derived from and thus implicate its downstream 
gene expression (Polo, Liu et al. 2010). Considering that gene transcription is 
a downstream of epigenetic regulation, we postulated that the deviation in 
DNA methylation status did not implicate on pluripotency maintenance in 
both iPCCs-NSCLC and iPSCs-IMR90 since we did not observe similar 
occurrence in the gene expression profiles. Furthermore, our gene ontology 
analysis of hypomethylated promoters in iPCCs-NSCLC showed an over-
representation of embryonic developmental-associated genes, such as 
embryonic morphogenesis, embryonic organ development and embryonic 
organ morphogenesis (Table 4). We also noticed that genes related to early 
differentiation were highly enriched in iPCCs-NSCLC, which is in agreement 
with published literature where genes related to differentiation, for instance 
signal/secreted glycoprotein and organ development were abundantly 
expressed in early passage iPSCs than human ESCs (Chin, Mason et al. 2009). 
Nonetheless, it is possible that the established iPSCs-IMR90 and iPCCs-






Figure 6  Global transcriptome assessment of iPCCs-NSCLC. 
 
Clustering of samples based on gene expression patterns revealed high 






Figure 7  Analysis of DNA methylation array by hierarchical 
clustering analysis and paired scatter plots. 
 
(A) Hierarchical clustering of overall methylation distinguished iPSCs-IMR90 
and iPCCs-NSCLC from human ESCs. (B) Paired scatter plots showed high 
similarities in gene expression levels (blue) between iPSCs/iPCCs and human 
ESCs while methylation levels (red) were only similar between iPSCs and 





Table 4  Gene ontology analysis of hypomethylated promoters in 
iPCCs-NSCLC. 
 




Pattern specification process 10.90 
Embryonic morphogenesis 9.45 
Anterior/posterior pattern formation 7.62 
Neuron differentiation 7.40 
Regulation of transcription, DNA-dependent 7.27 
Regulation of RNA metabolic process 6.77 
Embryonic organ development 6.50 
Skeletal system development 5.72 
Embryonic organ morphogenesis 5.50 
Positive regulation of transcription, DNA-dependent 5.44 
Regulation of transcription from RNA polymerase II promoter 5.39 
Positive regulation of RNA metabolic process 5.41 
Tube development 4.97 
Hindbrain development 4.97 
Positive regulation of gene expression 4.77 
Positive regulation of transcription 4.72 
Cell fate commitment 4.72 
Neuron fate commitment 4.59 
Proximal/distal pattern formation 4.57 
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3.2.3 In vitro and in vivo differentiation of iPCCs-NSCLC  
 
One of the defining characteristics of ESCs is pluripotency, defined as 
the ability to generate specific functional cell types. In human context, 
validation of pluripotency can be demonstrated both in vitro and in vivo. In 
vitro, ESCs are allowed to grow as a mass of cells, known as embryoid body 
(EB), within a defined length of time in suspension culture. EB will then form 
a multi-layer structure which consists of a mixed population of cells. 
Differentiated cells will then assess for cell-specific markers following in vitro 
differentiation via EB formation. Figure 8 outlines the schematic diagram of 
EB-mediated spontaneous differentiation. Briefly, to assay pluripotency in 
vitro, iPCCs-NSCLC were collagenased and cultured in suspension culture, 
allowed the formation of EBs. EBs were subsequently deposited onto gelatin-
coated plates and attached cells, known as postiPC cells, were allowed to grow 
and expand. Similar to human ESCs, iPCCs-NSCLC and iPSCs-IMR90 were 
able to differentiate into three embryonic germ layers in vitro. When compared 
to their respective untransduced parental counterparts, EBs and postiPS/C cells 
showed significant increased in endoderm geners i.e., GATA binding protein 4 
(GATA4) and forkhead box protein A2 (FOXA2), mesoderm genes i.e., msh 
homeobox 1 (MSX1) and BRACHYURY, and ectoderm markers i.e., paired box 
6 (PAX6) and caudal type homeobox 2 (CDX2) (Figure 9).  
 
To assess the potential of iPCCs-NSCLC to differentiate into specific 
lineages, iPCCs-NSCLC were assessed for their in vitro differentiation with an 
EB-mediated approach. For ectodermal or endodermal differentiation, iPCCs-
 75 
 
NSCLC were treated with retinoic acid (RA) or Activin A, respectively, for 
four consecutive days. Upon five days of treatment, the treated cells were 
stained with antibodies against primitive neural progenitor marker PAX6 and 
definitive endoderm marker SOX17. As shown in Figure 10A, 
immunocytochemistry data of the cells showed positive for these two markers, 
suggesting iPCCs-NSCLC readily induced and differentiated into neural and 
endoderm lineages.  
 
Teratoma formation in vivo is the gold standard of pluripotency 
validation for human ESCs. In view of this, to assay pluripotency in vivo, 
iPCCs-NSCLC were injected subcutaneously into SCID mice. Figure 10B 
illustrates the histologic sections of teratomas stained with H&E staining. 
Highly cystic containing multilobular structures, known as teratomas arose 
within six to eight weeks of injection. Subsequent histological assessment of 
teratomas showed the presence of various tissues, including muscle fibers, 
secretory glandular-like structures and squamous epithelium with 
keratinization structures, of which representative of three germ layers. 
Collectively, these support the notion that iPCCs-NSCLC could differentiate 








Figure 8  Schematic diagram of in vitro spontaneous differentiation of 
iPCCs-NSCLC. 
 
Collagenased iPSCs/iPCCs maintained in floating culture formed spherical 
three-dimensional cell aggregates, known as EBs. On day 8, EBs from iPSCs-
IMR90, iPCCs-H358 and iPCCs-H460 were subsequently transferred to 
gelatin-coated plates and allowed them to attach. The differentiation was 
observed primarily along the edges of the attached EB. Attached cells, termed 
as postiPS-IMR90, postiPC-H358 and postiPC-H460 cells, started to 






Figure 9  In vitro spontaneous differentiation of iPCCs-NSCLC. 
 
qPCR analysis of differentiation genes revealed that EBs and postiPS/C cells 
expressed markers of the three embryonic germ layers, including endoderm 
(FOXA2 and GATA4), mesoderm (MSX1 and BRACHYURY) and ectoderm 
(PAX6 and CDX2). All quantitative gene expression data were normalized to 
the expression levels of GAPDH. Data were presented as mean ± standard 
deviation from triplicate experiments and error bars representing standard 






Figure 10  Lineage-specific differentiation of iPCCs-NSCLC. 
 
(A) Directed neural and endoderm differentiation, via EBs, was performed. 
Immunocytochemistry analysis of pluripotent stem cells treated with RA for 
five days expressed primitive neural progenitor marker PAX6 (green 
fluorescence), meanwhile pluripotent stem cells treated with Activin A for five 
days expressed definitive endoderm marker SOX17 (green fluorescence). 
Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) and 
served as stain control. Bars represent 100 µm. (B) Subcutaneous injection of 
iPCCs-NSCLC into SCID mice resulted in teratoma formation. Representative 
image of an excised teratoma from SCID mice after eight weeks. Histological 
sections stained with H&E showed various lineages within the complex 
architecture of the tumor, including muscle fibers (mesoderm), secretory 




3.3 Reversal of NSCLC methylomes and transcriptomes upon 
reprogramming 
3.3.1 Identified aberrantly methylated promoters are hypomethylated 
upon reprogramming 
 
Compelling evidence suggests that the pivotal roles of epigenetics in 
cancer formation and progression (Sharma, Kelly et al. 2010). Aberrant 
promoter hypermethylation of tumor suppressor as well as global DNA 
hypomethylation are often seen in cancer cells. It is now vital to address 
whether these epigenetic changes are necessary for direct reprogramming or a 
consequence of the process to determine to what extent epigenetic alterations 
influence the reprogramming process in tumors. Moreover, accumulating 
studies have reported the abrogation of tumorigenicity in reprogrammed 
cancer cells, which may attribute to the genome-wide epigenetic alterations 
during the induction of pluripotency process. Nonetheless, a genome-wide 
analysis is lacking.  
 
In view of this, we profiled changes in DNA methylation status in 
reprogrammed NSCLC and asked whether inducing NSCLC cells to a 
pluripotent state is able to reset aberrant cancer-associated epigenetics marks. 
For this purpose, we generated four different gene sets, including aberrantly 
methylated promoters (AMPs), commonly upregulated genes in NSCLC 
(CURs), oncogenes and tumor suppressors. For AMPs, we compiled a list of 
237 promoters that are known to be aberrantly methylated in NSCLC from 
literature search (Tsou, Hagen et al. 2002, Zochbauer-Muller, Minna et al. 
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2002, Shames, Girard et al. 2006, Rauch, Wang et al. 2007, Helman, Naxerova 
et al. 2012) and the full list of AMPs in NSCLC can be found in Appendix 1. 
Among 237 unique AMPs that compiled from literature search, 217 genes 
were interrogated by our Illumina Infinium Human Methylation 27k BeadChip 
array (Table 5). These genes were over-represented among all methylated 
promoters in both H460 (OR = 2.33; P < 0.05) and H358 (OR = 2.66; P < 
0.05), but were under-represented among all methylated promoters in IMR90 
(OR < 1; P < 0.05).  
 
We first identified the AMPs in NSCLC by comparing them to IMR90. 
As shown in Figure 11A, 94 and 105 AMPs were identified in H460 and H358, 
respectively, and 84 AMPs overlapped between H460 and H358. Interestingly, 
among 105 identified AMPs in H358, 50 (53.2%) were less 
methylated/hypomethylated in reprogrammed H358 (OR > 1, P < 0.05) (Table 
6; Appendix 4). Similarly, 67.6% or 71 out of 94 AMPs were less methylated 
in iPCCs-H460 following reprogramming (OR > 1, P < 0.05) (Table 6; 
Appendix 5). Of all identified AMPs that were less 
methylated/hypomethylated upon reprogramming, 44 promoters were 
commonly shared between H460 and H358 (Figure 11B) and the majority 
were developmental-associated genes, for instance HOX gene clusters 
(HOXA1, HOXA2, HOXA4, HOXA5, HOXA6, HOXA9, HOXA11, HOXA13, 
HOXB2, HOXB3, HOXB4, HOXB5, HOXC9, HOXC10, HOXC12, HOXD8 
and HOXD13) and PAX7. On top of that, potential tumor suppressors i.e., 
WRN, TIMP3 and APC were also found to be hypomethylated following 
reprogramming. Considering that the epigenetic mechanisms, specifically 
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DNA methylation orchestrate the regulation of gene expression, we then asked 
whether the hypomethylated AMPs translate into active gene transcription. Of 
44 overlapped AMPs, 13 (26%) and 25 (35.2%) of the hypomethylated AMPs 
resulted in upregulation in gene transcript levels (≥ 2-fold change, FDR ≤ 0.05) 
in iPCCs-H460 and iPCCs-H358, respectively while the rest of the genes 
remained status quo (Figure 12). The latter can be explainable by the fact that 
hypomethylation at promoters does not necessarily result in gene upregulation 
concurrently, but has the potential to cause the upregulation subsequently 
(Mohn, Weber et al. 2008, Deaton and Bird 2011).  
 
We next examined the AMPs that showed the greatest differences in 
methylation status between parental NSCLC and reprogrammed NSCLC using 
methylation-specific PCR (MS-PCR) analysis. Two sets of primers, with one 
specific for the unmethylated DNA (Un pair) while another specific for the 
methylated DNA (M pair), were used in MS-PCR. Amplification from the M 
pair and the Un pair represent methylation and unmethylation, respectively. 
Accumulating studies have reported that methylation at adenomatous 
polyposis coli (APC) promoter, a tumor suppressor gene, is commonly found 
in the majority of NSCLC and well correlated with loss of APC expression 
(Virmani, Rathi et al. 2001). Recent reports suggested that hypermethylation 
of Slit homolog 2 (SLIT2), a secreted glycoprotein of the Slit family, was 
frequently detected in NSCLC (Suzuki, Shiraishi et al. 2013). Low SLIT2 
expression correlated with poorer survivability in lung cancer patients (Tseng, 
Lee et al. 2010). Notably, our MS-PCR results consistent with the reported 
findings where both NSCLC cell lines i.e., H460 and H358 were partially or 
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highly methylated in APC and SLIT2 (Figure 13). Following direct 
reprogramming, both APC and SLIT2 were demethylated or unmethylated in 
iPCCs-NSCLC. Further, both APC and SLIT2 genes were actively transcribed 
in iPCCs-NSCLC, as compared to their respective untransduced NSCLC cells, 
suggesting that the hypomethylation in iPCCs-NSCLC translated into active 
gene transcription.  
 
We noticed that a large proportion of HOX genes were found to be 
hypomethylated upon direct reprogramming. HOX genes encode a 
transcription factor family which is pivotal in embryogenesis. In lung cancers, 
numerous studies showed that HOX gene clusters are the targets of extensive 
de novo methylation (Shiraishi, Sekiguchi et al. 2002, Rauch, Wang et al. 
2007). However, the exact mechanism of de novo methylation at HOX genes 
to lung tumorigenesis remains largely unknown. We then analyzed the 
methylation status in several HOX genes using MS-PCR and bisulfite genomic 
sequencing. Unlike the untransduced parental NSCLC cells, iPCCs-NSCLC 
were hypomethylated in HOX genes i.e., HOXD13, HOXC9, HOXA7 and 
HOXA5 (Figure 14). To address if changes in DNA methylation state are 
associated with expression levels, we further examined the HOX gene 
expression using qPCR analysis. The gene expressions were found to be 
restored following direct reprogramming, in line with the hypomethylated 
status observed (Figure 14). Taken together, we showed the reversal of 
aberrant cancer methylomes by direct reprogramming and the 
hypomethylation events observed in iPCCs-NSCLC translated into restored 







Table 5  Number of AMPs identified in H358, H460 and IMR90. 
 
Samples AMPs Non-AMPs Total OR P values 
H358 154 6833 6987 2.66 6.4x10-12 
H460 148 6850 6998 2.33 1.8x10-9 
IMR90 60 6354 6414 0.48 2.8x10-7 
Legends: Fisher’s exact test was used to calculate odds ratio (OR) and P values against the 
expected background; OR > 1: over-representation, OR < 1: under-representation. 
 
 
Table 6  Number of identified AMPs that were hypomethylated in 
iPCCs-NSCLC. 
 








50 1745 1795 3.36 9.1x10-9 
Legends: Fisher’s exact test was used to calculate odds ratio (OR) and P values against the 






Figure 11  Overlapping AMPs identified in reprogrammed cells and 
their parental cells. 
 
(A) Venn diagram showed the number of identified AMPs in IMR90, H358, 
and H460. 94 and 105 AMPs were exclusively identified in H460 and H358, 
respectively, with 84 overlapped. (B) Venn diagram showed that 50 and 71 
AMPs were hypomethylated in iPCCs-H460 and iPCCs-H358 cells following 






Figure 12 Heat map of aberrant AMPs in iPCCs-NSCLC following 
direct reprogramming.  
 
Heat map representing methylomes of 44 AMPs and their correspond 
transcriptomes. The methylation status in parental NSCLC and iPCCs-NSCLC 
cells was shown in red (methylated) and green (unmethylated). Adjacently, 
changes in the gene expression in iPCCs-NSCLC cells, when compared to the 







Figure 13  Methylation-specific PCR and quantitative PCR analysis of 
APC and SLIT2 in iPCCs-NSCLC. 
 
MS-PCR results concurred with methylation array data where iPCCs-NSCLC 
became demethylated or unmethylated in APC and SLIT2 upon 
reprogramming, when compared to their respective parental NSCLC cells. 
qPCR analysis further confirmed that the hypomethylation observed in iPCCs-
NSCLC were translated into restored APC and SLIT2 gene expressions. All 
gene expressions were normalized to the expressions of the housekeeping gene, 
GAPDH. Data were expressed as mean of three independent experiments and 







Figure 14  Assessment of methylation and gene expression of HOX 
genes in iPCCs-NSCLC. 
 
Methylation-specific PCR (MS-PCR) and bisulfite genomic sequencing 
analysis of iPCCs-H358 and iPCCs-H460 revealed unmethylated or partially 
methylated status in several HOX gene promoters, i.e., HOXD13, HOXC9, 
HOXA7 and HOXA5. White circles represent unmethylated CpG dinucleotides 
while black circles denote methylated CpG dinucleotides. Numbers indicate 
the percentage of methylated CpGs. Furthermore, transcriptions of the same 
genes were significantly upregulated in iPCCs-NSCLC, when compared to 
parental NSCLC cells. This justified the hypomethylation event observed in 
iPCCs-NSCLC translated into restored gene expression. The mRNA 
expression was expressed in relative to GAPDH mRNA expression. Data were 
presented as mean ± standard deviation of triplicate experiments. Error bars 
representing standard deviation (**P < 0.05).  
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3.3.2 Commonly upregulated genes in NSCLC are downregulated 
following reprogramming 
 
We next examined whether the genes commonly upregulated in 
NSCLC, would be downregulated following reprogramming. Similar to AMPs, 
a list of 420 unique genes that was known to be aberrantly upregulated in 
NSCLC was compiled from published gene expression data of NSCLC 
clinical samples deposited in GEO database (GSE19188) (Hou, Aerts et al. 
2010) as well as literature search (Beer, Kardia et al. 2002, Kettunen, Anttila 
et al. 2004, Risch and Plass 2008, Valk, Vooder et al. 2010) (Appendix 2). 
From this master list, 391 genes were interrogated in our Illumina HumanHT-
12 array. Among 391 genes, 59 and 110 genes were found to be upregulated 
(≥ 2-fold change, FDR ≤ 0.05) in H460 and H358, respectively, when 
compared to IMR90 and we defined these genes as commonly upregulated 
genes (CURs) in our cancer samples.  
 
Our gene expression array detected 52 out of 110 genes (47.3%) were 
downregulated in iPCCs-H358 (Appendix 6). Similarly, among 59 genes that 
were upregulated, 25 genes (42.4%) were found to be downregulated in 
iPCCs-H460 (Appendix 7). They were all over-represented for genes 
downregulated upon reprogramming (OR > 1, P < 0.05) (Table 7). Notably, 13 
genes were overlapped in both iPCCs-H460 and iPCCs-H358 (Figure 15A). 
These include important lung prognostic factors such as PPAP2C, KRT7, 
KRT19, AGR2 and S100P (Hirashima, Takada et al. 1998, Wang, Liu et al. 
2002, Camilo, Capelozzi et al. 2006, Rotondo, Mastracci et al. 2008, Flanagan, 
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Funes et al. 2009, Arumugam and Logsdon 2011). Interestingly, CURs that 
were downregulated following reprogramming was explainable by DNA 
hypermethylation in iPCCs-H460 and iPCCs-H358 (Figure 15B).  
 
We chose nine CURs, namely AGR2, CD24, DUSP4, GALNT1, KRT7, 
STX1A, KYNU, PPAP2C and SERPINB5, which showed significant 
differences in gene expression array between reprogrammed NSCLC and 
parental NSCLC and validated their mRNA transcript levels using quantitative 
PCR analysis. As shown in Figure 16, our quantitative PCR analysis 
concurred with the microarray data, suggesting that CURs were silenced in 
iPCCs-NSCLC upon induction of pluripotency. Given that differential gene 
expression is correlated well with DNA methylation status, we proceeded to 
examine the methylation status of two CURs, i.e., S100P and KRT19 using 
MS-PCR and bisulfite sequencing analysis. S100P, a member of the S100 
family of small calcium-binding proteins, are functionally associated with 
malignant cancers, including lung cancers (Arumugam and Logsdon 2011). 
Studies have shown that silencing of S100P in lung cancers drastically 
reduced the angiogenesis and metastasis (Bulk, Hascher et al. 2008). On the 
other hand, KRT19, also known as CYFRA 21-1, was reported to be elevated in 
lung cancers, and thus serving as a potential biomarker for lung cancer 
detection (Vollmer, Govindan et al. 2003). Consistent with previous findings, 
untransduced parental NSCLC cells had higher expression of S100P and 
KRT19 (Figure 17). Further, both MS-PCR and bisulfite sequencing analysis 
results showed complete methylation at S100P and KRT19 promoters in 
iPCCs-NSCLC, which corroborated with the methylation array (Figure 17). 
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Together, our findings showed that gene silencing observed in iPCCs-NSCLC 
was satisfactorily explained by hypermethylation, suggesting that epigenetics, 
specifically DNA methylation, played a pivotal role in the dysregulation of 




Table 7  Number of identified CURs that were downregulated in 
iPCCs-NSCLC. 
 








25 712 737 30.68 <2.2x10-16 
Legends: Fisher’s exact test was used to calculate odds ratio (OR) and P values against the 






Figure 15  Reversal of CURs in iPCCs-NSCLC following 
reprogramming. 
 
(A) Venn diagram showed that 13 CURs shared between iPCCs-H358 and 
iPCCs-H460 were found to be downregulated upon reprogramming. (B) Heat 
maps illustrated the downregulation of CURs in iPCCs-NSCLC as a 
consequence to DNA hypermethylation. Gene silencing in CURs was 
explainable by hypermethylation in iPCCs-NSCLC. The methylation status in 
parental NSCLC and iPCCs-NSCLC cells was shown in red (methylated) and 
green (unmethylated). Adjacently, changes in the gene expression in iPCCs-
NSCLC cells, when compared to the parental NSCLC cells, were reflected in 







Figure 16 Gene expressions of nine CURs in iPCCs-NSCLC. 
 
qPCR analyses showed the downregulation of CURs in iPCCs-H358 and 
iPCCs-H460 cells that were initially expressed in the parental NSCLC cells. 
The mRNA expression was normalized to GAPDH mRNA expression. Data 









Figure 17 Silencing of KRT19 and S100P was attributed to 
hypermethylation events in iPCCs-NSCLC. 
 
qPCR analysis revealed significant downregulation in KRT19 and S100P 
expressions in iPCCs-NSCLC following reprogramming. Concurring with the 
microarrays, methylation-specific PCR and bisulfite sequencing of KRT19 and 
S100P promoters showed hypermethylated in iPCCs-NSCLC. White circles 
represent unmethylated CpGs, while black circles denote methylated CpGs. 




3.3.3 Fates of oncogenes and tumor suppressors in NSCLC upon 
reprogramming 
 
To investigate the differential regulation of oncogenes and tumor 
suppressors upon reprogramming, we obtained lists of oncogenes and tumor 
suppressors from the Memorial Sloan-Kettering Cancer Center Database 
(Higgins, Claremont et al. 2007) (cbio.mskcc.org/CancerGenes; accessed on 5 
Dec 2011) and compared the aberrant regulation of oncogenes and tumor 
suppressors in NSCLC, i.e., H460 and H358 to those of normal lung 
fibroblasts IMR90.  
  
From the list of 495 oncogenes, 29 and 42 identified oncogenes were 
found to be aberrantly upregulated in H460 and H358, respectively. More than 
half of the identified oncogenes in H358 were downregulated upon direct 
reprogramming (OR > 1, P < 0.05) (Table 8, Appendix 8). On the other hand, 
among 29 identified oncogenes in H460, 14 (48.3%) oncogenes were 
downregulated in iPCCs-H460 upon induction of pluripotency (OR > 1, P < 
0.05) (Table 8, Appendix 9). Of these oncogenes, ID1, known to play a role in 
promoting lung tumor cell proliferation (Cheng, Tsai et al. 2011), became 
downregulated in the both iPCCs-H460 and iPCCs-H358. Similarly, pro-
angiogenic factors i.e., CXCL2, CXCL1 and EFNA1 (Nojiri, Iwakawa et al. 
2009, Hatfield, Bedringsaas et al. 2010, Keeley, Mehrad et al. 2010) were also 
downregulated following reprogramming. Following this, we questioned 
whether DNA methylation could explain the regulation of these oncogenes. 
Notably, the regulation of oncogene gene expression in H358 and iPCCs-
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H358 was satisfactorily explained by differential DNA methylation (Figure 
18). For instance, hypomethylation of oncogene promoters in H358 and 
iPCCs-H358 correlated well with its aberrant upregulation in oncogenes, 
whereby DNA hypermethylation silenced these aberrantly upregulated genes. 
Nonetheless, the same cannot be said for H460 and its reprogrammed 
counterpart, iPCCs-H460 and we speculated that other gene regulation 
mechanisms were more favored in the case of H460 and iPCCs-H460. 
 
Similar to oncogene, we obtained a list of 873 tumor suppressor genes 
from the Memorial Sloan-Kettering Cancer Center Database (Higgins, 
Claremont et al. 2007). From this master list, 74 and 84 tumor suppressors 
were aberrantly downregulated in H460 and H358, respectively, when 
compared to IMR90 normal lung fibroblasts. Interestingly, we noticed that the 
percentages of tumor suppressors that were upregulated in H460 and H358 
were low. Specifically, upon reprogramming, only 21 (24.1%) out of 84 of 
tumor suppressors identified in H358 were significantly downregulated in 
iPCCs-H358 (OR > 1, P < 0.05) (Table 9; Appendix 10). However, only 8.1% 
or 6 tumor suppressors in H460 that were significantly upregulated in iPCCs-
H460 (OR > 1, P < 0.05) (Table 9; Appendix 11). Notably, we observed that 
the gene expression of the remaining large bulk of tumor suppressor genes had 
comparably low expression levels which were similar to those in human ESCs, 
and this finding was in agreement with studies that reported that low 
expression of tumor suppressor genes were required for human ESCs cell 
proliferation and survival (Hong, Takahashi et al. 2009). Of these, tumor 
suppressors i.e., PLAGL1 (Jarmalaite, Laurinaviciene et al. 2011) and CADM1 
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(Nowacki, Skowron et al. 2008) were transcriptionally elevated in both 
reprogrammed H460 and H358 as compared to their respective untransduced 
parental NSCLC cells. Following this, we investigated whether DNA 
methylation could explain the regulation of these tumor suppressors. The 
promoters of tumor suppressors were significantly hypermethylated, which 
corresponded to aberrant silencing of tumor suppressors in H358. Likewise, 
hypomethylated at the promoters of tumor suppressors correlated well with 
significant upregulation in tumor suppressors transcripts in its reprogrammed 
counterpart, iPCCs-H358. Nonetheless, we failed to observe similar 
occurrence in H460 and its reprogrammed counterpart, iPCCs-H460. 
Collectively, we provided the evidence that the dysregulation of oncogenes 
and tumor suppressors in NSCLC were reversed following induction of 
pluripotency and the dysregulations were partially explainable by intricate 




Table 8  Number of identified oncogenes that were downregulated in 













14 723 737 38.34 <2.2x10-16 
Legends: Fisher’s exact test was used to calculate odds ratio (OR) and P values against the 




Table 9  Number of identified tumor suppressors that were 















6 424 430 6.43 5x10-4 
Legends: Fisher’s exact test was used to calculate odds ratio (OR) and P values against the 






Figure 18  Fates of oncogenes following reprogramming. 
 
Heat maps illustrated DNA methylation controls the gene expression changes 
of oncogenes in H358 upon direct reprogramming, but not in H460. The 
methylation status in parental NSCLC and iPCCs-NSCLC cells was shown in 






Figure 19  Fates of tumor suppressors following reprogramming. 
 
Heat map illustrated hypomethylation of promoters in iPCCs-H358 on 
adjacent upregulated tumor suppressors, but not so in iPCCs-H460 cells. The 
methylation status in parental NSCLC and iPCCs-NSCLC cells was shown in 






3.4.1 Generation of cancer-specific iPSCs 
 
Briggs and King’s discovery of SCNT has paved way to understand 
cancer genetics and epigenetics. Reprogramming cancer cells via nuclear 
transfer was first demonstrated in a frog renal carcinoma model almost half a 
century ago (McKinnell, Deggins et al. 1969). Subsequent studies has reported 
the successful reprogramming cancer genome such as medulloblastomas (Li, 
Connelly et al. 2003), ECCs (Blelloch, Hochedlinger et al. 2004) and mice 
melanoma cell (Hochedlinger, Blelloch et al. 2004) by nuclear transplantation. 
In 2006, the advent of induced pluripotency using defined factors by 
Takahashi and Yamanaka has led to a blossoming of research in 
reprogramming cancer cells. Direct reprogramming using forced expression of 
defined transcription factors has been reported in a plethora of cancer cells, 
namely gastrointestinal cancer cells (Miyoshi, Ishii et al. 2010), CML (Carette, 
Pruszak et al. 2010), sarcoma (Zhang, Cruz et al. 2013) and melanoma (Utikal, 
Maherali et al. 2009). Together, there is an accumulating studies reported the 
induction of pluripotency in breast cancers, as well as melanoma and prostate 
cancer using integration-free methods. The former used oocyte extracts from 
amphibian Xenopus laevis (Allegrucci, Rushton et al. 2011) while miR-302 
was used in the latter (Lin, Chang et al. 2008). These reprogrammed cancer 
cells were found to mimic pluripotency properties of ESCs. Direct 
reprogramming of lung cancer cell A549 using defined transcription factors, 
however, resulted in partially reprogrammed state (Mathieu, Zhang et al. 
2011). Here we report the successful generation of cancer-derived iPCCs from 
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two NSCLC cell lines, namely adenocarcinoma H358 and large cell carcinoma 
H460. iPCCs-NSCLC possessed morphological, molecular and functional 
characteristics that similar to those of human ESCs. Specifically, iPCCs-
NSCLC demonstrated human ESCs-like features, including (1) 
immunodetection of pluripotency markers, (2) silencing and integration of 
retroviral transgenes, (3) DNA demethylation at the promoters of pluripotency 
genes, (4) functional telomerase expression, (5) high similarity in 
transcriptional profile analysis and (6) in vitro and in vivo differentiation 
assays via EBs and teratoma formation, respectively.  
 
3.4.2 Attenuation of cancer transcriptomes and methylomes upon direct 
reprogramming 
 
This is the first report of global characterization of the methylome and 
transcriptome of reprogrammed cancer cells, with comparison to those of the 
untransduced cancer counterparts, human ESCs and iPSCs. Early passages of 
iPSCs/iPCCs (passages 4 to 8) were used in our gene expression and DNA 
methylation analysis. The transcriptome of iPCCs-NSCLC was closely related 
to human ESCs, suggesting that cancer cells can be reprogrammed to acquire 
human ESCs-like characteristics. On the other hand, both transcriptomes and 
methylomes of iPCCs-NSCLC were similar to those of iPSCs-IMR90. 
However, our methylation analysis revealed that both iPCCs-NSCLC and 
iPSCs-IMR90 were deviated from human ESCs. We attributed this deviation 
to the early passages of iPSCs and iPCCs that we used in the assays and their 
epigenetic memory retained in iPSCs and iPCCs, in agreement with published 
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studies. Chin et al. reported that early passages of iPSCs deviated further from 
ESCs, however, continuous passaging of iPSCs diminished the differences 
(Chin, Mason et al. 2009). A similar finding by Polo et al. also revealed that 
somatic origin epigenetic memory in early passage of iPSCs led to differential 
transcriptomic profiles and attenuation in differentiation ability. However, 
transcriptional, epigenetic and functional differences were abrogated in late 
passages of iPSCs (Polo, Liu et al. 2010). Despite the epigenetic memory of 
early passages of iPSCs and iPCCs, deviation in DNA methylation, however, 
did not affect its downstream regulation of the transcriptomes. Furthermore, 
deviation in methylomes did not translate into differential gene expression and 
altered differentiation capacity. Both iPCCs-NSCLC and iPSCs-IMR90 were 
able to differentiate and give rise to three germ layers in vitro and in vivo.   
 
We next proceed to assess cancer-associated aberrant epigenetic 
alterations that account for tumorigenesis in these reprogrammed NSCLC. Our 
genome-wide transcriptome and methylome analysis revealed that these 
aberrant epigenetic alterations can be reversed following direct 
reprogramming. On the other hand, a recent study by Ron-Bigger and his 
colleagues also reported similar findings that reactivation of epigenetically 
silenced tumor suppressor gene CDKN2A as well as other aberrant methylated 
promoters in immortalized primary human embryonic lung fibroblasts WI-38 
following direct reprogramming (Ron-Bigger, Bar-Nur et al. 2010). However, 
immortalized WI-38 fibroblasts may not representative of an actual cancer cell 
as tumor-associated genetic mutations are less-likely to be present in these 
cells. Here, we have reprogrammed established NSCLC cell lines, which carry 
 105 
 
the oncogenic genetic mutations in lung cancers, to satisfactorily address the 
question whether cancer-associated aberrant epigenetic alterations can be 
reversed upon reprogramming.  
 
 DNA methylation, the first identified epigenetic mark, is commonly 
observed in lung cancers. Hypermethylation at the promoter CpG islands is 
associated with transcriptional repression and thus resulted in gene silencing 
(Deaton and Bird 2011). Aberrantly hypermethylated promoters are often 
implicated in genes controlling growth such as DNA repair enzymes and cell 
cycle regulators, as well as other potential tumor suppressors (Tsou, Hagen et 
al. 2002), with the rationale that possibly confer growth advantages to cancer 
cells. Moreover, accumulating studies reported that cancers recapitulate 
developmental gene expression patterns where early developmental genes are 
actively transcrived in cancers while late developmental genes are 
transcriptionally repressed and is explainable by DNA methylation (Borczuk, 
Gorenstein et al. 2003, Liu, Kho et al. 2006, Helman, Naxerova et al. 2012). 
However, the exact molecular mechanism lead to tumorigenesis remains 
elusive. In the current study, we showed that direct reprogramming of NSCLC 
cells were able to reverse the AMPs in lung cancers and, in some instances, 
translated into active gene transcription. Evidently, our data showed that 
identified AMPs that were hypomethylated following reprogramming were 
over-represented with developmental-associated genes such as Homeobox 
gene clusters and PAX7 as well as tumor suppressors for instance, WRN, 
TIMP3 and APC. It should be noted that despite early passages of iPCCs-
NSCLC may carry epigenetic memory from their respective cancer origin 
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(Chin, Mason et al. 2009, Polo, Liu et al. 2010), we were still succesful in 
proving that hypomethylation of AMPs. However, it is plausible that our data 
is underestimated.  
 
Another reversible alteration we observed in reprogrammed NSCLC 
was the CURs. A plethora of lung cancer molecular markers that distinguishes 
lung cancers from normal adjacent tissues has been reported. These 
biomarkers, mainly involve alterations in apoptotic signaling, proliferation, 
angiogenesis, and invasion, are plausibly pertinent in lung carcinogenesis 
(Palmer, Zaorsky et al. 2014). In light of this, we compiled a list of lung 
biomarkers that are actively transcribed or expressed in NSCLC compared to 
normal adjacent tissue, and we noticed that, following reprogramming, these 
genes were subsequently downregulated in reprogrammed NSCLC. For 
instance, KRT19, an important prognostic lung biomarker (Vollmer, Govindan 
et al. 2003) and S100P, molecular marker implicated in angiogenesis and 
metastasis (Bulk, Hascher et al. 2008) were found to be silenced in iPCCs-
NSCLC but not in untransduced parental counterparts. Furthermore, our gene 
expression array correlated well with methylation array where an increase in 
gene expression correlated to a decrease in promoter DNA methylation. 
Considering these molecular markers are pertinent in lung tumorigenesis 
(Fingleton 2003, Tweardy and Chang 2011), it is, therefore, interesting to note 
that these biomarkers were made silenced upon induction of pluripotency. 
Together, we also provided evidence that DNA methylation, and possibly by 
extension, epigenetics, were significant in explaining the regulation of these 
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genes and hence highlighted the importance of epigenetics in NSCLC 
progression.  
We further assessed the effect of direct reprogramming on a panel of 
tumor suppressors and oncogenes. Notably, we observed that epigenetically 
silenced tumor suppressors i.e., CADM1 and PLAGL1 were no longer silenced 
in the reprogrammed NSCLC cells. On the other hand, oncogene i.e., ID1 as 
well as pro-angiogenic factors i.e., EFNA1, CXCL1 and CXCL2 that work in 
concert to induce carcinogenesis were found to be reversed to the normal 
expression levels in both iPCCs-H460 and iPCCs-H358. Interestingly, we 
found that the differential regulation of gene expression in H358 and its 
reprogrammed counterpart, iPCCs-H358 correlated well with their DNA 
methylation status, except H460 and iPCCs-H460, implying that epigenetic 
mechanisms are more robust in regulating aberrant dysregulation of tumor 









Applying iPSCs technology in cancer cells offers a novel platform to 
investigate the role of the epigenetic in tumorigenesis. Moreover, iPSCs 
technology or epigenome modification through ectopic expression of defined 
transcription factors could be used to develop a novel therapeutic approach in 
cancer treatments. In the preceding chapter, we have demonstrated that 
aberrant cancer methylomes and transcriptomes were abrogated upon 
induction of pluripotency. Interestingly, we noticed that such epigenetic 
alterations were stably maintained even when the reprogrammed cancer cells 
were induced to redifferentiate spontaneously in vitro, which we termed as 
postiPC cells. This has motivated us to investigate to what extent NSCLC 
cancer cell reprogramming alters drug sensitivity in cancer cells and their 
differentiated cells. Considering that the epigenetics regulation may specific to 
certain cell types, and for this purpose, two different populations of 
differentiated iPCCs-NSCLC, namely postiPC cells, which consisted of a 
mixed population of three germ layers as well as Nk2 homeobox 1 (NKX2.1)-
positive lung endoderm cells, which consisted of a pure lung population were 






4.2 Lung endoderm differentiation of iPCCs-NSCLC 
 
Previously published studies have shown that the donor cell type 
greatly influences preferential differentiation of iPSCs (Bar-Nur, Russ et al. 
2011, Kim, Zhao et al. 2011). As such, we derived lung endoderm cells from 
iPCCs-NSCLC using a modified three-step differentiation protocol. In parallel, 
human ESCs, i.e., H9 and iPSCs-IMR90 were used to generate lung endoderm 
cells using the same differentiation conditions and they served as positive 
controls to our differentiation assay. In the first differentiation step, 
collagenased human pluripotent stem cells were cultured and maintained in 
basal medium enriched with 2% B27 supplement, Activin A and LY 294002 
for five consecutive days to derive definitive endoderm (DE) (Green, Chen et 
al. 2011). After five days of exposure to Activin A and LY 294002, CXCR4, a 
surface marker that distinguishes early visceral and DE from human ESCs 
(D'Amour, Agulnick et al. 2005), was analyzed using flow cytometry. As 
shown in Figure 20, more than half of the treated cell population expressed 
CXCR4 marker. None of the cells expressed CXCR4 marker in the untreated 
cell population (data not shown). Together with GATA4, SOX17 and FOXA2 
are DE-specific genes. GATA4 acts as key regulatory transcription factor for 
endoderm specification, while SOX17 activates transcription for initial 
formation of the endoderm through FOXA2 (Shen 2007). Their transcript 
levels, assessed by quantitative PCR analysis, were significantly upregulated 
in Activin A-treated cell cultures over that of control cultures (Figure 21A). 
On top of that, Activin A-treated cells were stained with antibodies against 
definitive endoderm markers SOX17 and FOXA2 upon exposure to Activin A 
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for five consecutive days. As shown in Figure 21B, immunocytochemistry 
data of the cells showed positive for these two DE-specific markers, 
suggesting iPCCs-NSCLC readily induced and differentiated into endoderm 
lineage.  
 
The second step of differentiation involves the induction of foregut 
endoderm cells from DE cells and for this purpose, DE cells were maintained 
in an enriched medium supplemented with 2% B27 and transforming growth 
factor-beta (TGFβ) inhibitor SB 431542 for four days. Studies have shown 
that TGFβ plays an important role in restricting lung endodermal cell 
proliferation and in contrary, inhibition of TGFβ pathway further enhanced 
lung endodermal differentiation and morphogenesis (Xing, Li et al. 2008). 
Following four days of exposure to TGFβ inhibitor, cells were then switched 
to an enriched medium comprised of epidermal growth factor (EGF), 
fibroblast growth factor basic (bFGF, also known as FGF-2) and WNT-3a for 
another four days or longer in the third differentiation step to allow the 
initiation of lung endoderm cells from foregut endoderm cells. Accumulating 
studies have demonstrated that activation of WNT pathway is critical in lung 
endodermal specification as it directly regulates the differentiation of human 
ESCs into lung lineage (Gadue, Huber et al. 2006, Green, Chen et al. 2011). 
Cells exposed to the differentiation condition were stained with primitive lung 
progenitor marker Nk2 homeobox 1 (NKX2.1). NKX2.1+ cells were then 
isolated and purified from the mixed population of cells using fluorescence 
activated cell sorting system (Figure 22A). Quantitative PCR analysis showed 
that the expression of early distal lung epithelial marker i.e., surfactant protein 
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C (SPC), mature distal lung epithelium i.e., SPA, SPB and clara cell secretory 
protein (CC10); and SPD were upregulated in NKX2.1+ lung endoderm cells 






Figure 20  Induction of CXCR4+ definitive endoderm cells from 
iPCCs-NSCLC. 
 
iPSCs-IMR90, iPCCs-H358 and iPCCs-H460 cells treated with Activin A and 
LY 294002 for five days were labeled with isotype control (blue) or anti-
CXCR4 antibody (red) for flow cytometry assay. Human ESCs served as 
positive control in the differentiation assay. Quantification of CXCR4+ cells 
revealed a higher percentage of CXCR4+ cells in iPCCs-H358 and iPCCs-
H460 cells after 5 days treatment with Activin A, compared with untreated 
controls (** P < 0.01). All data was expressed as the mean ± standard 







Figure 21  Expression of definitive endoderm markers in Activin-A 
treated pluripotent stem cells. 
 
(A) A significant upregulation in endoderm markers (SOX17, GATA4, FOXA2) 
in cells differentiated from iPCCs-NSCLC was observed, compared with 
untreated controls by qPCR analysis (**P<0.01). The mRNA expression was 
normalized to GAPDH mRNA expression. All data was expressed as the mean 
± standard deviation from three independent experiments. (B) Representative 
immunocytochemistry images of DE-differentiated pluripotent stem cells cells 
stained with anti-SOX17 (green fluorescence) and anti-FOXA2 (green 








Figure 22 Directed differentiation of pluripotent stem cells to 
NKX2.1+ lung endoderm cells, via definitive endoderm induction. 
 
(A) Cells were labeled with anti-NKX2.1 antibody and sorted using 
fluorescence activated cell sorting system. (B) qPCR analysis of lung-specific 
gene mRNAs indicated a significant increase in SPA, SPB, SPC, SPD, CC10, 
and NKX2.1 in lung endoderm cells differentiated from iPCCs-NSCLC 
(**P<0.01). All mRNA expressions were expressed in relative to GAPDH 
mRNA expression. Data was expressed as the mean ± standard deviation from 




4.3 NSCLC acquire chemoresistant phenotype following direct 
reprogramming  
4.3.1 Direct reprogramming of NSCLC attenuates apoptotic response 
 
Cisplatin is the scaffolding of anticancer drug for NSCLC treatment. 
To assess the cytotoxic response of differentiated iPCCs-NSCLC to cisplatin, 
cells were treated with different concentrations of cisplatin for 24 hours, and 
cell viability was quantified using 3-(4,5-dimethythiazol-2-yl-)-2,5-diphenyl 
tetrazolium bromide (MTT) colorimetric assay. Surprisingly, our MTT assays 
revealed a significant reduction in the sensitivity of differentiated iPCCs-
NSCLC to cisplatin when compared to the parental NSCLC cells (Figure 23A), 
indicating that differentiated iPCCs-NSCLC acquired chemoresistant to 
cisplatin.  
 
To investigate if the resistance to apoptosis was due to growth arrest at 
G1 or G2 phase, we performed cell cycle analysis. Cells treated with 100 µM 
cisplatin for 24 hours were stained with propidium iodide. Following cisplatin 
treatment, cell cycle profiles of both parental NSCLC cells, i.e., H358 and 
H460 revealed an increase in sub-G1 phase, indicative of cells undergoing 
apoptosis (Figure 23B, 23C). Specifically, the sub-G1 peak was more 
prominent in H460 than H358. This corroborated with previous findings 
where H358 was more resistant to apoptosis than H460 due to the p53-/- status 
in the cell line (Fujiwara, Grimm et al. 1994). In contrast, sub-G1 peak 
corresponding to apoptosis was very minimal in cisplatin-treated differentiated 
iPCCs-NSCLC. Intriguingly, cisplatin induced an increased accumulation in 
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G1 phase, accompanied with a decrease in the S phase of the cell cycle in the 
differentiated iPCCs-NSCLC (Figure 23B, 23C).  
 
Similar to other platinum-based compounds, cisplatin targets primarily 
DNA by forming covalent cross-linked adducts with DNA, which further 
blocks DNA replication. Cells respond to DNA strand breaks (DSBs) with the 
activation of an intricate network of DNA damage responses (DDR) (Shiloh 
2003). To fully understand the underlying mechanism of chemoresistance on 
differentiated iPCCs-NSCLC, whole cell lysates were extracted and 
immunoblotting was performed. In response to DNA damage, ATM and 
CHK2, serine/threonine protein kinases, are activated and subsequently 
phosphorylates numerous downstream substrates, including cell cycle 
regulators, DNA repair factors and proteins involved in apoptosis (Smith, Tho 
et al. 2010) (Figure 24A). ATM and its downstream effectors, i.e., CHK2 and 
p53 were activated upon cisplatin treatment in both parental NSCLC cells and 
differentiated iPCCs-NSCLC (Figure 24B). DNA damage induced by cisplatin 
phosphorylated ATM at serine 1981 (Ser1981) and CHK2 at threonine 68 
(Thr68), which further triggered the activation of p53 at serine 15 (Ser15) in 
parental NSCLC cells as well as in differentiated iPCCs-NSCLC.  
 
Notably, significant caspase-3 cleavage was seen in parental NSCLC 
cells following cisplatin treatment (Figure 25A), suggesting that cisplatin 
exerted its cytotoxic effects by inducing apoptosis in parental NSCLC cells. 
Unlike parental NSCLC cells, cisplatin-inflicted activation of caspase-3 was 
abolished in differentiated iPCCs-NSCLC (Figure 25A), indicating apoptosis 
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was more favored in parental NSCLC cells but not in differentiated iPCCs-
NSCLC. On the other hand, cells respond in G1 to DNA damage by p53-
mediated induction of p21 (Brugarolas, Moberg et al. 1999). Rb is a potent 
inhibitor of cell proliferation and dephosphorylation of Rb inhibits the 
progression into S phase. Classic markers of G1/S growth arrest, included 
increased p21 expression levels and decreased phospho-Rb levels, were seen 
in differentiated iPCCs-NSCLC (Figure 25B). This corroborated with our cell 
cycle analysis, indicating that DNA damage induced by cisplatin favored G1/S 







Figure 23  Differentiated iPCCs-NSCLC showed less sensitivity to 
cisplatin. 
 
(A) Cell viability of cells treated with different concentrations of cisplatin for 
24 hours by MTT assay. Values represented the mean ± standard deviation. (B) 
Cell cycle analysis of differentiated iPCCs-NSCLC treated with 100 µM 
cisplatin for 24 hours indicated a marked increase in the G1 peak. Sub-G1 peak 
was minimal in the differentiated iPCCs-NSCLC. All data was expressed as 






Figure 24  Cisplatin-induced DNA damage mediated the activation of 
ATM/Chk2/p53 signaling pathways in differentiated iPCCs-NSCLC. 
 
(A) Schematic diagram illustrated the mechanism of action of cisplatin. (B) 
Whole lysates of cells treated with 100 µM cisplatin for 24 hours were 
analyzed by immunoblotting. Western blots showing autophosphotylation of 






Figure 25  Cisplatin-induced apoptosis is abolished in differentiated 
iPCCs-NSCLC. 
 
(A) Immunodetection of cleaved caspase-3 by Western blot corroborated with 
cell cycle analysis that differentiated iPCCs-NSCLC showed negligible 
expression of cleaved caspase-3, while parental NSCLC cells showed high 
levels of cleaved caspase-3 that is indicative of cellular apoptosis. (B) 
Classical markers of G1 arrest were observed in differentiated iPCCs-NSCLC 




4.3.2 Differentiated iPCCs-NSCLC acquire higher protective effects to 
cisplatin-inflicted damages 
 
As drug sensitivity is correlated well with cell cycle progression and 
capability of DNA repair (Olive and Durand 1994, Bartek and Lukas 2001, 
Wu, Roth et al. 2005), we next asked whether cisplatin increases the 
opportunity of differentiated iPCCs-NSCLC to repair DNA damage after 
activating the G1/S checkpoint. For this, cells were immunostained with 
antibodies against γ-H2AX and 53BP1 (Figure 26) and numbers of γ-H2AX 
and 53BP1 foci formation were quantified (Figure 27). Studies has 
demonstrated that residual γ-H2AX foci level can be used as surrogate 
endpoint DNA strand breaks (DSBs) repair efficiency (Kinner, Wu et al. 2008, 
Redon, Nakamura et al. 2010) since it appears rapidly at DSBs and disappears 
as repair proceeds (Rogakou, Pilch et al. 1998). Likewise, the number of 
53BP1 foci formation showed a linear relationship with the severity of DNA 
damage (Rogakou, Boon et al. 1999). Indeed, we observed an increase in γ-
H2AX and 53BP1 foci in parental NSCLC cells and differentiated iPCCs-
NSCLC when treated with 100 µM concentration of cisplatin as early as at 4 
hours (Figure 27). DSBs foci were found to be consistently increased after 12 
and 24 hours. However, the numbers of γ-H2AX and 53BP1 foci in cisplatin-
resistant differentiated iPCCs-NSCLC were significantly lesser than parental 
NSCLC cells after 12 and 24 hours (Figure 27). This suggests differentiated 
iPCCs-NSCLC showed higher protective effects from cisplatin-inflicted 
damages and the capability in repairing DSBs, thus conferring resistance to 






Figure 26  Reduced residual of gamma-H2AX and 53BP1 DNA 
damage foci in cisplatin-treated differentiated iPCCs-NSCLC. 
 
Representative immunocytochemistry images of cells stained with anti-γ-
H2Ax and anti-53BP1 following treatment with 100 µM cisplatin for 4, 12, 













Figure 27  Quantification of gamma-H2AX and 53BP1 DNA damage 
foci in cisplatin-treated differentiated iPCCs-NSCLC. 
 
Quantification of 53BP1 and γ-H2Ax foci revealed an increase in DNA 
damage foci at 4 hours post-treatment. Upon 24 hours post-treatment, DNA 
damage foci were significantly reduced in differentiated iPCCs-NSCLC, but 
not in parental NSCLC cells. At least 50 nuclei were evaluated. Each bar 





4.4 Reversal of cisplatin resistant genes in differentiated iPCCs-
NSCLC 
 
Accumulating studies suggested that epigenetics play a pivotal role in 
development of drug resistance. To investigate the underlying mechanism that 
account for cisplatin resistant phenotype seen in differentiated iPCCs-NSCLC, 
a list of known cisplatin resistant methylated genes in lung cancer was 
compiled from literature (Strathdee, MacKean et al. 1999, Lord, Brabender et 
al. 2002, Ramirez, Rosell et al. 2005, O'Byrne, Barr et al. 2011, Guo, Wu et al. 
2013, Zhang, Zheng et al. 2014) (Appendix 3). Among these, the methylation 
status of nine genes namely GDA, ICAM1, IGFBP3, MLH1, S100P, SFN, 
WISP2, MT1G and GPR56 were found to be increased in the differentiated 
iPCCs-NSCLC, as compared to their respective parental cells (Appendix 12). 
Cells with hypermethylation in these promoters were reported to acquire more 
resistant to cisplatin (Ramirez, Rosell et al. 2005, Ibanez de Caceres, Cortes-
Sempere et al. 2010, Guo, Wu et al. 2013, Zhang, Zheng et al. 2014). 
Moreover, cisplatin-resistant ovarian cancer cell line was found to display 
methylation at the promoter of MLH1 gene (Strathdee, MacKean et al. 1999). 
On the other hand, transglutaminase 2 (TGM2) promoter-methylated cell lines 
were found to have higher sensitivity to cisplatin than the TGM2-expressing 
cell lines (Park, Kim et al. 2010). Our microarray data showed that TGM2 was 
found to be less methylated in the differentiated iPCCs-NSCLC (Appendix 12).  
 
To further verify the observation, we performed methylation-specific 
PCR (MS-PCR) assay on two genes that showed significant differences 
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between differentiated iPCCs-NSCLC and parental NSCLC cells. As shown in 
Figure 28, parental NSCLC cells were partially methylated at MLH1 and 
IGFBP3 promoters. However, the same cannot be said upon reprogramming 
followed by redifferentiation. Differentiated iPCCs-NSCLC became 
hypermethylated at these two promoters. Together, our finding provided 
evidence that direct reprogramming attenuated drug sensitivity by reversing 






Figure 28 Methylation-specific PCR analysis of MLH1 and IGFBP3 in 
differentiated iPCCs-NSCLC. 
 
Methylation specific (MS-PCR) analysis of cisplatin resistant methylated 
genes, i.e., MLH1 and IGFBP3 revealed hypermethylation status in 
differentiated iPCCs-NSCLC, but not in parental NSCLC cells. Un and M 




4.5.1 Cancer-specific iPSCs provide an ex vivo source for drug screening 
 
Tumor is known to be inherently heterogeneous with respect to the 
various karyotypes (Nicholson and Duesberg 2009, Duesberg, Mandrioli et al. 
2011) and the functional analysis of cancer cells are technically challenging 
because of their genetic diversity (Lai, Kong et al. 2013). Each established 
cancer-specific iPSCs clone is assumed to be genetically homogeneous as it 
captures the exact genetic complement of a parental cancer cell, and thus 
makes it possible to examine the functional analysis specific to the 
investigated cancer-associated genotype. Reprogramming cancer cells 
followed by redifferentiation into specific lineage, therefore, may aid in the 
discovery of novel cancer treatments, be it for drug screening for resistance or 
susceptibility. In our study, unlocking the ability of human iPCCs-NSCLC to 
differentiate to lung endoderm lineage not only serves as an invaluable tool for 
pharmaceutical screening, but also provides a source of cells to address a wide 
spectrum of molecular research questions. 
 
NSCLC accounts for more than 80% of all lung cancers and the 
majority have advanced NSCLC disease at diagnosis. To date, the 
chemoresistance of tumor cells continues to be a formidable challenge in the 
management of NSCLC. Despite these challenges, chemotherapy remains the 
cornerstone of treatment for patients with resected early and advanced NSCLC 
(Winton, Livingston et al. 2005, Pepe, Hasan et al. 2007). Since 1980s, 
cisplatin remains the scaffolding of chemotherapeutic agent for NSCLC 
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treatment. Given the increasing impact of epigenetics in cancer, be it in cancer 
initiation and progression as well as drug resistance, future works should aim 
to unravel the regulation of epigenetics in the process of direct reprogramming. 
This will aid in the development of novel cancer therapeutics aiming at drug 
resistant cancer cells that can escape tumor recurrence.  
 
4.5.2 Direct reprogramming attenuates drug sensitivity via alterations 
in cancer epigenomes  
 
In the current study, we showed that direct reprogramming followed by 
redifferentiation resulted in alterations of cisplatin sensitivity in differentiated 
iPCCs-NSCLC. Cisplatin, similar to other platinum-based compounds, targets 
primarily DNA by forming covalent cross-linked adducts with DNA, which 
further blocks DNA replication. It then triggers survival, proliferation and 
apoptotic signaling pathways concomitantly; the final fate of the cells depends 
on which signal that predominates. Following cisplatin treatment, 
differentiated iPCCs-NSCLC possessed chemoresistant phenotype by showing 
an attenuated apoptotic response coupled with increased DNA repair ability. 
Our results demonstrated that ATM and its downstream effectors, CHK2 and 
p53 were activated upon cisplatin treatment in both parental NSCLC cells and 
differentiated iPCCs-NSCLC. In parental NSCLC cells, however, DNA 
damage induced a pro-apoptotic signal, mediated by the effector caspase-3 
that led to an irreversible cascade of events progressing towards cell death. On 
the other hand, we showed that cisplatin-induced DNA damage caused an 
upregulation in expression levels of p21, coupled with an activation of Rb 
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protein through dephosphorylation in differentiated iPCCs-NSCLC. Drug 
resistance is correlated with cell cycle progression and capability of DNA 
repair (Olive and Durand 1994, Bartek and Lukas 2001, Wu, Roth et al. 2005). 
The formation of DSBs foci in parental NSCLC cells were found to be 
consistently increased after 12 hours and 24 hours of cisplatin treatment, but 
not in differentiated iPCCs-NSCLC. Increased DSBs repair efficiency allowed 
the cells to evade apoptosis despite the extensive cisplatin-induced DNA 
damage, and thus explains the cisplatin resistant phenotype observed in 
differentiated iPCCs-NSCLC.    
 
Epigenetics was first reported in human cancer in 1983 (Feinberg and 
Vogelstein 1983) and thenceforth, increasing evidence showing that human 
cancer cells harbor global epigenetic abnormalities, in addition to their genetic 
alterations (Jones and Baylin 2002, Jones and Baylin 2007). Cancer arises as a 
consequent of genomic mutations and epigenetics alterations. In cancer cells, 
DNA methylation and chromatin structure are profoundly altered and include 
genome-wide losses of, and regional gains in, DNA methylation (Jones and 
Baylin 2002). Global hypomethylation causes genetic instability and aberrant 
promoter hypermethylation or heterochromatinization that associates with 
inappropriate gene silencing leads to repression of associated tumor 
suppressor genes and affect virtually every step in cancer progression (Jones 
and Baylin 2002). In recent years, compelling evidence suggests that the 
pivotal role of epigenetics mechanism in the development of chemoresistance 
through transcriptional silencing of genes. A retrospective study has shown 
that the methylation level of O6-methylguanine methyltransferase (MGMT) in 
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glioblastoma patients was correlated well with resistance to alkylating agents 
carmustine (Belanich, Pastor et al. 1996). Similarly, MLH1 hypermethylation 
in colorectal cancer has been shown to confer resistance to chemotherapeutic 
agents (Arnold, Goel et al. 2003). Moreover, accumulating studies have shown 
that epigenetically silenced genes by DNA methylation play a role in cisplatin 
resistance. For instance, IGFBP3 was methylated in NSCLC, both in cell lines 
and clinical specimen (Ibanez de Caceres, Cortes-Sempere et al. 2010). 
Further investigation of the cisplatin resistance mechanism revealed that 
IGFBP3 methylation activated IGFIR/AKT pathway which in turn conferred 
NSCLC the chemoresistant phenotype to cisplatin (Cortes-Sempere, de 
Miguel et al. 2013). Therefore, analyze the epigenetic marks in tumors will 
shed light on how the tumors will respond to the chemotherapeutic drugs.  
 
Considering that gene expression plays a role in altering drugs 
susceptibility/resistance and the transcriptional mechanism is tightly regulated 
by genetic and epigenetic mechanisms, we therefore proceeded to assess the 
methylation status in the differentiated iPCCs-NSCLC. For this purpose, we 
compiled a list of known cisplatin resistant methylated genes in cancer from 
literature. Our genome-wide methylation analysis further revealed 
hypermethylation in cisplatin resistant methylation promoters in the 
differentiated iPCCs-NSCLC. Notably, IGFBP3, MLH1, GDA, ICAM1, S100P, 
SFN, WISP2, MT1G and GPR56 were hypermethylated in differentiated 
iPCCs-NSCLC, but not in parental NSCLC cells. Validation using MS-PCR 
further corroborated with our global DNA methylation microarray. 
Collectively, our study provided evidence that direct reprogramming altered 
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the drug sensitivity in cancer cells by reversing the cisplatin resistant genes. 
This suggests a combinatorial of epigenetic modifying and chemotherapeutic 
drug may have translational benefit in preventing the emergence of drug 
resistant cancer cells. 
 
Direct reprogramming of cancer cells using defined transcription 
factors has been shown to override developmentally established epigenetic 
landscapes, conferring both somatic and cancer cells to an embryonic stem 
cell-like state. Studies also showed that direct reprogramming of cancer cells 
resulted in the reversal of epigenetically silenced tumor suppressors and lost of 
tumorigenicity. Despite the underlying mechanisms of epigenetic remodeling 
are not yet fully understood, direct reprogramming may hold great promise in 
cancer treatments. Previously, Carette and coworkers reported that the 
neuronal cells and fibroblast-like cells differentiated from the reprogrammed 
malignant blood cells acquired resistance to imatinib (Carette, Pruszak et al. 
2010), suggesting epigenetic modifications conferred the reprogrammed 
malignant blood cells resistant to imatinib during the reprogramming process. 
Similarly, a study done by Kumano et al. reported lost of BCR-ABL oncogene 
dependency in the reprogrammed CML, indicating that the signaling for 
pluripotency might compensate for the inhibition of oncogenic signals during 
the reprogramming process. In our study, we have observed similar 
chemoresistance phenotype in the reprogrammed cancer cells. Moreover, our 
study provided evidence that direct reprogramming was able to alter the 
epigenetics of NSCLC, resulted in chemoresistance to anticancer drug. It 
would be of utmost interest to delineate the underlying epigenetic mechanisms 
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that alter the cisplatin sensitivity in NSCLC cells during the reprogramming 








Yamanaka’s groundbreaking discovery of iPSCs holds tremendous 
promises in medical research. These iPSCs may be useful in novel drug 
discovery and disease modeling. Most importantly, the ability to provide 
unlimited supply of autologous cells makes iPSCs an attractive alternative in 
cell replacement therapy. However, a major bottleneck of defined factor 
transcription factor reprogramming is its low efficiency and slow kinetic, 
which limits its use in clinical applications. The stochastic as well as elite 
models have been proposed to account for low efficiency in iPSCs generation. 
Despite the stochastic model prevails in explaining the inherent low efficiency 
of iPSCs generation, the same model cannot be said in the context of 
reprogramming cancer cells. Furthermore, there is increasing studies 
demonstrated that certain types of the cells follow elite, a non-stochastic 
model. Tumor is inherently heterogeneous and tumor cell variants arose within 
developing tumors with respect to metastatic ability (Fidler and Kripke 1977). 
Considering each established cancer-specific iPCCs is clonal from a single 
parental cancer cell, it is, therefore, allowing us to investigate whether the 
reprogramming cancer cells are biased. This will provide insights into the 




5.2 Detection of deleted genes in iPCCs-NSCLC 
5.2.1 Presence of TP53 observed in iPCCs-H358  
 
H358 carries homozygously deleted TP53 (Takahashi, Nau et al. 1989). 
To our surprise, our gene expression microarray detected the expression of 
TP53 in iPCCs-H358 (P < 0.05) whereas an undetectable or similar to 
background noise levels in TP53 was seen for all three biological replicates of 
H358 (Table 10). To validate the microarray data, we harvested ten randomly 
picked colonies from our established iPCCs-H358 cell line and examined the 
TP53 status by semi-quantitative RT-PCR and immunoblotting. Notably, both 
assays unanimously agreed with our gene expression array, as shown in Figure 
29A. H358 transduced with GFP-control vector was included in both assays as 
infection control (Figure 29B) and the results confirmed that the infection did 
not implicate in the re-expression of TP53 in iPCCs-H358. Furthermore, TP53 
coding region sequencing in three randomly picked colonies of iPCCs-H358 
















TP53 4.428 6.396 1.967 0.003 






Figure 29  Assessment of TP53 expression in iPCCs-H358 by RT-PCR 
and immunoblotting. 
 
(A) The expressions of TP53 in ten randomly picked colonies of iPCCs-H358 
were validated using semi-quantitative RT-PCR and immunoblotting (IB) 
assays. IMR90 normal lung fibroblasts served as positive controls in the RT-
PCR assay. Meanwhile untransduced H358, HeLa and human ESCs i.e., H1 
were used as negative controls to the assays. Also, H358 transduced with GFP 
control vector served as infection control to iPCCs-H358. Legends: gDNA, 
genomic DNA; cDNA, complementary DNA. (B) Representative phase 
contrast and fluorescence images of H358 transduced with GFP control vector, 
using the same retrovirus transduction protocol as mentioned in Chapter 2. 
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5.2.2 CDKN2A and CDKN2B not mutated in iPCCs-H460  
 
Motivating by this, we proceeded to examine if a similar phenomenon 
was seen in H460 and its reprogrammed counterpart, iPCCs-H460. H460 was 
reported to carry homozygous deleted CDKN2A (Ikediobi, Davies et al. 2006) 
and mutant CDKN2B (unpublished data). Figure 30A showed the heat map 
indicating methylation status of CDKN2A and CDKN2B promoters in three 
biological replicates of H460 and iPCCs-H460. Similar phenomenon was seen 
in iPCCs-H460 where the probe sets of DNA methylation microarray for both 
CDKN2A and CDKN2B promoters were able to hybridize and produce signals 
for all three biological replicates of iPCCs-H460. However, the same cannot 
be said for parental cancer cell, where empty bars were seen in some 
interrogated loci. Empty bars observed in heat map were likely due to 
mutations at the interrogated loci.  
 
To exclude microarray artifacts, we adapted two primer pairs that 
hybridize the coding region of CDKN2A and CDKN2B from a study published 
by Shan and coworkers (Shan, Parker et al. 2004). In Shan et al. study, no 
PCR amplified products were yielded when H460 genomic DNA was utilized. 
In light of this, the same primer pairs were used to amplify CDKN2A and 
CDKN2B in H460 and its reprogrammed counterpart, iPCCs-H460, under the 
same cycling conditions. Indeed, the same primer pairs failed to give any 
amplified products from our parental cancer cell H460 (Figure 30B). However, 
to our surprise, all ten randomly picked iPCCs-H460 colonies yielded 
amplified PCR products under the same cycling conditions, as shown in 
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Figure 30B. Furthermore, CDKN2A and CDKN2B coding regions sequencing 
using published primer sequences (Schmidt, Ichimura et al. 1997, Monzon, 
Liu et al. 1998) in three randomly picked iPCCs-H460 colonies suggested that 
to be wild-type (GenBank accession: JQ694043 - JQ694048).  
 
At the protein level, on the other hand, CDKN2A that is known to be 
deleted in H460 was expressed and detectable by immunoblotting in all ten 
randomly picked colonies of iPCCs-H460 (Figure 30B). Despite amplification 
of CDKN2B yielded no PCR products from H460 genomic DNA, CDKN2B 
protein was actively expressed in H460 (Figure 30B). Similarly, our 
immunoblotting assay also detected the presence of CDKN2B protein in three 
biological replicates of iPCCs-H460 (Figure 30B). H460 transduced with 
GFP-control vector was included as infection control in both semi-quantitative 
PCR and immunoblotting assays (Figure 30C) and the results showed that the 
infection played no role in the re-expression of CDKN2A and CDKN2B. 
 
On a side note, we noticed that small putative mutation in CDKN2B 
coding region, instead of the whole CDKN2B gene deletion, rendered the 
established PCR methods to fail, but did not perturb the protein expression. 
This observation was confirmed in another H460 cells which obtained from an 
independent source (a kind gift from Professor Phillip Koeffler’s laboratory). 
As seen in Figure 30D, despite carrying mutation, CDKN2B protein was 
constitutively expressed in H460. Moreover, an alternative primer pair 
designed by our laboratory was able to amplify CDKN2B in H460 genomic 






Figure 30  CDKN2A and CDKN2B not mutated in iPCCs-H460.  
 
(A) Heat map illustrated the methylation array probes (rows) failed to 
hybridize to CDKN2A and CDKN2B promoters in H460 (empty bars), but not 
so in iPCCs-H460. (B) Semi-quantitative RT-PCR and IB assays confirmed 
the expressions of CDKN2A and CDKN2B in iPCCs-H460. CDKN2B is 
mutated in H460 that renders all PCR assays to fail but did not perturb its 
protein expression. (C) Representative phase contrast and fluorescence images 
of H460 transduced with GFP control vector, using the same retrovirus 
transduction protocol as mentioned in Chapter 2. (D) CDKN2B protein can be 
detected in H460 cells from our laboratory (H460 #1) and another source, 
Professor Phillip Koeffler’s laboratory (H460 #2). (E) An alternative primer 
pairs we designed were able to amplify CDKN2B in both genomic DNA and 
cDNA of H460.   
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5.2.3 Expression of deleted genes persists through late passage of iPCCs-
NSCLC 
 
Previous published studies suggested that late passages (> 20 passages) 
of iPSCs colonies behaved differentially to those of early passages 
counterparts (Chin, Mason et al. 2009). In view of this, we harvested the 
iPCCs-NSCLC at late passages (passage number > 20) and examined the 
expressions of TP53, CDKN2A and CDKN2B in the late passage iPCCs-
NSCLC. Notably, we observed that continuously passaging of iPCCs-NSCLC 
had no effect in their expressions behavior. Figure 31A showed that TP53 
remained expressed in late-passage of iPCCs-H358. Both semi-quantitative 
PCR and IB assays, shown in Figure 31B, also detected the expression of 
CDKN2A and CDKN2B in late-passages of iPCCs-H460. 
 
To rule out the possibility of contamination with other cell lines or 
fibroblasts during the reprogramming process, we performed metaphase 
spread on postiPC cells, which were spontaneously differentiated iPCCs-
NSCLC cells, via EBs formation (Figure 31C). American Type Collection 
Culture database reported a modal chromosome number of 57, ranged from 53 
to 65 chromosomes in H460 meanwhile H358 was reported to have near 
triploidy chromosomes (Park, Choi et al. 2001). Quantification of metaphase 
spreads showed that postiPC cells remained aneuploid or near triploidy as 
their untransduced parental counterparts (Table 11), therefore excluded the 
possibility that our established iPCCs-NSCLC were contaminating with 






Figure 31  Expression of deleted genes persists through late passages 
of iPCCs-NSCLC. 
 
(A) PCR and IB assays showing TP53 are detectable in late passages of 
iPCCs-H358. IMR90 normal lung fibroblasts and H358 served as positive and 
negative controls, respectively. (B) PCR and IB assays showing CDKN2A and 
CDKN2B are detectable in late passages of iPCCs-H460. IMR90 normal lung 
fibroblasts and H358 served as positive and negative controls, respectively. (C) 
Representative metaphase spreads shows that postiPC cells differentiated from 
iPCCs-NSCLC were aneuploid. Cells were stained with antibodies against 
CENP-A (red fluorescence), which targets to the kinetochore region of 
centromeres and TRF2 (green fluorescence), which targets the telomeric ends. 
The chromosomes were counterstained with DAPI (blue fluorescence). Bars 
represent 10 µm.   
 142 
 
Table 11 Counts of chromosomes from metaphase spreads. 
 

















Maximum 46 68 68 133 154 
Mean 46 58 56 85 73 
Median 46 61 53 69 64 
Minimum 46 47 41 62 53 
Legends: n: number of replicates 
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5.3 Reprogramming discriminates heterogeneous cancer cell 
population 
5.3.1 Presence of minute mutation-free subpopulation in cancer cell 
population  
 
In order to explain why the re-expression of TP53 and CDKN2A in 
H358 and H460, respectively following reprogramming, we hypothesized that 
cancer cells that do not carry TP53 or CDKN2A homozygous deletion (for 
simplicity, we referred these cells as mutation-free subpopulation), was more 
favored and selected during the reprogramming process than the majority of 
the cells population with homozygously deleted in TP53 or CDKN2A. A 
recent publication by Navin et al. has demonstrated the presence of tumor 
heterogeneity in primary tumor samples (Navin, Kendall et al. 2011). Using 
single nucleus sequencing, Navin and coworkers showed that approximately 
half of the population was aneuploid and the other half was diploid or 
pseudodiploid. Notably, they found that copy number amplification of KRAS, 
an important oncogene, is unique to the aneuploid population. This 
observation led us to hypothesize that cellular heterogeneity exists in H358 
and H460 with respect to their different mutational status. Presence of cell 
population heterogeneity, especially in established cancer cell lines, is sensible 
considering the technique of generating cancer cell lines from excised tumors 
is crude (Brower, Carney et al. 1986). It is possible that the original excised 
tumor possessed detectable proportion of cancer cells that are not 
homozygously deleted in TP53 or CDKN2A in H358 and H460, respectively 
(for simplicity, we referred these cells as mutation-free subpopulation). 
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Nonetheless, continuous passaging and a combination of unknown factors 
conferred growth advantages to homozygously deleted TP53 or CDKN2A cells, 
and thus may explain why the mutation-free subpopulation is not observable. 
Thus, it can be inferred that the hypothesized minute subpopulation is innate 
to these cell lines.  
 
In order to estimate the proportion of minor mutation-free 
subpopulation, we performed a serial dilution assay. For this purpose, IMR90 
genomic DNA was two-fold serially diluted with H358 genomic DNA and 
PCR was done to assess the efficacy to amplify TP53. Our PCR analysis, as 
shown in Figure 32A, showed that PCR band corresponding to TP53 was 
marginally appreciable at four-fold dilution, which gave us an estimate that 
one cell is mutation-free in every four H358 cells (estimated proportion 0.25). 
Likewise, IMR90 genomic DNA was two-fold serially diluted with H460 
genomic DNA and assessed the efficacies to amplify CDKN2A and CDKN2B. 
Despite CDKN2A amplification efficiency was jeopardized by non-specific 
amplification products (Figure 32B), PCR band was marginally visible at 32-
fold dilution, therefore gave us an estimate that one cell is mutation-free for 
every 32 H460 cells (estimated proportion 0.03125). Notably, amplification of 
CDKN2B was the most efficient among all amplifications; neither primer-
dimer formation nor non-specific amplification was seen. The maximum 
proportion of H460 cells without mutant CDKN2B was 1×10-37, or in other 
words, one cell is mutation-free in every 5000 H460 cells (estimated 






Figure 32  Two-fold serial dilution assay to estimate the mutation-free 
subpopulation. 
 
(A) IMR90 genome was serially diluted with H358 genome and assessed the 
efficacy to amplify TP53 by PCR. PCR band corresponding to TP53 was 
marginally appreciable at four-fold dilution. (B) Similarly, IMR90 genome 
was serially diluted with H460 genome. Although amplification efficiency of 
CDKN2A was jeopardized by non-specific products, the PCR band was 
marginally visible at 32-fold dilution. (C) Serial dilution assay showed that 





5.3.2 Elite model of reprogramming predicts our observations 
 
Considering that H358 and H460 are heterogeneous with respect to 
their gene mutation status, we then asked whether all ten randomly picked 
iPCCs-NSCLC colonies that do not possess TP53 or CDKN2A deletion were 
by random chance that follows stochastic model or were consequent from the 
selective, non-stochastic process (elite model). By stochastic model definition, 
every cell is competent to reprogramming by transcription factors. Successful 
reprogramming, however, follows a Bernoulli distribution with extremely low 
success probability. The elite model, on the other hand, purports that only a 
subset of cells, whether by innate features of the cells or random chance, in a 
cell population is competent to reprogramming. For this purpose, we 
established a probability model to calculate the probability of observing all 
randomly picked iPCCs-NSCLC colonies that were derived from the 
mutation-free subpopulation (Figure 33).  
 
Assuming X is a Bernoulli random variable and 0 and 1 denote mutant 
and mutation-free, respectively. From our serial dilution assay, the maximum 
estimated proportion was 1 in 5000 cells. Thus, X1, X2, …, Xn ~ Bern (P = 
1/5000). Likewise, assuming Y is a Bernoulli random variable and 0 and 1 
denote unsuccessful reprogramming and successful reprogramming, 
respectively. Thus, Y1, Y2, …, Yn ~ Bern (P). We defined our null hypothesis 
(H0) as reprogramming follows a stochastic model which was independence of 
X and Y, given that every cell is competent to reprogramming by transcription 
factors by the definition of stochastic model. From the serial dilution assay, 
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the maximum proportion of H460 cells without mutant CDKN2B was 1 in 
5000 cells. If X is independent of Y, P(X|Y)=P(X)=1/5000. With this estimate, 
the probability of observing all randomly picked iPCCs-NSCLC colonies that 
were derived from the mutation-free subpopulation was calculated. The 
probability of attaining iPCCs-H358 colonies that were derived from the 
mutation-free subpopulation in all six randomly picked iPCCs-H358 colonies 
was 6.4 x 10-23. Likewise, for iPCCs-H460, the probability of attaining iPCCs-
H460 colonies that were derived from the mutation-free subpopulation in all 
four randomly picked iPCCs-H460 colonies was 1.6 x 10-15. Both suggested a 
highly unlikely scenario. Moreover, the smallest possible proportion to give a 
probability of 0.05 or more in this probability model was 0.75 (10C10 × 0.7510 × 
0.250 > 0.05), i.e., if the starting population had no less than three mutation-
free cells for every four cells. Such proportion, however, was not anywhere 
near 0.25, which was the poorest estimated proportion from the least efficient 
amplification of the serial dilution assays. Therefore, null hypothesis was 
rejected and we concluded that cancer cell reprogramming follows the elite 






Figure 33 Probability model to test the null hypothesis: “Generation 




5.3.3 Defining the mutation-free subpopulation 
 
Given that our data suggests that the reprogramming of cancer cells 
was selective and favored for mutation-free subpopulation, we proceeded to 
enrich this elusive mutation-free subpopulation from the heterogeneous cell 
population by fluorescence-activated cell sorting (FACS) and generating 
explant tumors. To sort TP53 positive H358 cells, H358 was stained with 
antibody against p53 and HeLa was included as positive control in the assay. 
As shown in Figure 34, distinct peaks between secondary antibody control and 
TP53-labelled cells were observed in HeLa population, but not in H358 
population. We gated TP53 positive population with HeLa sample to sort out 
TP53 positive and negative populations in H358 cells. Genomic DNA of 
sorted cells was collected and assessed the amplification for TP53. However, 
we did not see any TP53 amplification against expectations. We postulated 
that although a subpopulation of H358 cells retained TP53 (likewise a 
subpopulation of H460 retained CDKN2A), these cells may have suppressed 
the expression of these genes as an alternative mechanism to deletion. Hence, 
sorting the cells by probing the protein was not successful.  
 
Previous studies suggested that cancer cells inoculated into severe 
combined immunodeficient (SCID) mice experience selection pressure within 
the subcutaneous environment of the SCID mice. The resulting secondary 
tumor was proposed to be a result of clonal expansion of the tumorigenic 
subpopulation, which survived the aforementioned selection pressure (Chang, 
Khoo et al. 2003, Hochedlinger, Blelloch et al. 2004). Chang and coworkers 
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reported that the derivative explants tumors from tumor cell lines were not as 
heterogeneous as the tumor cell lines (Chang, Khoo et al. 2003). Moreover, a 
study done by Hochedlinger and coworkers demonstrated that the karyotypes 
of the explant tumors were similar to those of reprogrammed cancer cells, 
suggesting that injection of cancer cell lines into immunodeficient mice 
conferred selectivity to a tumorigenic subpopulation with cytogenetic features 
similar to those of reprogrammed cancer cells (Hochedlinger, Blelloch et al. 
2004). To test this, H358 and H460 were subcutaneously injected into SCID 
mice. After three to four weeks, tumors were excised and extracted for 
genomic DNA. We then amplified the genes of interest, i.e., TP53 in H358 
explant tumors and CDKN2A and CDKN2B in H460 explant tumors. However, 
only one out of four H358 explant tumors showed the detectable TP53 on its 
genomic DNA, as shown in Figure 35A. None of H460 explant tumors were 
enriched for CDKN2A or CDKN2B (Figure 35B). Therefore, inoculation of 







Figure 34  Fluorescence activated cell sorting analysis of TP53 positive 
population in H358. 
 
Distinct peaks between secondary antibody control (blue, unfilled) and TP53 
stained cells (red, filled) were observed in HeLa (positive control) population 
but not in H358 population. Genomic DNA of TP53 positive and negative 
populations in H358 cells were collected. However, we could not detect the 
presence of TP53 gene in either population. FSC: forward scatter channel; 






Figure 35  Enrichment of mutation-free subpopulation using explant 
tumors of H358 and H460. 
 
(A) Only one (SCID-H358 #2) out of four generated H358 explant tumors 
showed the presence of TP53 in the genome. This implied the enrichment of 
the elusive mutation-free subpopulation. (B) Nonetheless, none of the 
generated H460 explant tumors were enriched for mutation-free subpopulation. 
The low amplification of CDKN2A in IMR90 was due to a stringent 
amplification protocol that was used. (C) Without a stringent amplification 
protocol, our assay was jeopardized by non-specific amplicons. Genomic 
DNA of SCID mice tail was used to control for mice DNA contamination in 





5.4.1 Reprogramming discriminates heterogeneous cancer cell 
population 
 
Heterogeneity in cancer cells has been reported by several independent 
research groups in the seventies (Fidler and Kripke 1977, Heppner 1984, 
Mackillop, Bizarri et al. 1985). Recent study reported on transplantation of 
melanoma nuclei into enucleated oocytes has produced preliminary surprising 
results (Hochedlinger, Blelloch et al. 2004). Using a crude, but high-
throughput method of comparative genomic hybridization (CGH) to analyze 
karyotype, Hochedlinger and co-workers reported that the population of 
nucleus donor with heterogenous karyotype configuration was reversed to a 
rather homogenous and diploid karyotype upon nuclear transfer. Moreover, 
nucleus that failed to reprogram perish, suggesting that the success of this 
reprogramming selects for certain configuration of karyotype. Similarly, direct 
reprogramming of cancer cells that are inherently heterogeneous using defined 
transcription factors enables us to observe which variable biases towards the 
successful generation of cancer-specific iPSCs. In the present study, we 
noticed the re-expression of deleted genes, i.e. TP53 and CDKN2A in iPCCs-
H358 and iPCCs-H460, respectively. To explain such intriguing observations, 
we hypothesized that our starting cancer cell populations are heterogeneous 
with respect to varying degrees of genetic insults. Despite lack of experimental 
data supporting the heterogeneity in cancer cells, our study has shown that 
reprogramming of cancer cells enriches a minor subpopulation which is 
mutation-free, against the majority. Our finding corroborated with 
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Hochedlinger and coworker’s published study where the heterogeneous 
karyotype of the mice melanoma becomes homogeneous following 
reprogramming by nuclear transfer (Hochedlinger, Blelloch et al. 2004). 
Although our study suggest that reprogramming of cancer cells follows a non-
stochastic, elite model, our conclusion does not falsify previous proposal that 
the generation of iPSCs follows the stochastic model, given that cancer cells 
are different from that of normal somatic cells.  
 
The enrichment of the elusive mutation-free subpopulation in its native 
state is technically challenging. Neither Southern blot (Takahashi, Nau et al. 
1989) nor our PCR method were able to detect the genes in the mutation-free 
subpopulation. We attributed that the proportion of mutation-free 
subpopulation was too minute to provide sufficient template for PCR 
amplifications, and thus failed to yield any amplification products for ethidium 
bromide detection. Future experiments such as flow-fluorescence in situ 
hybridization (FISH) to sort out the mutation-free subpopulation followed by 
single nucleus sequencing will provide evidence to corroborate or falsify this 
hypothesis. Moreover, both Chang et al. (2013) and Hochedlinger et al. (2014) 
suggested that cancer cells inoculated into SCID mice experience selection 
pressure within the subcutaneous environment of the SCID mice (Chang, 
Khoo et al. 2003, Hochedlinger, Blelloch et al. 2004). The resulting secondary 
tumor was proposed to be a result of clonal expansion of the tumorigenic 
subpopulation, which survived the aforementioned selection pressure. We are 
of the opinion that the peculiar explant tumor (SCID-H358#2) which is a TP53 
positive was a product of this clonal expansion also. Further genetic studies on 
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SCID-H358#2 will be of interest in addressing why it happened to only one 
out of four H358 explant tumors. Nevertheless, our serial dilution assay 
confirmed that diluting IMR90 genome of at least 5000 times will mask the 
detection of CDKN2B amplicon. From this, we estimated the maximum 
proportion of H358 and H460 cells without mutant TP53 and CDKN2B, 
respectively was 1 in 5000 cells. Therefore, to obtain iPCCs-H358 and iPCCs-
H460 from this elusive mutation-free subpopulation is highly unlikely if the 
reprogramming process follows a stochastic model. An elite model is more 
favored in explaining our observation.  
 
5.4.2 Early tumor progenies may define competency towards 
reprogramming 
 
The inherently low reprogramming efficiency is one of the barriers for 
applying iPSCs technology in regenerative medicine and drug screening. 
Methods to enhance the reprogramming efficiency would significantly 
increase the feasibility of iPSCs technology. There is increasing number of 
studies suggests that certain cell types and their differentiation status affect the 
reprogramming efficiency (Eminli, Foudi et al. 2009). In addition, 
reprogramming of fibroblasts expressing SSEA3 (Byrne, Nguyen et al. 2009) 
or ARF (Utikal, Polo et al. 2009) had higher reprogramming efficiency than 
those did not express. Similarly, a subset of preexisting adult stem cells in 
human dermal fibroblasts exclusively gave rise to iPSCs colonies (Wakao, 
Kitada et al. 2011). However, most of the studies were done in normal somatic 




Since our study showed that cancer cell reprogramming discriminates a 
heterogeneous cancer cell population, it would be of interest to dissect the 
underlying characteristics in cancer cells that determine its competency 
towards reprogramming. Previous studies have shown that reprogramming-
induced senescence is a barrier towards reprogramming (Li, Collado et al. 
2009, Marion, Strati et al. 2009, Banito and Gil 2010) and disruption of 
senescence effectors (i.e., TP53 and CDKN2A) dramatically increases the 
reprogramming efficiency. Surprisingly, none of the randomly picked iPCCs-
NSCLC colonies were null for these genes, although gene deletion of these 
barriers in majority of H358 and H460 cells. Moreover, we observed that 
tumorigenic potential assessed by SCID mice inoculation weakly emulates the 
enrichment by the reprogramming process, suggesting that the derivatives of 
iPCCs-NSCLC are putative early progenies of the tumor population.  
 
Moreover, given that the mutated genes in question (TP53, CDKN2A 
and CDKN2B) are important for the integrity of the genome, it is likely that 
these mutation-free cells have a lower extent of genetic-level insults. 
Paradoxically, though, these cells are aneuploid and display wider spread of 
chromosome counts than their parental cells, plausibly corroborating the 
theory that aneuploidy promotes genomic instability (Sheltzer, Blank et al. 
2011). Corroborated with this, studies have shown that copy number 
amplification of an oncogene, KRAS is unique to aneuploid tumor population 
(Navin, Kendall et al. 2011). Therefore, we propose a guiding hypothesis that 
reprogramming selects cancer cells from the earlier progenies of 
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tumorigenesis, where genetic-level insults are low but grossly aneuploid, as 
shown in Figure 35. Studies have shown that genetic integrity maintained by 
TP53 and CDKN2A, among others, may be necessary in order to preserve the 
tightly regulated pluripotency circuitry to ensure reprogramming success 
(Boyer, Lee et al. 2005, Loh, Wu et al. 2006, Kim, Chu et al. 2008). Apart 
from explaining why iPCCs-NSCLC generated from H358 and H460 were not 
TP53 null and CDKN2A null, respectively, this may answer an intriguing 
question posed by Zhang and colleagues as to how a reprogrammed sarcoma 





Figure 36 Schematic diagram illustrating the putative origins of the 
mutation-free subpopulation selected for reprogramming. 
 
In order to identify the underlying characteristics in cancer cells that determine 
its competency towards reprogramming, we observed that the derivatives of 
iPCCs-NSCLC possessed following characteristics: (i) lack of genetic 
mutation (i.e., TP53, CDKN2A); (ii) aneuploidy and (iii) minute subpopulation. 
Considering these characteristics, we speculate that these derivatives were 
early progenies of the tumor population (orange filled circles without ‘x’). 
Therefore, aneuploidy is possibly first acquired prior to critical mutations to 
drive further advantageous genetic mutations, which is in agreement with 
Navin and coworker’s observation (2011). Less genetic insults in cells (orange 
filled circles without ‘x’) will ensure the integrity of pluripotency circuitry and 
thus a successful establishment of cancer-specific iPSCs (purple filled circles). 
‘x’ denotes genetic mutations.  
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Chapter 6 Conclusions and Future Directions 
 
6.1 Main conclusions 
 
Since the introduction of induced pluripotency using defined 
transcription factors back in 2006, the iPSCs technology has paved the way 
towards its potential applications in regenerative medicine. Reports of loss of 
tumorigenicity in cancer cells by direct reprogramming making iPSCs 
technology an exciting new avenue of cancer therapeutic. However, 
reprogramming of cancer cells has many more uncertainties to address. For 
instance, to what extent does NSCLC cancer cell reprogramming alters 
cancer-associated epigenetic alterations and drug sensitivity? What is the 
underlying mechanism for cancer cell reprogramming?  
 
To address these questions, we successfully established cancer-specific 
iPSCs from two NSCLC cell lines, namely H358 and H460. In this study, we 
introduced four transcription factors into NSCLC cells, successfully 
generating iPCCs-NSCLC that attained ESCs-like characteristics. Unlike 
parental NSCLC, reprogrammed NSCLC acquired differential potency which 
allowed them to differentiate to three embryonic germ layers in vitro and in 
vivo. Further, our study was the first report of global characterization of the 
methylome and transcriptome of reprogrammed cancer cells, with comparison 
to those of the untransduced cancer counterparts, human ESCs and iPSCs. 
Published studies have shown that abnormal methylation at promoters 
associated with cell cycle, DNA replication and repair, cell growth and 
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differentiation leads to lung cancer formation (Balgkouranidou, Liloglou et al. 
2013). Analysis of methylation data have shown that epigenetic lesions 
associated with cancer cells can be reversed upon applying four defined 
transcription factors to the NSCLC, supporting the notion that DNA 
methylation is important for tumorigenesis. The hypomethylation events 
observed in iPCCs-NSCLC translated into restored gene expression and even 
stably maintained in the differentiated iPCCs-NSCLC. Moreover, the 
regulations of oncogenes and tumor suppressors were reverted to normal upon 
induction of pluripotency and the reversal was partially explainable by DNA 
methylation. Together, this provide evidence that direct reprogramming of 
NSCLC reverses the aberrantly dysregulated genes in NSCLC both 
epigenetically and transcriptionally, which have significantly increased our 
understanding of cancer.       
 
Cancer-specific iPSCs provide a potential in vitro renewable and most 
disease-relevant model. It allows the development of new possibilities of 
cancer treatments, such as reprogramming cancer cells to induce their drug 
susceptibility or directly to disease-corrected ones. A central question remains 
unanswered is to what extent does NSCLC cancer cell reprogramming alter 
drug sensitivity in cancer cells? To address this, we performed a stepwise 
directed differentiation of iPCCs-NSCLC to lung endoderm cells. Remarkably, 
direct reprogramming of NSCLC resulted in alterations of cisplatin sensitivity. 
Unlike the parental NSCLC, we observed an abrogation of apoptosis response 
in the differentiated cells. Moreover, cisplatin-inflicted DNA damage elicited 
G1/S growth arrest via activation of p21 coupled with a reduction in the 
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residual DNA double strand breaks foci in the differentiated iPCCs-NSCLC. 
Further dissecting the cisplatin resistant mechanism revealed 
hypermethylation in cisplatin resistant promoters in the differentiated iPCCs-
NSCLC, suggesting that direct reprogramming altered the drug sensitivity by 
reversing the cisplatin resistant genes. This suggests a combinatorial of 
epigenetic modifying agent and chemotherapeutic drug may have translational 
benefit in preventing the emergence of drug resistant cancer cells. 
 
Generation of iPSCs is a slow kinetic process with low efficiency. Two 
contending models, namely the stochastic model and elite model was proposed 
by Yamanaka in order to explain the inefficiency in reprogramming. Despite 
the former is more favorable to explain the inherent low efficiency, the studies 
were done in normal somatic cells. Cancer cells are known to be inherently 
heterogeneous with respect to distinctive characteristics, and reprogramming 
cancer cells offers a suitable platform to test whether the reprogramming 
process is biased. Surprisingly, we observed that all randomly picked iPCCs-
NSCLC established previously do not possess mutations known in the parental 
cancer cell population. To explain such intriguing observations, we 
hypothesized that our starting cancer cell populations are heterogeneous with 
respect to varying degrees of genetic insults. Despite lack of experimental data 
supporting the heterogeneity in cancer cells, our study has shown that 
reprogramming of cancer cells enriches a minor subpopulation which is 
mutation-free, against the majority. This unanticipated observation is most 
parsimoniously explained by the elite model, whereby putative early tumor 




6.2 Limitations and future works 
 
Considering the rapid advances in iPSCs technology, we are cautiously 
optimistic that iPSCs technology could improve our understanding of cancer, 
as well as open up new avenues for therapeutic interventions. Our study 
reported a successful reprogramming from established lung cancer cell lines 
and genome-wide methylation analysis showed the reversal of aberrant cancer 
methylomes in the reprogrammed cancer cells. Nonetheless, the generation of 
iPSCs from primary cancer cells has remained a significant challenge, with 
limited studies reported on successful reprogramming of primary cancer cells. 
It would be, therefore, of interest to determine if our findings are reflected in 
clinical realities by reprogramming primary lung tumor samples.  
 
Current reprogramming methods heavily rely on viral vectors and the 
generation of cancer-specific iPSCs requires infecting the cells with multiple 
viral vectors. Retroviral vectors were used in our study to generate cancer-
specific iPSCs from NSCLC. Although retroviral vectors have the 
fundamental advantage of providing prolonged expression of the 
reprogramming factors which is essential for efficient reprogramming, one 
major concern of using retroviral vectors or in general, viral delivery system is 
that they can preferentially integrate into the host genome. Moreover, safety 
concerns arose in regards with the use of oncogenes or oncogenic-like 
transcription factors such as c-MYC and KLF4. Replacing these factors with 
small molecules or chemical genetics has been extensively studied. Future 
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experiments by applying non-viral, integration-free reprogramming 
technologies in cancer cells may overcome safety concerns associated with 
risk of oncogenic factors and insertional mutagenesis and shed new light on 
cancer research.  
 
Current epigenetic-based therapy such as 5-azacytidine, a DNA 
demethylating agent, has been shown to inhibit growth of tumor cells (Yoo 
and Jones 2006, Boumber and Issa 2011). However, such therapy is non-
specific as it often results in global hypomethylation. Our study showed that 
epigenetically modifying a reprogrammed cancer cell could correct some 
malignant effects of oncogene activation and suppressor gene inactivation, 
suggesting a novel strategy to control tumor progression. Moreover, our study 
provided evidence that direct reprogramming was able to alter the epigenetics 
of NSCLC, resulted in chemoresistance to anticancer drug. As such, it would 
be of interest to elucidate the roles of Yamanaka factors in manipulating and 
modifying cancer epigenomes at specific gene loci, i.e., tumor suppressors, 
oncogenes, drug resistant promoters. Better understanding of this mechanism 
would certainly contribute to a more targeted cancer treatment than currently 
non-specific epigenetic-based therapy.  
 
Future elucidation of associated characteristics in the mutation-free 
subpopulation which underlies its competency towards reprogramming 
process will undoubtedly extend the potential applications of iPSCs in basic 
research as well as in regenerative medicine. Experiments such as flow-FSH to 
sort out the mutation-free subpopulation followed by single nucleus 
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sequencing will unravel the underlying heterogeneous make-up of tumors and 
its dynamic progression, which will be the key in anti-cancer therapeutics. 
Moreover, studying these cells will complete our finding that reprogramming 
cancer cells follows the elite model. In addition, further work on the genome 
of explant tumor H358 will be of interest in validating our proposed guiding 
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Appendix 1 List of AMPs obtained from literature. 
Descriptions (Citation) Gene(s) 
Hypermethylation of promoter CpG islands in human lung cancer 
(Tsou, Hagen et al. 2002) 
AR GSTP1 S100A2 EGFR 
APC HIC1 PRKCDBP ESR1 
BCL2 HOXB TIMP3 ESR2 
CALCA HTR1B CADM1 FHIT 
CDH1 MGMT EDN1 GDF10 
CDH13 MTHFR DAPK1 PTGS2 
CDKN2A MYOD1 RARB PTHLH 
PRDM2 PGR RASSF1  
Methylated genes in lung cancers (Zochbauer-Muller, Minna et al. 
2002) 
APC DAPK1 P16 TIMP3 
CDH1 FHIT RARB RASSF1 
CDH13 MGMT   
Well-established methylation markers that have tumor suppressor 
activity (Shames, Girard et al. 2006) 
CDH1 RASSF1 TIMP3 SFRP1 
p16    
Novel methylation candidates in NSCLC (Shames, Girard et al. 2006) BIK DUSP1 TFPI2 TWIST1 
CCNA1 LOX   
Preferential targets for DNA methylation in cancer cell lines and in 
early-stage lung cancer (Rauch, Wang et al. 2007) 
HOXA1 HOXC4 HOXD1 EN1 
HOXA2 HOXC5 HOSD3 EN2 
HOXA3 HOXC6 HOXD4 LHX1 
HOXA4 HOXC8 HOXD8 PAX2 
HOXA5 HOXC9 HOXD9 PAX3 






Appendix 1 List of AMPs obtained from literature (cont’d). 
Descriptions (Citation) Gene(s) 
Preferential targets for DNA methylation in cancer cell lines and in 
early-stage lung cancer (Rauch, Wang et al. 2007) (cont’d) 
HOXA7 HOXC11 HOXD11 PAX6 
HOXA9 HOXC12 HOXD12 PAX7 
HOXA10 HOXC13 HOXD13 PAX9 
HOXA11 HOXB2 SIX2 HOXB6 
HOXA13 HOXB3 SIX3 HOXB7 
HOXB1 HOXB4 HOXB5 HOXB8 
HOXB9    
Tumor vs. normal sample (Helman, Naxerova et al. 2012) MSC HOXD13 IRX1 CDX2 
SOX2 ECAT1 HOXA1 FOXG1B 
BARHL2 BOLL OSR1 SFMBT2 
HOXD9 NXPH1 GRK7 KIAA1024 
SALL3 ZIC4 TWIST1 DMRT2 
PRDM13 DMRT3 SIX3 GRIK2 
LOC442425 KATNAL2 TFAP2C DLX5 
PROX1 LOC389549 HOXD3 HTRA4 
OTX1 FLJ46347 TITF1 HOXD12 
C20orf103 ONECUT2 SSTR1 FOXD2 
ST8SIA3 CBLN4 PRDM1 ZNF146 
IRX2 LBXCOR1 PCDHGA11 DLX6 






Appendix 1 List of AMP obtained from literature (cont’d). 
Descriptions (Citation) Gene(s) 
Tumor vs. normal sample (Helman, Naxerova et al. 2012) (cont’d) VAX1 SIX6 MSX1 HOXB13 
LRRTM1 GSC HOXD8 VAX2 
FOXD3 EPS8L1 HOXA9 HOXC4 
TFAP2A HOXD10 ZNF274 HOXC11 
RUNX1 PCDHGA12 TRIM59 LHX9 
WT1 EN2 HOXC13 SIM1 
FAM19A2 HMX2 MAFB ZIC1 
EN1 NRN1 NR2E1 LHX2 
SIM2 PCGF4 DPP6 ZNF577 
INSM1 PAX9 OTX2 SPATA17 
ZNF497 ALX3 PRDM14 MEIS1 
OSR2 SLC32A1 FOXF2 GP5 
ZIC3 TBX15   
Human Lung Cancer EpiTect Methyl qPCR Arrays (Qiagen): Apoptosis 
and anti-apoptosis 
ACIN1 CDKN2A FHIT SFN 
APC CDKN2A PGF TNFRSF10C 
BRCA1 CDKN2B PTEN TNFRSF25 
CADM1 DAPK1 PYCARD TWIST1 
CDKN1C ENG RECK  
Bone Morphogenesis Signaling pathway GREM1    
Drug metabolism CYP1A1 CYP1B1 GSTP1  






Appendix 1 List of AMP obtained from literature (cont’d). 
Descriptions (Citation) Gene(s) 
Human Lung Cancer EpiTect Methyl qPCR Arrays (Qiagen)  
(cont’d): Cell adhesion and migration 
APC CDH13 CTNNB1 ENG 
CADM1 CDH1 DLC1 OPCML 
Cell adhesion molecule-like genes ROBO1 THBS1   
Cell cycle, growth, differentiation and development AKAP12 CDKN2B HOXC9 RASSF2 
ALDH1A3 CEBPA HOXD1 RASSF4 
APC DLC1 IGFBP3 SFN 
BRCA1 FHIT MLH1 SPARC 
CADM1 GADD45G ONECUT2 TCF21 
CCNA1 GREM1 PGF TGFBI 
CCND2 CDKN1C RARB TWIST1 
CDKN1A CDKN2A RASSF1 WIF1 
CDKN1C PRDM2 PTEN XPC 
Chemokines, cytokines and receptor CXCL12 TNFRSF10C TNFRSF25 IL20RA 
Neuronal adaptor protein APBA1    
DNA methyltransferases MGMT PRDM2   
Dual oxidase DUOX2    
DNA damage repair APC MLH1 RASSF1 WRN 
BRCA1 FANCF RASSF4 XPC 
CDKN1A XRCC5   






Appendix 1 List of AMP obtained from literature (cont’d). 
Descriptions (Citation) Gene(s) 
Human Lung Cancer EpiTect Methyl qPCR Arrays (Qiagen) 
(cont’d): Extracellular matrix remodeling 
LOX SPARC THBS1 WIF1 
SLIT2 TGFBI   
Growth factors GDNF PGF WIF1 IGFBP7 
GTPase activating proteins RASGRF2 DAB2IP   
Heparan sulfate biosynthetic enzyme HS3ST2    
Histidine triad gene family FHIT    
Hormone receptor ESR1    
Hypoxia response PTEN    
Inflammation PYCARD    
Insulin signaling pathway CDX2 IGFBP3   
Lipid metabolism LRP1B    
Nuclear receptors ESR1 RARB   
Oncogene ENG    
One carbon unit metabolism MTHFR    
p53 signaling pathway RPRM XPC   
PI3K signaling pathway PTEN    
Proteases and protease inhibitors CTSZ PRSS3 THBS1  






Appendix 1 List of AMP obtained from literature (cont’d). 
Descriptions (Citation) Gene(s) 
Human Lung Cancer EpiTect Methyl qPCR Arrays (Qiagen) 
(cont’d): Protein kinases and protein kinase adaptor proteins 
AKAP12 DAB2IP PRKCDBP  
Retinoid acid signaling ALDH1A3 RARB   
Pure cerebellar ataxia SYNE1    
Transcription factors CDX2 HOXA5 PRDM1 TCF21 
CEBPA HOXC9 RUNX3 TGFBI 
GATA4 HOXD1 ONECUT2 TWIST1 
GATA5 MSX1   
Tumor suppressor gene candidates APC CDKN2A CDKN2B RUNX3 
BRCA1 CDKN2A ENG SFN 
CDKN1A LRP1B RECK XPC 
CDKN1C MLH1 PRKCDBP RASSF1 
PTEN RASSF2   
Wnt signaling pathway APC SFRP2 SFRP4 SFRP1 
Others C20orf85 RAMP2 HTR1B ZMYND10 






Appendix 2 List of CURs obtained from literature and GSE19188. 
Descriptions (Citation) Gene(s) 
Tumor samples vs. normal (Beer, Kardia et al. 2002) ADM DEFB1 H2AFZ KYNU 
AGFG1 EIF1 HCFC1R1 MSH3 
ALDH3B2 ERBB2 HMBS NFYC 
ALDOA FADD HPCAL1 NME2 
BZW1 FEZ2 HSPA8 P2RX5 
CDC6 FUCA1 HSU53209 PDAP1 
CDS1 FURIN INHA PDE7A 
CRK FUT3 ITGA2 PEX7 
CSTB FXYD3 KIAA0020 POLD3 
DBP GAPDH KIAA0317 PPIF 
RPS3 GARS KRT18 REG1A 
RPS6KB1 GCNT1 KRT19 RPS26 
RTCD1 GRB7 KRT7 VEGFA 
S100P STARD3 TTLL12 WNT1 
SCGB2A2 STC1 TUBA4A WNT10B 
SERPINE1 STX1A UGP2 TPBG 
SLC20A1 TMF1 VDAC2 TP63 
SLC2A1    
Tumor samples (Kettunen, Anttila et al. 2004) COL2A1 JAG1 KRT2 RARG 
DSC3 KRT10 MIF ITGA6 






Appendix 2 List of CURs obtained from literature and GSE19188 (cont’d). 
Descriptions (Citation) Gene(s) 
Review citing from studies done on tumor samples (Risch and Plass 
2008) 
BCL2 CCND1 EGFR MYC 
Tumor samples vs. normal (Valk, Vooder et al. 2010) ANLN CDCA8 IGFBP3 NCAPH 
ASPM CDK1 KIAA0101 NDC80 
AURKA CDKN3 KIF11 PAK1 
AURKB CEP55 KIF14 PTTG2 
BIK CKS1B LOXL2 SPP1 
BUB1B COL3A1 MCM2 TIMP1 
CCNA2 COL7A1 MDK TK1 
CCNB1 FAP MIF TMPRSS4 
CCNB2 FEN1 MMP1 TTK 
CCT5 FOXM1 MMP11 TYMS 
CDC20 GMNN MMP9 UHRF1 
CDC45 HMMR MYBL2  
Tumor samples vs. normal (Hou, Aerts et al. 2010) ABP1 ANKRD22 BCL11A C16orf75 
ADAM12 ANLN BIRC5 C2CD4A 
ADAM28 ARNTL2 BLM C4orf7 
ADAMDEC1 ASPM BRIP1 C7orf68 
AIM2 ATAD2 BUB1 C9orf140 
AK4 AURKA BUB1B CASC5 






Appendix 2 List of CURs obtained from literature and GSE19188 (cont’d).  
Descriptions (Citation) Gene(s) 
Tumor samples vs. normal (Hou, Aerts et al. 2010) 
(cont’d) 
CCNA2 CEP55 CENPN FAP 
CCNB1 CHEK1 DNAH14 FBXO32 
CCNB2 CLDN10 DNAJC12 FCRL5 
CCNE1 COCH DSCC1 FERMT1 
CCNE2 COL10A1 DSP FGB 
CDC20 COL11A1 DTL FGL1 
CDC45 COL1A1 DUSP4 FLJ40330 
CDC6 COL3A1 E2F8 FNDC1 
CDCA2 COL5A2 ECT2 FOXM1 
CDCA3 CPS1 EGLN3 GABBR1 
CDCA5 CRABP2 EPR1 GALNT14 
CDCA7 CTHRC1 ERO1L GCNT3 
CDCA8 CTTN EXO1 GINS1 
CDK1 CXCL13 EZH2 GINS2 
CDKN2A CXCL9 FAM72A GJB2 
CDKN3 CXorf61 FAM72B GNG4 
CDT1 CYP24A1 FAM72C GOLM1 
CENPA DEPDC1 FAM72D GPT2 
CENPE DEPDC1B FAM83A GPX2 
CENPF DERL3 FAM83D GREM1 






Appendix 2 List of CURs obtained from literature and GSE19188 (cont’d).  
Descriptions (Citation) Gene(s) 
Tumor samples vs. normal (Hou, Aerts et al. 2010) 
(cont’d) 
HELLS IGHG2 IGLV1-44 LOC100290006 
HIST1H2BC IGHG3 IGLV3-19 LOC100291917 
HIST1H2BD IGHG4 IQGAP3 LOC652694 
HIST1H2BG IGHM KIAA0101 LOC84740 
HIST1H2BH IGHV1-69 KIF11 LOC96610 
HIST3H2A IGHV2-70 KIF14 LRRC15 
HJURP IGHV3-23 KIF15 LY6K 
HMGB3 IGHV3-48 KIF18B MAD2L1 
HMGB3L1 IGHV4-31 KIF20A MAGEA3 
HMMR IGHV4-59 KIF23 MAGEA6 
HN1 IGK@ KIF2C MCM10 
HOXC10 IGKC KIF4A MCM2 
HOXC6 IGKV1-5 KISS1R MCM4 
HS6ST2 IGKV3-20 KNTC1 MDK 
IGF2BP3 IGKV3D-15 KRT17 MELK 
IGFBP3 IGKV4-1 KRT6A MGC29506 
IGHA1 IGL@ KRT6B MKI67 
IGHA2 IGLJ3 KRT6C MLF1IP 
IGHD IGLV1-36 LGR4 MMP1 






Appendix 2 List of CURs obtained from literature and GSE19188 (cont’d).  
Descriptions (Citation) Gene(s) 
Tumor samples vs. normal (Hou, Aerts et al. 2010) 
(cont’d) 
MMP9 PLEK2 SIX1 TFF1 
MND1 POSTN SLAMF7 THBS2 
MS4A1 POU2AF1 SLC12A8 THY1 
MYBL2 PPAT SLC16A14 TK1 
NCAPG PRC1 SLC2A1 TMPRSS4 
NDC80 PRR11 SLC2A5 TNNT1 
NEK2 PSAT1 SLC44A5 TOP2A 
NFE2L3 PTTG1 SLC6A10P TPX2 
NMU PYCR1 SLC6A8 TRIM59 
NUF2 RAD51 SOX4 TRIP13 
NUSAP1 RAD51AP1 SPAG4 TTK 
OIP5 RALGPS2 SPAG5 TUBB2B 
ORC6L RASSF6 SPC25 TYMS 
PAEP RFC4 SPINK1 UBD 
PAFAH1B3 RNASEH2A SPP1 UBE2C 
PAICS RRM2 SRD5A1 UBE2S 
PBK SCG5 STIL UBE2T 
PCP4 SERPINB5 SULF1 UCHL1 
PI15 SGOL2 SYT13 UCK2 






Appendix 2 List of CURs obtained from literature and GSE19188 (cont’d).  
Descriptions (Citation) Gene(s) 
Tumor samples vs. normal (Hou, Aerts et al. 2010) 
(cont’d) 
UGT1A10 UGT1A6 UGT8 ZWILCH 
UGT1A3 UGT1A7 UHRF1 ZWINT 
UGT1A4 UGT1A8 WDR72 UGT1A9 
UGT1A5    
Tumor samples enriched with CD166 (Zhang, Shyh-Chang et al. 2012) ABCC3 COL1A2 HMGA1 MMP7 
AGR2 COL3A1 HMGB3 NME1 
AKR1B10 CP HS6ST2 NME1 
ANLN CRABP2 IGF2BP3 NME1 
BAIAP2L1 CXCL13 IGFBP2 NQO1 
C1orf106 CXCL14 IGFBP3 PAICS 
C6orf168 DNAJC12 KCNK1 PAICS 
CD24 DNAJC12 KDELR2 PHLDA2 
CDC20 DNAJC12 KDELR3 PLA2G4A 
CDCA7 EPCAM KIAA0101 PPAP2C 
CDH1 ERO1L KIAA0101 PRDX4 
CDH3 FAM199X LAPTM4B PSAT1 
CEACAM1 FERMT1 LCN2 PTGFRN 
CLDN10 GCNT3 LSR RRM2 
CLDN3 GGCT MDK S100A2 






Appendix 2 List of CURs obtained from literature and GSE19188 (cont’d).  
Descriptions (Citation) Gene(s) 
Tumor samples enriched with CD166 (Zhang, Shyh-Chang et al. 2012) 
(cont’d) 
COL1A1 HIST1H2BD MMP12 SLC7A11 
THBS2 TOP2A ZWINT SMPDL3B 
TMEM106B TRIM2 SRD5A1 SORD 
TMPRSS4 WFDC2 ST14 SPINK1 







Appendix 3 List of cisplatin resistant genes obtained from literature. 
Descriptions (Citation) Gene(s) 
Candidate genes associated with cisplatin resistance in NSCLC (Zhang, 
Zheng et al. 2014) 
S100P GDA WISP2 ICAM1 
LOXL1 TIMP4 ASAM (CLMP) GAS1 
BMP2    
Methylated genes associated with sensitivity to cisplatin based therapy 
(O'Byrne, Barr et al. 2011) 
CHK2 EMX2 HTRA3 TGM2 
IGFBP3    
Potential methylation markers associated with acquired multidrug 
resistant (Guo, Wu et al. 2013) 
MT1G GPR56 RASSF1  
Drug resistance (Strathdee, MacKean et al. 1999) MLH1    
Prognostic marker for survival receiving platinum-based therapy 
(Ramirez, Rosell et al. 2005) 
SFN    
Predictive factor for survival after cisplatin therapy (Lord, Brabender et 
al. 2002) 







Appendix 4 List of identified AMPs that were hypomethylated in iPCCs-H358 upon reprogramming. 
Gene 
symbol 














APC adenomatosis polyposis coli cg01240931 NM_000038.3 5.651 -3.201 0.513 
APC adenomatosis polyposis coli cg15020645 NM_000038.3 4.669 -4.717 -0.930 
APC adenomatosis polyposis coli cg16970232 NT_034772.5 8.984 -6.579 3.047 
APC adenomatosis polyposis coli cg20311501 NT_034772.5 5.498 -5.611 -0.327 
APC adenomatosis polyposis coli cg21634602 NM_000038.3 6.921 -6.280 0.403 
APC adenomatosis polyposis coli cg24332422 NM_000038.3 3.471 -3.485 -0.527 
CDX2 caudal type homeo box transcription factor 2 cg01424107 NM_001265.2 8.739 -9.327 -0.705 
CDX2 caudal type homeo box transcription factor 2 cg02055963 NM_001265.2 9.830 -10.950 0.864 
EN1 engrailed homolog 1 cg03266453 NM_001426.2 8.336 2.123 12.799 
EN1 engrailed homolog 1 cg22231902 NM_001426.2 9.215 -10.319 0.414 
FOXG1B forkhead box G1B cg02681442 NM_005249.3 10.982 -13.691 -0.942 
FOXG1B forkhead box G1B cg10300684 NM_005249.3 6.615 -8.733 -0.601 
FOXF2 forkhead box F2 cg03848675 NM_001452.1 1.271 -7.644 2.162 
FOXF2 forkhead box F2 cg08045570 NM_001452.1 15.993 -13.652 2.152 
GDNF 
glial cell derived neurotrophic factor isoform 1 
preproprotein 
cg07442479 NM_000514.2 8.731 -4.469 4.486 
GDNF 
glial cell derived neurotrophic factor isoform 1 
preproprotein 
cg07715201 NM_000514.2 6.370 -9.227 -3.569 







Appendix 4 List of identified AMPs that were hypomethylated in iPCCs-H358 upon reprogramming (cont’d). 
Gene 
symbol 














HOXA1 homeobox A1 protein isoform a cg03700462 NM_005522.3 8.937 -8.478 -0.357 
HOXA1 homeobox A1 protein isoform a cg12686016 NM_005522.3 13.162 -12.691 0.296 
HOXA2 homeobox A2 cg09871315 NM_006735.3 13.497 -8.878 3.508 
HOXA4 homeobox protein A4 cg04317399 NM_002141.2 7.810 -7.962 -0.805 
HOXA4 homeobox protein A4 cg24169822 NM_002141.2 6.277 -8.664 -0.342 
HOXA5 homeobox A5 cg02248486 NM_019102.2 12.216 -11.064 -1.636 
HOXA5 homeobox A5 cg12128839 NM_019102.2 12.179 -10.305 1.185 
HOXA6 homeobox A6 cg04265576 NM_024014.2 8.712 -13.055 -3.719 
HOXA9 homeobox protein A9 isoform a cg01354473 NM_152739.2 7.964 -3.133 4.501 
HOXA9 homeobox protein A9 isoform a cg01381846 NM_152739.2 6.018 -1.872 3.742 
HOXA9 homeobox protein A9 isoform a cg07778029 NM_152739.2 8.139 -3.341 3.508 
HOXA9 homeobox protein A9 isoform a cg25047280 NM_152739.2 7.587 -5.631 0.028 
HOXA9 homeobox protein A9 isoform a cg26521404 NM_152739.2 13.960 -8.569 2.725 
HOXA9 homeobox protein A9 isoform a cg27009703 NM_152739.2 8.162 -4.628 3.972 
HOXA11 homeobox protein A11 cg15760840 NM_005523.4 3.979 -5.525 -1.420 
HOXA11 homeobox protein A11 cg17950095 NM_005523.4 6.797 -10.186 -3.747 
HOXA13 homeobox protein A13 cg06397837 NM_000522.2 13.566 -12.215 1.983 






Appendix 4 List of identified AMPs that were hypomethylated in iPCCs-H358 upon reprogramming (cont’d). 
Gene 
symbol 














HOXA13 homeobox protein A13 cg10883303 NM_000522.2 11.967 -13.741 -0.910 
HOXB2 homeo box B2 cg09313705 NM_002145.2 5.950 -5.430 -0.535 
HOXB2 homeo box B2 cg25882366 NM_002145.2 8.594 -8.018 -0.397 
HOXB3 homeo box B3 cg12910797 NM_002146.3 7.140 -5.822 1.408 
HOXB4 homeo box B4 cg02422694 NM_024015.3 9.371 -8.991 0.088 
HOXB4 homeo box B4 cg04609859 NM_024015.3 7.219 -6.347 -0.468 
HOXB4 homeo box B4 cg06760035 NM_024015.3 10.504 -10.290 -2.218 
HOXB4 homeo box B4 cg08089301 NM_024015.3 12.790 -11.926 0.496 
HOXB4 homeo box B4 cg14458834 NM_024015.3 6.694 -6.360 -0.100 
HOXB4 homeo box B4 cg21460081 NM_024015.3 9.470 -7.147 2.399 
HOXB4 homeo box B4 cg21546671 NM_024015.3 6.222 -5.603 0.954 
HOXB4 homeo box B4 cg25145670 NM_024015.3 6.725 -6.739 -1.389 
HOXB5 homeo box B5 cg01405107 NM_002147.2 7.481 -7.058 -1.464 
HOXB5 homeo box B5 cg16495265 NM_002147.2 8.116 -5.649 0.350 
HOXC9 homeobox C9 cg21272774 NM_006897.1 4.397 -6.075 -1.251 
HOXC9 homeobox C9 cg26829131 NM_006897.1 5.227 -5.792 -0.315 
HOXC10 homeo box C10 cg08900043 NM_017409.2 -1.609 -3.368 -1.621 






Appendix 4 List of identified AMPs that were hypomethylated in iPCCs-H358 upon reprogramming (cont’d). 
Gene 
symbol 














HOXC10 homeo box C10 cg26153631 NM_017409.2 2.642 -4.398 -2.451 
HOXC12 homeobox C12 cg05589246 NM_173860.1 5.561 -1.876 1.606 
HOXC12 homeobox C12 cg19928450 NM_173860.1 2.430 -2.619 -0.934 
HOXD8 homeobox D8 cg15520279 NM_019558.2 17.646 -21.811 -3.976 
HOXD8 homeobox D8 cg21815667 NM_019558.2 8.532 -4.641 5.020 
HOXD13 homeobox D13 cg07175883 NM_000523.2 9.614 -11.065 0.802 
HOXD13 homeobox D13 cg19325985 NM_000523.2 5.350 -1.512 3.839 
PAX7 paired box gene 7 isoform 1 cg07536847 NM_002584.1 9.297 -2.663 8.740 
PAX7 paired box gene 7 isoform 1 cg11428724 NM_002584.1 9.765 -7.821 2.267 
SFRP1 secreted frizzled-related protein 1 cg02388150 NT_007995.14 5.076 -5.617 3.911 
SFRP1 secreted frizzled-related protein 1 cg06166767 NM_003012.3 1.821 0.333 3.827 
SFRP1 secreted frizzled-related protein 1 cg13398291 NT_007995.14 11.923 -4.470 8.108 
SFRP1 secreted frizzled-related protein 1 cg15839448 NM_003012.3 9.834 -3.366 6.683 
SFRP1 secreted frizzled-related protein 1 cg22418909 NM_003012.3 10.671 -5.112 4.579 
SIM1 single-minded homolog 1 cg11540692 NM_005068.2 6.252 -3.731 3.330 
SIM1 single-minded homolog 1 cg12865837 NM_005068.2 8.251 -6.194 6.614 
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secreted protein; acidic; cysteine-rich 
(osteonectin) 
cg08331313 NM_003118.2 10.146 -6.223 3.423 
SPARC 
secreted protein; acidic; cysteine-rich 
(osteonectin) 
cg25913233 NM_003118.2 7.921 -4.904 1.927 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg05260966 NM_000362.4 2.689 -2.647 -0.728 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg05288803 NT_011520.11 6.321 -5.645 0.141 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg22578204 NT_011520.11 5.577 -5.608 -0.493 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg24080529 NM_000362.4 -4.991 5.825 -0.274 
TWIST1 twist cg00240432 NM_000474.3 10.490 -9.952 0.444 
TWIST1 twist cg09674215 NM_000474.3 5.082 0.630 7.862 
TWIST1 twist cg20052718 NT_007819.16 11.404 -10.771 0.311 
TWIST1 twist cg20498685 NT_007819.16 11.789 -11.380 -0.127 
TWIST1 twist cg22498251 NM_000474.3 4.226 -1.614 4.642 
TWIST1 twist cg24446548 NM_000474.3 13.955 -13.710 0.262 
TWIST1 twist cg26312150 NM_000474.3 9.098 -8.188 0.056 
WRN Werner syndrome protein cg09945801 NM_000553.2 7.723 -9.683 -0.787 
WRN Werner syndrome protein cg10709021 NM_000553.2 7.974 -10.071 -1.517 
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ZIC1 zinc finger protein of the cerebellum 1 cg05073035 NM_003412.3 10.909 -5.812 7.105 
ZIC1 zinc finger protein of the cerebellum 1 cg14456683 NM_003412.3 10.596 -6.252 7.714 
MSC musculin (activated B-cell factor-1) cg06269753 NM_005098.2 8.209 -1.548 6.201 
MSC musculin (activated B-cell factor-1) cg23710218 NM_005098.2 7.788 -6.941 0.878 
SLIT2 slit homolog 2 cg03742003 NM_004787.1 4.450 -4.975 -1.020 
SLIT2 slit homolog 2 cg18972811 NM_004787.1 0.741 -0.299 -0.279 
ONECUT2 one cut domain; family member 2 cg02250594 NM_004852.1 8.980 -6.766 6.062 
ONECUT2 one cut domain; family member 2 cg09879099 NM_004852.1 0.322 -0.241 -0.555 
HOXB13 homeo box B13 cg15786837 NM_006361.4 5.615 -7.752 -3.096 
HOXB13 homeo box B13 cg21842478 NM_006361.4 9.070 -10.290 -1.408 
SOX21 SRY-box 21 cg11208483 NM_007084.2 2.646 -0.224 2.995 
SOX21 SRY-box 21 cg19063972 NM_007084.2 4.603 -6.115 0.515 
SYNE1 nesprin 1 isoform beta cg26620959 NM_015293.1 7.783 -4.741 2.315 
SYNE1 nesprin 1 isoform beta cg27316956 NM_015293.1 3.716 -0.502 -0.860 
C20orf103 
chromosome 20 open reading frame 103 
precursor 
cg01144286 NM_012261.2 1.765 -3.835 0.579 
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chromosome 20 open reading frame 103 
precursor 
cg09119967 NM_012261.2 2.982 -1.594 3.354 
FOXD3 forkhead box D3 cg15462232 NM_012183.1 0.868 -0.315 0.960 
FOXD3 forkhead box D3 cg22815110 NM_012183.1 6.417 -7.797 0.829 
SALL3 sal-like 3 cg08118311 NM_171999.1 9.652 -4.069 6.680 
SALL3 sal-like 3 cg15191648 NM_171999.1 12.848 -5.919 8.986 
NRN1 neuritin precursor cg11504897 NM_016588.2 7.998 -7.991 -0.523 
NRN1 neuritin precursor cg25511429 NM_016588.2 5.655 -7.049 -0.332 
RPRM 
reprimo; TP53 dependant G2 arrest mediator 
candidate 
cg18411898 NM_019845.2 3.006 -3.756 -2.096 
RPRM 
reprimo; TP53 dependant G2 arrest mediator 
candidate 
cg27420236 NM_019845.2 1.136 -2.949 0.067 
DMRT3 
doublesex and mab-3 related transcription 
factor 3 
cg12420104 NM_021240.2 5.670 -6.563 0.812 
DMRT3 
doublesex and mab-3 related transcription 
factor 3 
cg26489108 NM_021240.2 3.088 4.159 7.655 
BARHL2 BarH-like 2 cg06384463 NM_020063.1 5.991 -1.473 4.760 
BARHL2 BarH-like 2 cg17241310 NM_020063.1 11.924 -8.883 4.556 
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CCND2 cyclin D2 cg00888007 NM_001759.2 5.296 -8.330 -0.099 
CCND2 cyclin D2 cg02765328 NM_001759.2 10.196 -11.631 0.129 
CCND2 cyclin D2 cg08069899 NT_009759.15 5.600 -5.807 -0.371 
CCND2 cyclin D2 cg12382902 NM_001759.2 12.886 -12.651 1.458 
CCND2 cyclin D2 cg13574590 NM_001759.2 5.895 -4.973 0.847 
CCND2 cyclin D2 cg13801381 NT_009759.15 5.468 -10.775 1.339 
CCND2 cyclin D2 cg14914982 NM_001759.2 3.905 -3.225 -0.007 
CCND2 cyclin D2 cg16310717 NM_001759.2 6.745 -6.168 1.000 
CCND2 cyclin D2 cg16994506 NM_001759.2 9.193 -8.321 0.091 
CCND2 cyclin D2 cg17580045 NT_009759.15 9.412 -9.363 0.290 
CCND2 cyclin D2 cg17886028 NM_001759.2 11.049 -10.862 0.512 
CCND2 cyclin D2 cg25425078 NM_001759.2 9.817 -10.598 1.334 
CCND2 cyclin D2 cg26989531 NM_001759.2 2.562 -3.152 0.029 
CYP1A1 
cytochrome P450; family 1; subfamily A; 
polypeptide 1 
cg10481417 NM_000499.2 5.955 -7.387 0.029 
CYP1A1 
cytochrome P450; family 1; subfamily A; 
polypeptide 1 
cg19817399 NM_000499.2 4.847 -5.032 -0.310 
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cytochrome P450; family 1; subfamily A; 
polypeptide 1 
cg20433014 NM_000499.2 7.385 -7.545 0.179 
CYP1A1 
cytochrome P450; family 1; subfamily A; 
polypeptide 1 
cg26704579 NM_000499.2 3.533 -2.998 -0.166 
ESR1 estrogen receptor 1 cg00655307 NM_000125.2 8.824 -4.783 3.930 
ESR1 estrogen receptor 1 cg02720618 NT_025741.14 11.259 -11.912 -0.997 
ESR1 estrogen receptor 1 cg07671949 NM_000125.2 9.156 -6.029 0.432 
ESR1 estrogen receptor 1 cg11251858 NM_000125.2 9.394 -7.147 0.473 
ESR1 estrogen receptor 1 cg15626350 NT_025741.14 8.893 -5.523 0.687 
ESR1 estrogen receptor 1 cg20253551 NT_025741.14 8.529 -8.239 1.388 
ESR1 estrogen receptor 1 cg20627916 NM_000125.2 10.342 -8.606 0.366 
GRIK2 glutamate receptor 6 isoform 1 precursor cg16009558 NM_021956.2 6.684 -3.208 1.971 
GRIK2 glutamate receptor 6 isoform 1 precursor cg26316946 NM_021956.2 6.306 -0.422 3.333 
GSTP1 glutathione transferase cg02659086 NT_033903.7 5.872 -5.433 -0.250 
GSTP1 glutathione transferase cg04920951 NT_033903.7 7.154 -6.665 -0.400 
GSTP1 glutathione transferase cg05244766 NM_000852.2 -7.383 -3.943 -9.628 
GSTP1 glutathione transferase cg09038676 NM_000852.2 4.880 -4.433 0.634 
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GSTP1 glutathione transferase cg11566244 NT_033903.7 1.652 -1.313 0.004 
GSTP1 glutathione transferase cg22224704 NM_000852.2 4.289 -0.093 2.960 
GSTP1 glutathione transferase cg25025243 NM_000852.2 -6.530 0.482 -5.621 
HOXB7 homeo box B7 cg06493080 NM_004502.2 4.451 -4.095 0.104 
HOXB7 homeo box B7 cg09357097 NM_004502.2 5.505 -5.175 -1.727 
HOXB9 homeo box B9 cg12370791 NM_024017.3 9.149 -10.919 -2.058 
HOXB9 homeo box B9 cg13643585 NM_024017.3 11.405 -11.425 -0.250 
HOXC4 homeobox C4 cg10918927 NM_014620.2 1.334 -2.463 -1.178 
HOXC4 homeobox C4 cg21487207 NM_014620.2 4.687 -7.256 -2.743 
HOXC13 homeobox C13 cg20587394 NM_017410.2 6.647 -9.870 -1.257 
LHX1 LIM homeobox protein 1 cg07747970 NM_005568.2 5.709 -6.367 0.214 
LHX1 LIM homeobox protein 1 cg22660578 NM_005568.2 6.029 -7.063 -0.725 
PAX2 paired box protein 2 isoform a cg15416233 NM_003987.2 3.600 -3.005 0.063 
PAX2 paired box protein 2 isoform a cg26677448 NM_003987.2 6.635 -7.236 0.215 
RARB retinoic acid receptor; beta isoform 1 cg02499249 NM_000965.2 0.613 -1.090 1.590 
RARB retinoic acid receptor; beta isoform 1 cg10712623 NT_022517.17 -0.166 0.153 -0.502 
RARB retinoic acid receptor; beta isoform 1 cg26124016 NM_000965.2 2.758 -2.916 -1.409 






Appendix 4 List of identified AMPs that were hypomethylated in iPCCs-H358 upon reprogramming (cont’d). 
Gene 
symbol 














RARB retinoic acid receptor; beta isoform 1 cg27486427 NM_000965.2 7.444 -8.975 -1.418 
RASGRF2 
Ras protein-specific guanine nucleotide-
releasing factor 2 
cg09952204 NM_006909.1 6.058 -6.613 0.729 
SIM2 single-minded homolog 2 short isoform cg02672220 NM_009586.1 2.960 3.642 6.890 
SIM2 single-minded homolog 2 short isoform cg13694867 NM_009586.1 8.449 -9.288 -0.461 
TFAP2A transcription factor AP-2 alpha isoform a cg12439899 NM_003220.1 9.207 -11.841 -4.448 
TFAP2A transcription factor AP-2 alpha isoform a cg25202471 NM_003220.1 4.991 -5.970 -0.080 
NR2E1 
nuclear receptor subfamily 2; group E; member 
1 
cg03958979 NM_003269.2 10.224 -5.685 7.843 
NR2E1 
nuclear receptor subfamily 2; group E; member 
1 
cg19697981 NM_003269.2 8.631 -0.258 8.918 
LHX2 LIM homeobox protein 2 cg07109287 NM_004789.3 9.100 -6.503 6.688 
LHX2 LIM homeobox protein 2 cg18904346 NM_004789.3 7.571 -8.943 0.041 
RASSF2 Ras association domain family 2 isoform 2 cg16884569 NM_170773.1 6.058 -5.663 2.885 
RASSF2 Ras association domain family 2 isoform 2 cg19614321 NM_170773.1 3.739 -5.558 2.227 
MAFB transcription factor MAFB cg02497758 NM_005461.3 6.525 -7.024 -0.458 
GSC goosecoid cg19224837 NM_173849.2 10.423 -13.748 1.899 
GSC goosecoid cg20804555 NM_173849.2 6.977 -2.391 5.067 
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heparan sulfate D-glucosaminyl 3-O-
sulfotransferase 2 
cg19064258 NM_006043.1 5.559 -1.424 5.028 
HS3ST2 
heparan sulfate D-glucosaminyl 3-O-
sulfotransferase 2 
cg20023231 NM_006043.1 6.522 -2.732 4.769 
RAMP2 
receptor (calcitonin) activity modifying protein 
2 precursor 
cg14436761 NM_005854.1 6.723 -0.984 6.223 
RAMP2 
receptor (calcitonin) activity modifying protein 
2 precursor 
cg26990660 NM_005854.1 6.771 -0.191 6.195 
VAX1 ventral anterior homeobox 1 cg00263760 NM_199131.1 9.274 -9.647 0.262 
VAX2 ventral anterior homeobox 2 cg12374431 NM_012476.1 1.840 -1.347 0.687 
VAX2 ventral anterior homeobox 2 cg20699736 NM_012476.1 5.218 -5.272 -0.468 
ZNF577 zinc finger protein 577 cg16731240 NM_032679.1 10.605 -3.415 -0.087 
ZNF577 zinc finger protein 577 cg22472290 NM_032679.1 2.595 2.409 4.239 
SLC32A1 solute carrier family 32; member 1 cg03556497 NM_080552.2 3.835 -3.900 -0.117 
SLC32A1 solute carrier family 32; member 1 cg08535373 NM_080552.2 5.407 -3.993 1.787 
LRRTM1 leucine rich repeat transmembrane neuronal 1 cg00465284 NM_178839.3 3.043 -4.591 -0.954 
LRRTM1 leucine rich repeat transmembrane neuronal 1 cg21621248 NM_178839.3 3.426 -4.443 -0.545 
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APC adenomatosis polyposis coli cg01240931 NM_000038.3 5.459 -3.207 0.316 
APC adenomatosis polyposis coli cg15020645 NM_000038.3 6.018 -6.100 -0.964 
APC adenomatosis polyposis coli cg16970232 NT_034772.5 10.657 -7.821 3.478 
APC adenomatosis polyposis coli cg20311501 NT_034772.5 7.055 -6.513 0.327 
APC adenomatosis polyposis coli cg21634602 NM_000038.3 8.138 -6.845 1.055 
APC adenomatosis polyposis coli cg24332422 NM_000038.3 4.704 -4.533 -0.342 
CDX2 caudal type homeo box transcription factor 2 cg01424107 NM_001265.2 6.343 -7.277 -1.050 
CDX2 caudal type homeo box transcription factor 2 cg02055963 NM_001265.2 10.304 -11.039 1.249 
EN1 engrailed homolog 1 cg03266453 NM_001426.2 10.669 -1.436 11.573 
EN1 engrailed homolog 1 cg22231902 NM_001426.2 7.273 -7.302 1.489 
FOXG1B forkhead box G1B cg02681442 NM_005249.3 5.420 -6.538 0.650 
FOXG1B forkhead box G1B cg10300684 NM_005249.3 5.738 -7.209 0.046 
FOXF2 forkhead box F2 cg03848675 NM_001452.1 0.745 -5.191 4.090 
FOXF2 forkhead box F2 cg08045570 NM_001452.1 8.008 -5.422 2.398 
GDNF 
glial cell derived neurotrophic factor isoform 1 
preproprotein cg07442479 NM_000514.2 4.105 -0.708 3.622 
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glial cell derived neurotrophic factor isoform 1 
preproprotein cg07715201 NM_000514.2 4.830 -7.120 -3.002 
HOXA1 homeobox A1 protein isoform a cg03700462 NM_005522.3 8.684 -7.660 0.208 
HOXA1 homeobox A1 protein isoform a cg12686016 NM_005522.3 12.676 -11.908 0.594 
HOXA2 homeobox A2 cg09871315 NM_006735.3 13.393 -10.167 2.116 
HOXA2 homeobox A2 cg26069745 NM_006735.3 11.299 -2.644 6.641 
HOXA4 homeobox protein A4 cg04317399 NM_002141.2 8.190 -7.876 -0.339 
HOXA4 homeobox protein A4 cg24169822 NM_002141.2 6.401 -8.592 -0.147 
HOXA5 homeobox A5 cg02248486 NM_019102.2 12.660 -10.883 -1.011 
HOXA5 homeobox A5 cg12128839 NM_019102.2 13.563 -12.828 0.045 
HOXA6 homeobox A6 cg04265576 NM_024014.2 6.568 -10.790 -3.598 
HOXA9 homeobox protein A9 isoform a cg01354473 NM_152739.2 8.771 -4.505 3.935 
HOXA9 homeobox protein A9 isoform a cg01381846 NM_152739.2 6.954 -3.317 3.233 
HOXA9 homeobox protein A9 isoform a cg07778029 NM_152739.2 9.225 -5.447 2.487 
HOXA9 homeobox protein A9 isoform a cg25047280 NM_152739.2 8.289 -7.481 -1.120 
HOXA9 homeobox protein A9 isoform a cg26521404 NM_152739.2 16.946 -11.999 2.281 
HOXA9 homeobox protein A9 isoform a cg27009703 NM_152739.2 8.705 -5.462 3.681 
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HOXA11 homeobox protein A11 cg15760840 NM_005523.4 4.831 -6.579 -1.623 
HOXA11 homeobox protein A11 cg17950095 NM_005523.4 4.024 -6.700 -3.034 
HOXA13 homeobox protein A13 cg06397837 NM_000522.2 5.706 -3.702 2.636 
HOXA13 homeobox protein A13 cg10883303 NM_000522.2 5.921 -6.479 0.305 
HOXB2 homeo box B2 cg09313705 NM_002145.2 8.139 -8.007 -0.923 
HOXB2 homeo box B2 cg25882366 NM_002145.2 9.081 -7.738 0.369 
HOXB3 homeo box B3 cg12910797 NM_002146.3 9.618 -9.189 0.519 
HOXB4 homeo box B4 cg02422694 NM_024015.3 8.655 -7.861 0.503 
HOXB4 homeo box B4 cg04609859 NM_024015.3 7.594 -6.982 -0.730 
HOXB4 homeo box B4 cg06760035 NM_024015.3 17.764 -15.324 0.008 
HOXB4 homeo box B4 cg08089301 NM_024015.3 13.543 -12.229 0.946 
HOXB4 homeo box B4 cg14458834 NM_024015.3 9.349 -8.991 -0.076 
HOXB4 homeo box B4 cg21460081 NM_024015.3 10.438 -8.642 1.871 
HOXB4 homeo box B4 cg21546671 NM_024015.3 8.829 -7.923 1.241 
HOXB4 homeo box B4 cg25145670 NM_024015.3 8.296 -8.092 -1.172 
HOXB5 homeo box B5 cg01405107 NM_002147.2 8.438 -7.632 -1.081 
HOXB5 homeo box B5 cg16495265 NM_002147.2 9.629 -8.377 -0.865 
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HOXC9 homeobox C9 cg21272774 NM_006897.1 5.548 -7.085 -1.111 
HOXC9 homeobox C9 cg26829131 NM_006897.1 7.016 -7.360 -0.094 
HOXC10 homeo box C10 cg08900043 NM_017409.2 -4.274 -0.614 -1.532 
HOXC10 homeo box C10 cg26153631 NM_017409.2 3.965 -5.086 -1.816 
HOXC12 homeobox C12 cg05589246 NM_173860.1 8.143 -5.831 0.233 
HOXC12 homeobox C12 cg19928450 NM_173860.1 4.913 -5.461 -1.293 
HOXD8 homeobox D8 cg15520279 NM_019558.2 -2.750 1.266 -1.295 
HOXD8 homeobox D8 cg21815667 NM_019558.2 8.926 -5.894 4.160 
HOXD13 homeobox D13 cg07175883 NM_000523.2 -1.780 -0.020 0.453 
HOXD13 homeobox D13 cg19325985 NM_000523.2 6.669 -3.070 3.601 
PAX7 paired box gene 7 isoform 1 cg07536847 NM_002584.1 8.763 -4.893 5.976 
PAX7 paired box gene 7 isoform 1 cg11428724 NM_002584.1 -1.018 1.289 0.593 
SFRP1 secreted frizzled-related protein 1 cg02388150 NT_007995.14 4.643 -2.706 6.389 
SFRP1 secreted frizzled-related protein 1 cg06166767 NM_003012.3 3.719 0.245 5.638 
SFRP1 secreted frizzled-related protein 1 cg13398291 NT_007995.14 11.838 -4.054 8.438 
SFRP1 secreted frizzled-related protein 1 cg15839448 NM_003012.3 11.383 -4.774 6.825 
SFRP1 secreted frizzled-related protein 1 cg22418909 NM_003012.3 11.566 -4.768 5.818 
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SIM1 single-minded homolog 1 cg11540692 NM_005068.2 6.296 -3.768 3.336 
SIM1 single-minded homolog 1 cg12865837 NM_005068.2 9.107 -6.948 6.717 
SPARC 
secreted protein; acidic; cysteine-rich 
(osteonectin) cg08331313 NM_003118.2 10.954 -3.924 6.531 
SPARC 
secreted protein; acidic; cysteine-rich 
(osteonectin) cg25913233 NM_003118.2 6.456 -1.417 3.949 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg05260966 NM_000362.4 2.478 -2.444 -0.736 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg05288803 NT_011520.11 5.533 -4.111 0.886 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg22578204 NT_011520.11 4.388 -4.085 -0.159 
TIMP3 tissue inhibitor of metalloproteinase 3 precursor cg24080529 NM_000362.4 -4.000 4.361 -0.747 
TWIST1 twist cg00240432 NM_000474.3 9.969 -9.455 0.418 
TWIST1 twist cg09674215 NM_000474.3 4.376 1.158 7.684 
TWIST1 twist cg20052718 NT_007819.16 10.626 -9.786 0.518 
TWIST1 twist cg20498685 NT_007819.16 11.348 -10.120 0.691 
TWIST1 twist cg22498251 NM_000474.3 2.671 0.001 4.702 
TWIST1 twist cg24446548 NM_000474.3 12.438 -12.126 0.329 
TWIST1 twist cg26312150 NM_000474.3 8.613 -7.162 0.597 
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WRN Werner syndrome protein cg09945801 NM_000553.2 7.049 -7.875 0.347 
WRN Werner syndrome protein cg10709021 NM_000553.2 6.066 -8.151 -1.505 
ZIC1 zinc finger protein of the cerebellum 1 cg05073035 NM_003412.3 10.195 -5.461 6.742 
ZIC1 zinc finger protein of the cerebellum 1 cg14456683 NM_003412.3 9.702 -5.816 7.255 
MSC musculin (activated B-cell factor-1) cg06269753 NM_005098.2 9.369 -4.519 4.390 
MSC musculin (activated B-cell factor-1) cg23710218 NM_005098.2 8.317 -7.098 1.251 
SLIT2 slit homolog 2 cg03742003 NM_004787.1 4.090 -4.436 -0.841 
SLIT2 slit homolog 2 cg18972811 NM_004787.1 5.805 -5.082 0.002 
ONECUT2 one cut domain; family member 2 cg02250594 NM_004852.1 9.100 -8.095 4.853 
ONECUT2 one cut domain; family member 2 cg09879099 NM_004852.1 0.220 -0.232 -0.647 
HOXB13 homeo box B13 cg15786837 NM_006361.4 5.310 -7.035 -2.686 
HOXB13 homeo box B13 cg21842478 NM_006361.4 -1.784 2.252 0.281 
SOX21 SRY-box 21 cg11208483 NM_007084.2 3.085 -1.194 2.465 
SOX21 SRY-box 21 cg19063972 NM_007084.2 3.223 -4.514 0.736 
SYNE1 nesprin 1 isoform beta cg26620959 NM_015293.1 5.337 -3.887 0.723 
SYNE1 nesprin 1 isoform beta cg27316956 NM_015293.1 3.370 -0.774 -1.479 
Legends: M – M value (log2 (methylated probe/unmethylated probe)); Colored cell – H358 ∩ H460. 
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